{
  "responseHeader":{
    "status":0,
    "QTime":15,
    "params":{
      "q":"(Background: esophageal cancer OR Esophageal carcinoma OR esophageal squamous-cell carcinoma OR ESCC OR esophageal adenocarcinoma OR EAC OR Doc_title: esophageal cancer OR Esophageal carcinoma OR esophageal squamous-cell carcinoma OR ESCC OR esophageal adenocarcinoma OR EAC) AND (Background: EGFR OR \"Epidermal Growth Factor Receptor\" OR \"ERBB\" OR \"HER1\" OR \"mENA\" OR \"ERBB1\" OR \"PIG61\" OR \"NISBD2\" OR Doc_title: EGFR OR \"Epidermal Growth Factor Receptor\" OR \"ERBB\" OR \"HER1\" OR \"mENA\" OR \"ERBB1\" OR \"PIG61\" OR \"NISBD2\")"}},
  "response":{"numFound":4557,"start":0,"docs":[
      {
        "Meeting_name":" Comprehensive genomic profiling of advanced stage esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC).",
        "Background":"['Background', '    Esophageal Squamous Cell Carcinomas (ESCC) and Esophageal Adenocarcinomas (EAC) account for > 95% of esophageal malignancies. Using a sensitive sequencing assay, we compared the genomic profiles of ESCC and EAC focused on the ability to identify potential targets for therapy in the 2 diseases.   Methods', '    DNA was extracted from 40u of FFPE sections from 71 clinically advanced ESCC and 231 EAC. Next generation sequencing based comprehensive genomic profiling (NGS) was performed on hybridization-captured, adaptor ligation based libraries to a median coverage depth of > 650x for 236 cancer-related genes. The results were evaluated for all classes of genomic alterations (GA). Clinically relevant genomic alterations (CRGA) were defined as GA linked to drugs on the market or under evaluation in mechanism driven clinical trials.  Results', '  There were no significant differences in the age range for ESCC and EAC (median', ' 63 vs. 60 years). All ESCC and EAC were at an advanced stage (Stage III/IV) at the time of sequencing. GA per sample on average in 71 ESCC and 231 EAC were 7.4 and 5.6 respectively. The frequency of CRGA in ESCC (2.6/sample; 94.4% of cases) and EAC (2.7/sample; 93.1% of cases) were similar. CRGA more frequently identified in ESCC than EAC included PIK3CA (24% vs 10%), PTEN (11% vs 4%), CCND1 (42% vs 13%) and NOTCH1 (17% vs 3%). CRGA more frequently altered in EAC than ESCC included KRAS (23% vs 6%) and ERBB2 (23% vs 3%). Other GA that were significantly different in the 2 tumor types included SMAD4 (1% ESCC vs 14% EAC), SOX2 (18% ESCC vs 1% EAC) and NFE2L2 (24% ESCC vs 1% EAC). EGFR was altered in 8% of ESCC and 15% of EAC. Clinical case examples of patient responses to targeted therapy will be presented.   Conclusions', '    ESCC and EAC share common high frequencies of overall and clinically relevant GA. However, PI3K/mTOR (PIK3CA and PTEN) and Notch pathway genes were significantly enriched in ESCC, and RAS/MEK pathway genes (ERBB2 and KRAS) were significantly enriched in EAC. Comprehensive genomic profiling shows significant promise to identify CRGA in both ESCC and EAC and lead to potential use of clinical outcome altering targeted therapies in both major types of esophageal cancer.']",
        "Doc_id":"ASCO_149918-156",
        "Doc_title":" Comprehensive genomic profiling of advanced stage esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC).",
        "_version_":1606189027661185024},
      {
        "Meeting_name":" A bispecific enediyne-energized fusion protein Ec-LDP-Hr-AE enhances anti-cancer efficacy on esophageal cancer cells by targeting EGFR and HER2.",
        "Background":"['Esophageal cancer is one of the most common cancers, and the 5-year survival rate is less than 10% due to lack of effective therapeutic agents. This study was to evaluate antitumor activity of Ec-LDP-Hr-AE, a recently developed bispecific enediyne-energized fusion protein, on esophageal carcinoma, targeting both EGFR (epidermal growth factor receptor) and HER2 (human epidermal growth factor receptor 2), because both EGFR and HER2 have been shown overexpression in over 30% of esophageal cancers. The fusion protein Ec-LDP-Hr-AE was encoded by a gene that was genetically constructed by fusing the oligopeptides ligand Ec (22 amino acids of EGF COOH-terminal) and Hr (VH CDR3 region of anti-HER2 C6.5 antibody) with lidamycin (LDM, an enediyne antibiotic with potent cytotoxicity) via two (G4S)3-linker. The encoded 18.4 kDa fusion protein was expressed in Escherichia coli and characterized its binding affinity with esophageal squamous cell carcinoma (ESCC) cells by flow-cytometry-based immunofluorescence assay. The results showed that Ec-LDP-Hr-AE protein bound to ESCC cells EC9706 and KYSE150 with high affinity (the Kd values were 5.283mol/L and 3.562mol/L, respectively). The potency of Ec-LDP-Hr-AE was determined on four human ESCC cell lines with differential expression of EGFR and HER2 using MTT assay. The bispecific Ec-LDP-Hr-AE showed potent cytotoxicity to EC1, EC109, EC9706 and KYSE150 cells with IC50 values in the picomolar level. Moreover, the bispecific Ec-LDP-Hr-AE was more potent than the monospecific counterparts (Ec-LDP-AE and LDP-Hr-AE) and LDM. Cell cycle distribution assay revealed that Ec-LDP-Hr-AE caused G2-M arrest in EC9706 and KYSE150 cells, in which the G2-M phase cells reached the peak with 0.1nmol/L of Ec-LDP-Hr-AE treatment. Ec-LDP-Hr-AE also induced cancer cell apoptosis in EC9706 and KYSE150 cells and the induction of apoptosis was in a dosage-dependent manner. The apoptotic index in the EC9706 cells exposed to 0.1, 0.5, or 1 nmol/L of Ec-LDP-Hr-AE were 15.0  0.3%, 38.1  0.6%, and 50.0  0.4%, respectively. Western blotting showed that Ec-LDP-Hr-AE promoted caspase-3 and caspase-7 activities as well as PARP cleavage, indicating that Ec-LDP-Hr-AE-induced apoptosis was associated with mitochondria-caspase cascade. Moreover, Ec-LDP-Hr-AE inhibited KYSE150 cancer cell proliferation via decreasing phosphorylation of EGFR and HER2, and further exerted inhibition of the activation of their downstream signaling molecules (e.g. AKT and ERK). In summary, the bispecific energized fusion protein Ec-LDP-Hr-AE exhibited potent cytotoxicity to ESCC cells in vitro, leading to cell cycle arrest and apoptosis via targeting EGFR and HER2. These results suggest that Ec-LDP-Hr-AE could be a promising candidate for esophageal cancer targeting therapy.']",
        "Doc_id":"AACR_2013-5478",
        "Doc_title":" A bispecific enediyne-energized fusion protein Ec-LDP-Hr-AE enhances anti-cancer efficacy on esophageal cancer cells by targeting EGFR and HER2.",
        "_version_":1606188986386087936},
      {
        "Meeting_name":" Comparative molecular analyses of esophageal cancer",
        "Background":"['Background', ' Patients (pts) with esophageal cancer (EsophCa) have a poor prognosis and limited treatment options. The effect of histological subtype on tumor molecular profile remains unknown. Here we aim to compare the molecular aberrations in esophageal adenocarcinoma (EAC) and squamous cell carcinoma (ESCC). Methods', ' EsophCa tumors submitted to Caris Life Sciences for IHC (protein expression), ISH (gene amplification), and NGS sequencing between 2009 and 2015 were studied and correlated with pt outcomes. Chi-square tests determined differences between histological subtypes. Kaplan-Meier methodology estimated survival. Results', ' A total of 966 tumors (883 EACs and 113 ESCCs) were examined. Most frequently mutated genes were TP53 (71%), BRCA2 (10%), HNF1A (9%), APC (8%), SMAD4 (6.3%), PIK3CA (4.4%), ATM (5.3%), cMET (3%), ERBB2 (2.2%), PTEN (2%), and NOTCH1 (1%). When we compared EACs with ESCCs, KRAS (6.5%), NRAS (1.4%), GNAS (1%), and BRAF (0.7%) mutations were seen only in EACs, whereas, NFE2L2 mutations (R34P and E79G), and HER-2/neu overexpression (12%) and amplification (20%), were seen only in ESCCs (p < 0.001). EACs had higher overexpression of P-glycoprotein (PGP) (51% vs. 8%, p < 0.01) compared with ESCCs. ESCCs showed higher PD-L1 expression (19% vs. 6%, p < 0.01), but there was no difference in the frequency of PD-1 expression on tumor-infiltrating lymphocytes. ESCCs also had higher overexpression of ERCC1 (55% vs. 36%, p = 0.01), MGMT (62% vs. 49%, p = 0.01), EGFR (93% vs. 75%, p = 0.003), TLE3 (70% vs. 34%, p < 0.001), RRM1 (52% vs. 36%, p = 0.006), PTEN (67% vs. 50%, p = 0.001), and TOPO1 (76% vs. 61%, p = 0.002) compared with EACs. In a small subset of pts, survival data were available, and low PGP expression was associated with prolonged survival (HR = 8.7, p = 0.004).Conclusions', ' Molecular profile differences between EACs and ESCCs indicate different carcinogenic pathways, and biology, that may influence response to therapy. Low frequency mutations in several druggable genes may provide therapeutic opportunities. Correlation of low PGP with prolonged survival implicates PGP as a prognostic biomarker, and highlights the importance of targeting multi-drug resistance.']",
        "Doc_id":"ASCO_164659-176",
        "Doc_title":" Comparative molecular analyses of esophageal cancer",
        "_version_":1606189009405476864},
      {
        "Meeting_name":" The BK5.erbB2 mouse as a novel model of esophageal adenocarcinoma",
        "Background":"[\"The incidence of esophageal adenocarcinoma (EAC) is rising rapidly throughout the Western world, and is associated with gastroesophageal reflux disease (GERD) and Barrett's esophagus (BE). BE is intestinal metaplasia of squamous esophageal epithelium, important clinically due to the fact that it increases an individual's chance of progression to EAC 30 to 125-fold higher than people without BE. Despite its clinical importance, the molecular pathogenesis of BE is poorly understood. One limitation in the study of BE pathogenesis has been the lack of suitable experimental models. There is a critical need to develop good preclinical models of BE. ErbB2 was reported to be amplified and overexpressed in BE, EAC, and esophageal squamous cell carcinoma (ESCC). However, the role of erbB2 in the development and progression of esophageal cancer is still unknown. In this study, we utilized BK5.erbB2 mice, in which erbB2 is overexpressed in epithelial cells under the control of the bovine keratin 5 promoter to determine whether the interaction between erbB2 and bile acids is important in the etiology of esophageal cancers. BK5.erbB2 mice (2 months of age, n=8) and age matched wild type mice (n=10) were treated with porcine bile extract (10mg/mouse in 200L water), taurochenodeoxycholate (TCDC) (0.1mol/mouse in 200L water), or water control, 3 times weekly for 14 weeks by gavage. In the BK5.erbB2 mice, exophytic tumors in the forestomach, which has the same histological structure of esophagus, were observed in 20%, 33%, and 0% of mice treated with bile extract, TCDC, and water control, respectively. No tumors were observed in wild type mice. All tumors observed in BK5.erbB2 mice were diagnosed as SCC. Western blotting analysis demonstrated that the bile acid treatment increased the levels of p-EGFR, p-MAPK, and p-Akt in the forestomachs of the BK5.erbB2 mice. Furthermore, CDX2 (a marker of BE) was significantly expressed in BK5.erbB2 mice treated with bile extract or TCDC. No development of intestinal metaplasia in forestomach was found. We further investigated using a surgically manipulated reflux model. Eleven 7 week-old BK5.erbB2 and 5 wild type mice were given an esophagogastroduodenostomy. Mice were sacrificed at post-operative week 8, and examined histologically. Hyperkeratosis and intestinal metaplasia were observed at the anastomosis sites in both BK5.erbB2 and wild type mice. These histological changes were more prominent in BK5.erbB2 mice. Interestingly, dysplastic lesions were observed only in BK5.erbB2 mice. These results indicate that more persistent exposure of bile via surgery induce the development of not only SCC, but also precancerous lesions of adenocarcinoma in the esophagus/forestomach of BK5.erbB2 mice. The interaction between erbB2 and bile acids is important in esophageal tumor formation and intestinal metaplasia. A surgical model using BK5.erbB2 mice could possibly be a promising model for the study of the development of EAC.\"]",
        "Doc_id":"AACR_2012-1331",
        "Doc_title":" The BK5.erbB2 mouse as a novel model of esophageal adenocarcinoma",
        "_version_":1606189007381725184},
      {
        "Meeting_name":" A three-gene signature predicts esophageal squamous cell carcinoma prognosis",
        "Background":"['The 5-year survival rate of esophageal squamous cell carcinoma (ESCC) remains dismal despite improvements in treatments such as surgical resection and adjuvant chemoradiation, and current clinical staging approaches are limited in their ability to effectively stratify patients for treatment options. To improve the clinical risk assessment for ESCC patients, we developed an immunohistochemistry-based predictor model by evaluating the prognostic value of a three-gene signature, i.e. epidermal growth factor receptor, phosphorylated Specificity protein 1, and Fascin, which constitute a regulatory axis in ESCC cells as revealed by our previously study. The presence of this three-gene signature and the association with clinical outcomes were analyzed in 185 esophageal curative resection specimens (generation dataset), and the findings were validated using an independent cohort of 130 specimens (validation dataset). We revealed that the protein expression of this three-gene signature was highly predictive of ESCC survival in both generation and validation datasets (P=0.001). Regression analysis showed that this three-gene signature was an independently predictor of overall survival (hazard ratio=1.990 [95% CI, 1.256-3.154], P=0.003 in generation dataset; hazard ratio=2.358 [95% CI, 1.391-3.996], P=0.001 in validation dataset). Importantly, the predictive ability of the 3-gene signature was more robust than that of each individual factor. In conclusion, this immunohistochemistry-based molecular model accurately predicts ESCC patient survival, and thus could serve as a complement to current approached in clinical risk stratification.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2014-2205",
        "Doc_title":" A three-gene signature predicts esophageal squamous cell carcinoma prognosis",
        "_version_":1606189015573200896},
      {
        "Meeting_name":" ljm716, an anti her3 antibody that inhibits her3 dimerization, displays anti-tumor activity in esophageal squamous cell cancer",
        "Background":"['Background', ' Esophageal cancer is the eighth most common cancer and the sixth most common cause of cancer related death in the world. Squamous cell carcinoma is the predominant histologic subtype of esophageal cancer, particularly in Asia. Currently, no targeted therapy has been approved for treating this type of disease. Platinum-based combination chemotherapy remains to be the standard care for first line treatment of advanced or metastatic esophageal cancer with limited efficacy. Activation of EGFR/HER3/PI3K pathway is frequently observed in esophageal cancer, however, their therapeutic value remains to be further tested.Methods', ' In this study, we evaluated the anti-tumor activity of LJM716, a fully human anti-HER3 antibody, either alone or in combination with anti-EGFR antibody cetuximab or PI3K alpha subunit inhibitor BYL719 in esophageal squamous cancer. LJM716, cetuximab and BYL719 single agent as well as their pair-wised combination activity were assessed in 24 esophageal squamous cancer cell (ESCC) lines using the CellTiter-Glo Luminescent Cell Viability Assay. Single agent and combination anti-tumor activities of these reagents were also tested in selected cell line xenograft and patient derived xenograft mouse models.Results', ' NRG1 expression (60%), PIK3CA mutation (8%), moderate PIK3CA (30%) and EGFR (30%) amplification were detected in a panel of 24 ESCC lines. Anti-HER3 antibody LJM716 potently inhibited HER3 phosphorylation and decreased pAKT level in these cell lines. In vitro, LJM716 inhibited proliferation of a sub-set of ESCC lines. LJM716 further enhanced and broadened the anti-tumor activities of both BYL719 and cetuximab in ESCC lines. In mouse xenograft models, LJM716 single agent treatment induced tumor stasis while combination with either BYL719 or cetuximab induced model dependent tumor regression.Conclusion', ' NRG1-HER3-PI3K pathway activation is commonly observed in esophageal squamous cell cancer. Activation of HER3 is a potential mechanism leading to resistance to EGFR or PI3K targeted therapies, and combining anti-HER3 therapies with therapies targeting PI3K/EGFR may provide new therapeutic strategy for patients with esophageal squamous cell cancer.']",
        "Doc_id":"AACR_2014-2612",
        "Doc_title":" ljm716, an anti her3 antibody that inhibits her3 dimerization, displays anti-tumor activity in esophageal squamous cell cancer",
        "_version_":1606189032495120384},
      {
        "Meeting_name":" Immune dysfunction and fungal infection contribute to esophageal carcinogenesis.",
        "Background":"['Human esophageal cancer is the sixth leading cause of cancer death worldwide. More than 90% of esophageal cancer is esophageal squamous cell carcinoma (ESCC). While the etiological causes remain unclear, esophageal mucosal fungal infection is very common in esophageal cancer patients, including patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) who have more than 20-fold risk of ESCC when compared to the healthy population. Here, we report that kinase-dead Ikka knock-in mice (hereafter referred to as mutant mice) develop APECED-like autoimmune disease due to developmental defects in thymus and lack of central tolerance. Similar to human APECED patients who develop esophageal mucosal fungal infection on average at the age of five, mutant mice develop fungal infection in oral cavity and esophagus as early as seven weeks old. About 20% of mutant mice develop ESCC during aging, which exhibits specific molecular signatures observed in human ESCC, such as p16 gene silencing, elevated EGFR phosphorylation and PD-L1 expression, etc. Autoreactive T cell depletion, or central tolerance reconstitution and/or normal T cell transfer prevents fungal infection and ESCC development in mutant mice. Importantly, antifungal drug treatment inhibits inflammation and ESCC development in mutant mice. However, oral inoculation of Clasdosporium, one of the major fungal species isolated from mutant mice, increases the tumor incidence from 20% to 63% in mutant mice. These results reveal that immune dysfunction and fungal infection is associated with ESCC development, which sheds new light on ESCC etiological factors, prevention and treatment.']",
        "Doc_id":"AACR_2017-4802",
        "Doc_title":" Immune dysfunction and fungal infection contribute to esophageal carcinogenesis.",
        "_version_":1606188975841607680},
      {
        "Meeting_name":" A phase II single-arm pilot study of second-line icotinib treatment in advanced esophageal cancer with EGFR over-expression or amplification.",
        "Background":"['Background', '    Epidermal growth factor receptor (EGFR) has been reported to be overexpressed in esophageal cancer, suggesting EGFR-directed treatment is a potential option. Here we report the antitumor activities of icotinib, a selective EGFR tyrosine kinase inhibitor (TKI), as second-line treatment for advanced esophageal cancer with EGFR over-expression or amplification. Methods', '    In this phase II, single-arm study, eligible patients were adults with advanced esophageal cancer confirmed by histology, who had received at least first-line chemotherapy, with EGFR over-expression [immunohistochemistry (IHC), 3+] or amplification [positive fluorescence in-situ hybridisation (FISH)]. Participants were treated with oral icotinib (250 mg, three times daily).The primary endpoint was objective response rate (ORR).  Results', '    Between December, 2013 and January, 2015, 38 patients were enrolled (37 with squamous cell carcinoma, 1 with adenocarcinoma) with a median age of 60, in which 36 were IHC 3+ (94.7%) and 2 were IHC 2+ with positive FISH. And as of the December 31, 2014 cutoff, 33 patients were evaluable for response. The ORR was 15.2% (5/33), consisting of 1 CR and 4 PRs, and the disease control rate was 54.5% (18/33). The median duration of treatment in 18 patients (CR + PR + SD) is 12.3 weeks with the longest being 28+ weeks. Twenty-three out of 33 patients (69.7%) experienced at least one adverse event (AE) with rash (42.4%), diarrhea (24.2%), pain (21.2%), fatigue (15.2%) and vomiting (12.1%) as the most common ones. Most AEs were mild and reversible and no grade 3 or 4 AEs were reported.  Conclusions', '    Second-line icotinib treatment in advanced esophageal cancer with EGFR over-expression or amplification demonstrated favorable outcome along with a high safety profile. However, the role of EGFR over-expression or amplification as predictive biomarker still needs further exploration. Clinical trial information', ' NCT01855854.  Clinical trial information', ' NCT01855854.']",
        "Doc_id":"ASCO_147457-156",
        "Doc_title":" A phase II single-arm pilot study of second-line icotinib treatment in advanced esophageal cancer with EGFR over-expression or amplification.",
        "_version_":1606188986874724353},
      {
        "Meeting_name":" Gene amplification of EGFR, HER2, HER3 and HER4 in esophageal squamous cell carcinoma",
        "Background":"['Overexpression of epidermal growth factor receptor (EGFR) and its family members HER2, HER3 and HER4 are found in a variety of human malignancies and their roles in cancer development and progression has been widely recognized for long time. Molecular drugs targeting EGFR family, such as small-molecule inhibitors and specific monoclonal antibodies, are now under intensive investigation in clinical setting. In esophageal squamous cell carcinoma (ESCC), EGFR and HER2 are frequently overexpressed and their poor prognostic impacts have been reported to date. However, there is no study evaluating gene amplification of EGFR, HER2, HER3 and HER4 simultaneously in ESCC in a large cohort. We examined gene amplification of EGFR, HER2, HER3 and HER4 using realtime PCR-based copy number assay on 196 surgical specimens of formalin-fixed, paraffin-embedded (FFPE) samples. Gene amplification of EGFR and HER2 (copy number > 4) was observed in 7 % and 11%, respectively. Although the copy numbers were relatively low, we found gene amplification of HER3 and HER4 to be observed in 8% and 7%, respectively. Gene amplification at least one or more genes was observed in 23 % (45/196) of ESCC samples. Overlapping gene amplification was identified in 8 % (15/196) of samples. In relation with clinical characteristics, gene amplification of HER2 and HER4 was significantly involved in shorter relapse-free survivals in stage III ESCC. In conclusion, gene amplification of EGFR family was frequently observed in ESCC and PCR-based copy number assay could be a powerful tool for detecting gene amplification using FFPE samples. Our results strongly encourage the development of EGFR family-targeted therapy for ESCC with gene amplification.']",
        "Doc_id":"AACR_2012-4",
        "Doc_title":" Gene amplification of EGFR, HER2, HER3 and HER4 in esophageal squamous cell carcinoma",
        "_version_":1606188998679592960},
      {
        "Meeting_name":" Preclinical efficacy of Sym004, novel anti-EGFR antibody, in esophageal squamous cell carcinoma cell lines",
        "Background":"['Background', ' Epidermal growth factor receptor (EGFR) is a well-validated oncology target molecule for monoclonal antibody therapies. Sym004 is a novel anti-EGFR antibody mixture that consists of two recombinant IgG1 antibodies against domain III of the EGFR. The primary mechanism of action of Sym004 is thought to be EGFR cross-linking, internalization and degradation of the EGFR from the cell surface. EGFR is highly expressed in the overwhelming majority of esophageal squamous cell carcinoma (ESCC). We, therefore, investigated the effect of Sym004 in human ESCC cell lines in the present study.Method', ' In this preclinical study, approximately 50 ESCC cell lines and 3 kinds of anti-EGFR antibodies (Sym004, cetuximab, and panitumumab) were used. According to protein expression status and gene mutation status analyzed by Western blotting and next generation sequencing, these ESCC cell lines were classified into several groups. High EGFR-expressing cell lines were used for further investigations. Internalization of anti-EGFR antibodies into ESCC cells and inhibition of the EGFR signaling cascade by anti-EGFR antibodies were studied in in vitro experiments. Growth inhibitions by anti-EGFR antibody treatment were investigated in in vitro and in vivo experiments. The present preclinical studies were conducted at the National Cancer Center East Japan as collaborative studies with Merck Serono.Result', ' Even though protein expression of EGFR was detected in all ESCC cell lines, a variety of the expression levels were seen among the cell lines consistent with the previous data of clinical specimens. In addition, following gene alterations were found', ' EGFR amplification, Ras mutation, and PIK3CA mutation, and their frequency was 17% (8/48), 6.3% (3/48) and 8.3% (4/48), respectively. More effective internalization of Sym004 was observed than cetuximab and panitumumab in the high EGFR-expression cell lines. In a growth inhibition assay, more potent anti-proliferative activity of Sym004 was observed than those of other anti-EGFR antibodies in some cell lines. No obvious correlation between EGFR expression and the anti-proliferative activity was observed, although cell lines with higher EGFR expression showed a trend toward higher sensitivity to Sym004. In vivo xenograft studies of Sym004 using human ESCC cell lines are currently underway and will be presented in the annual meeting.Conclusions', ' These studies showed that Sym004 exhibited antitumor activity in some ESCC cell lines in preclinical settings, and are expected to provide a scientific rationale along with a possible clinical indication of ESCC in clinical setting.']",
        "Doc_id":"AACR_2015-1669",
        "Doc_title":" Preclinical efficacy of Sym004, novel anti-EGFR antibody, in esophageal squamous cell carcinoma cell lines",
        "_version_":1606189013500166144},
      {
        "Meeting_name":" Nimotuzumab in combination with preoperative concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma",
        "Background":"['Background', '   Preoperative chemoradiotherapy is an accepted standard treatment for patients with locally advanced esophageal cancer. Nimotuzumab is a monoclonal antihuman EGFR IgG1 antibody that has demonstrated synergistic activity with both radiotherapy and platinum-based chemotherapy in some solid tumors. The aim of this study is to investigate the safety and efficacy of nimotuzumab in combination with preoperative concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (ESCC). Methods', '   Previously untreated patients with stage II-III ESCC received nimotuzumab (200mg per week in weeks1-5), paclitaxel(45 mg/m2 per week in weeks 2-5), cisplatin(20 mg/m2 per week in weeks 2-5) and radiotherapy at a total dose of 40 Gy (2.0Gy/d,5 days per week in weeks 2-5). Esophagectomy was performed 4 weeks after the completion of preoperative strategies. Results', '   Eighteen eligible patients were enrolled. All patients completed the preoperative regimen, and seventeen patients underwent surgery. The clinical response rate was 94.4% (17/18). The most frequent Grade 1/2 toxicities were esophagitis(12/17), leukocytopenia(14/17), nausea/vomiting(8/17) and fatigue(4/17). Grade 3 leukocytopenia was observed in 11.8 % of patients (3/17). The rate of radical resection was 100%, and the pathological complete response rate was 41.2%(7/17). Downstaging occurred in 15/17 (88.2 %) patients by T stage and 8/17 (47.1%) by N stage. The incidences of postoperative anastomotic leak, pulmonary infection, hoarseness and arrhythmia were 11.8%, 11.8%, 5.9%, and 5.9%, respectively. No perioperative deaths occurred in the study. Conclusions', '  The regimen of nimotuzumab in combination with preoperative concurrent chemoradiotherapy is safe for locally advanced ESCC. The preoperative strategy is able to achieve substantially high clinical response rate and pathological complete response rate.']",
        "Doc_id":"ASCO_159004-173",
        "Doc_title":" Nimotuzumab in combination with preoperative concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma",
        "_version_":1606188993808957441},
      {
        "Meeting_name":" Nimotuzumab plus paclitaxel and cisplatin as 1st line treatment for unresectable esophageal squamous cell carcinoma",
        "Background":"['Background', ' The role of anti-epidermal growth factor receptor (EGFR) targeting treatment in esophageal squamous cell carcinoma (ESCC) is still uncertain. We conducted a prospective phase 2 study of paclitaxel, cisplatin, and nimotuzumab (TPN) as first-line treatment in unresectable or metastatic ESCC (NCT01336049). The objective response rate was 51.8%. Here we reported long-term follow-up results of that initial trial. Methods', ' 59 patients were enrolled from Mar 2011 to Apr 2013 and treated with the TPN regimen (nimotuzumab 200mg weekly, paclitaxel 175mg/m2 on day1, and cisplatin 30mg/m2 on day1 and 2, repeat every 3 weeks for total six cycles). Patients were allowed to receive sequential radiotherapy in case of local-regional disease or controlling symptom. Results', ' 56 of 59 patients were eligible for evaluation. After a median follow-up of 32.2months, the median progression-free survival (PFS) and overall survival (OS) were 18.14.2 months (95% Confidence', ' 9.8-26.4) and 26.210.0 months (95% Confidence', ' 6.6-45.8) in 29 patients with unresectable local-regional disease, while those were 6.60.4 months (95% Confidence', ' 5.8-7.5) and 11.53.7 months (95% Confidence', ' 4.2-18.8) respectively in 27 patients with metastatic disease. Patients of male, with multiple lymph node station metastasis, visceral metastasis, no response to TPN treatment, and without radiotherapy had worse OS. Even in some patients with multiple stations lymph node metastasis or recurrent disease of local-regional lymph node metastasis, TPN with sequential radiation seemed could bring longer survival time. But multivariate cox-regression analysis only confirmed that the TPN treatment was associations with OS. Compared with those of complete and partial response, patients of stable disease and progression had poor OS (HR = 2.32, 95% CI', ' 1.03-5.05, p = 0.03). Conclusions', ' the combination of nimotuzumab, paclitaxel, and cisplatin is effective as first-line treatment for patients with unresectable and metastatic ESCC, especially those with sequential radiotherapy. Clinical trial information', ' NCT01336049']",
        "Doc_id":"ASCO_188895-199",
        "Doc_title":" Nimotuzumab plus paclitaxel and cisplatin as 1st line treatment for unresectable esophageal squamous cell carcinoma",
        "_version_":1606188998695321600},
      {
        "Meeting_name":" Comprehensive genomic profiling (CGP) of esophageal and tubular GI tumors to identify frequencies of ErbB family member amplification with therapeutic implications.",
        "Background":"['Background', ' As described in the MyPathway study, amplification and other mutations in ErbB-family proteins are actionable events across solid tumors. Targeting ERBB2 amplifications (amp) in tubular GI cancers (TGC) improves patient outcomes. ErbB family comparisons across anatomic sites is lacking and here we describe the largest known series in TGC. Methods', ' DNA was extracted from 12,685 FFPE clinical TGC specimens, including 1,720 esophageal CA*. CGP was performed on hybrid-capture, adaptor ligation based libraries to a mean coverage depth of 720X for up to 315 genes plus 47 introns from 19 genes frequently rearranged in cancer. Results', ' Across all TGC cases, amp was the most frequent genomic alteration among ErbB members at 8.7%. ERBB2 amp was 2.3x as common as EGFR amp across TGC. Across TGC sites, EGFR amp was most frequent in esophageal SCC (13.7%) and ERBB2 amp was most common in gastroesophageal junction adenoCA (21%) compared with overall frequencies of 2.7% and 5.5% respectively. ERBB3 and ERBB4 amp were rare, and most common in gastroesophageal adenoCA relative to other TGC. Clinical support with outcomes for patients treated with anti-ErbB targeted therapy across TGC will be presented, including profiling from cases of acquired resistance to anti-ErbB targeted therapy. Conclusions', ' Among TGC, esophageal CA harbored the most ErbB family member amp with variation by histology. Profiling across ErbB proteins in TGC suggests biologic differences and may affect response to treatment. CGP can expand the population who may benefit from anti-ErbB directed therapies and refine treatment choices. Further research is warranted. Disease CategoryEGFR ampERBB2 ampERBB3 ampERBB4 ampEsophagus SCC13.7% (28/203)2.5% (5/203)0.49% (1/203)0.00% (0/203)Gastroesophageal junction adenoCA8.7% (126/1,455)21% (306/1,455)1.7% (25/1,455)0.34% (5/1,455)All esophageal tumor types9.1% (157/1,720)18% (313/1,720)1.5% (26/1,720)0.29% (5/1,720)Colon/rectum adenoCA1.55% (132/8,486)3.24% (275/8,486)0.02% (2/8,486)0.07% (6/8,486)All GI CA2.7% (343/12,685)5.5% (700/12,685)0.36% (46/12,685)0.10% (13/12,685)*CA = Carcinoma']",
        "Doc_id":"ASCO_177144-195",
        "Doc_title":" Comprehensive genomic profiling (CGP) of esophageal and tubular GI tumors to identify frequencies of ErbB family member amplification with therapeutic implications.",
        "_version_":1606189041150066688},
      {
        "Meeting_name":" Clonal evolution in noncancerous esophageal mucosa in normal and cancer-bearing individuals",
        "Background":"['BackgroundEsophageal squamous cell carcinoma (ESCC) represents the most common form of esophageal cancer worldwide, especially in East Asia, where alcohol drinking and smoking have been implicated in the field carcinogenesis of ESCC. However, the oncogenic process therein has been poorly understood in terms of gene mutations.Patients & MethodsA total of 100 samples, including cancer, dysplastic, and non-dysplastic esophageal tissues, were obtained from 24 individual with (N = 14) or without (N = 10) ESCC (a median of 2.5 samples per case', ' 129) either by endoscopy or surgery and were subjected to whole exome sequencing (WES). An additional paired cancer/non-caner samples from 32 patients was analyzed by targeted sequencing (TS). All samples were analyzed for copy number alterations (CNAs) using SNP array- and/or digital sequencing-based karyotyping.ResultsIn WES, clonal evolution in esophageal epithelia, as determined by the presence of somatic mutations, was detected in 21 of 21 cancer, 12 of 12 dysplastic, and 63 of 67 non-dysplastic samples, where the mean number of mutation per sample showed a significant trend to increase in cancer (65) and dysplastic samples (50) compared to non-dysplastic samples (13) (P = 2.110-11). CNAs, especially those involving CDKN2A, CCND1, YAP1, and EGFR, were frequently affected in cancer samples, but rarely so in non-dysplastic samples. Non-dysplastic samples tended to have smaller allelic burden and therefore, clone size, compared to dysplastic and cancer samples (P = 2.210-16). Mutations had a predominant age-related signature in non-dysplastic samples but increasing APOBEC3A/3B patterns was observed in cancer and dysplastic samples. Shared mutations were found only within cancer tissues but never among dysplastic or non-dysplastic samples, suggesting the latter lesions are clonally independent from each other. In accordance with previous reports, TP53 mutations were found in 21/21 cancer samples and also found in dysplastic (11/12) and non-dysplastic samples at a lower frequency (26/67). Strikingly, non-dysplastic samples harbored a very high frequency of NOTCH1 mutations (51/67), which were also found in cancer (3/21) and non-dysplastic (8/12) samples but at much lower frequencies (P = 6.610-7). TS of validation samples confirmed the trend of higher NOTCH1 (84% vs. 25%) and lower TP53 mutation rates (38% vs. 100%) in non-dysplastic samples compared to cancer samples. The number of mutations in non-dysplastic samples was higher in drinkers than non-drinkers. Multiple NOTCH1 mutations were more common in cancer patients and drinkers than non-drinkers.ConclusionClonal proliferation in non-cancer esophageal epithelia is common even in non-ESCC cases and extensive in ESCC cases. NOTCH1 and TP53 mutations play major roles in clonal evolution in common but may have differential impacts on esophageal carcinogenesis, which is likely to be shaped by APOBEC-induced mutations and CNAs.']",
        "Doc_id":"AACR_2016-164",
        "Doc_title":" Clonal evolution in noncancerous esophageal mucosa in normal and cancer-bearing individuals",
        "_version_":1606188984062443520},
      {
        "Meeting_name":" Phase II study of irinotecan plus panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma (EAC).",
        "Background":"['Background', ' Esophageal carcinoma is highly lethal and the incidence is increasing, especially the subtype of EAC. Our group demonstrated that overexpression of the epidermal growth factor receptor (EGFR) correlates with lower survival in EAC. Panitumumab (P) is a high affinity fully human IgG2 monoclonal antibody directed against human EGFR. Cetuximab combined with irinotecan (I) is effective for second-line treatment of advanced colorectal cancer (CRC). P alone is active in EGFR expressing CRC. Our group has empiric evidence for the activity of cetuximab + I. As such, we composed this phase II study of P + I as second-line therapy for advanced EAC. Methods', ' The primary endpoint is overall response (OR) as measured by RECIST (imaging every 2 cycles). Secondary endpoints include overall survival, safety/toxicity and correlative studies. Patients with a history of one prior treatment will be treated with P 9 mg/m2 on day 1 and I 125 mg/m2 on days 1 and 8 of each 21 day cycle to a maximum of 6 cycles. Inclusion criteria include confirmed EAC, measurable disease, no prior I or P, PS <2 and normal organ function. Exclusion criteria include use of CYP 3A4 inhibitors, prior anti-EGFR therapy, uncontrolled intercurrent illness. A Simon two-stage design uses power of 80% and a type I error of 0.05. 18 patients will be tested in the first stage, and the trial will be terminated if 2 or fewer respond. In the second stage, a total of 43 patients will be studied. Correlative Studies', ' Research blood and tissue will be obtained pre-treatment and during the third week of cycle 2. Blood will be studied for the role of FcgR receptors on the effector cell surface leading to antibody-directed cellular cytotoxicity. Tumor tissues will be analyzed for pharmacodynamic (PD) and pharmacogenomic (PG) effects by measurement of EGFR pathway components using FISH and IHC and by kras mutation analysis. Enrollment', ' The study recently opened at UPMC, and two patients are enrolled. Significance', ' Along with the primary endpoint of OR, the goal of this trial is to utilize sequential tumor and blood sampling to study PD and PG correlates. The goal is to improve patient selection for targeted therapies in future trials.']",
        "Doc_id":"ASCO_49136-74",
        "Doc_title":" Phase II study of irinotecan plus panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma (EAC).",
        "_version_":1606188993090682880},
      {
        "Meeting_name":" Molecular imaging of human esophageal cancer for early detection.",
        "Background":"['Esophageal cancer was the sixth common cancer for incidence and ranks fourth for death rate in China, and squamous cell carcinoma is the main histological type. It is usually in an advanced stage at the time of diagnosis, resulting in an overall 5-year survival rate of <15%. Early detection can lead to an improvement in patient outcomes but is limited by nonspecific contrast mechanisms. As all we know, antibody and peptides establish a biological basis for image contrast, which could achieve sufficient target-to-background ratio for in vivo detection. In this paper, an EGFR antibody (Cetuximab) conjugated with an NIR dye (NIRDye800) was used for early detection of esophageal cancer. We demonstrated our technology could identify esophageal cancer in small size (<1 mm) and high-grade dysplasia from low-grade dysplasia. And 4.2-fold greater fluorescence intensity for esophageal cancer compared with surrounding normal esophageal tissues. No toxicity was observed in our experiments. The result indicated that this targeted, antibody-based imaging agents have great potential in early detection of esophageal cancer and other epidermal cancer.']",
        "Doc_id":"AACR_2017-1868",
        "Doc_title":" Molecular imaging of human esophageal cancer for early detection.",
        "_version_":1606188978719948800},
      {
        "Meeting_name":" Screening for somatic mutations in esophageal squamous cell carcinoma using OncoMap 4.0.",
        "Background":"['Background', '     Analysis of gene mutations in tumor specimens is essential to treat cancers with molecular target agents. Given the high incidence of metastatic esophageal squamous cell carcinoma in East Asia, we screened for the presence of somatic mutations using OncoMap 4.0 with the aim of establishing novel treatment strategy.  Methods', '     We analyzed 87 tissue specimens obtained from 80 patients who were pathologically confirmed of esophageal squamous cell carcinoma and received 5-fluoropyrimidine/platinum-based chemotherapy. OncoMap 4.0 is designed to interrogate >700 mutations in 113 genes. Tumor specimens were prepared from primary cancer sites in 70 patients and from metastatic sites in 17 patients. In order to test the concordance between primary and metastatic sites from the patient for mutations, we analyzed 7 paired (primary-metastatic) specimens. All specimens were formalin-fixed paraffin embedded tissues and tumor content was > 70%.  Results', '     In total, we have detected 23 mutations out of 87 specimens tested. The most frequent mutation was PIK3CA mutation (four E545K, five H1047R and one H1047L) (N=10, 11.5%) followed by MLH1 V384D (N=7,8.0%), TP53(R306, R175H and R273C)(N=3, 3.5%), BRAF V600E (N=1, 1.2%), CTNNB1 D32N (N=1, 1.2%), and EGFR P733L (N=1, 1.2%). Distributions of somatic mutations were not different according to anatomic sites of esophageal cancer (cervical/upper, mid, lower). In addition, there was no difference in mutations between primary-metastasis paired samples.  Conclusions', '    PIK3CA and BRAF mutations can be new targets for novel molecular agents to treat esophageal squamous cell carcinoma.']",
        "Doc_id":"ASCO_88903-115",
        "Doc_title":" Screening for somatic mutations in esophageal squamous cell carcinoma using OncoMap 4.0.",
        "_version_":1606188973801078785},
      {
        "Meeting_name":" Neoadjuvant chemoradiotherapy with 5-fluorouracil-cisplatin combined with cetuximab in patients with resectable locally advanced esophageal carcinoma",
        "Background":"['Background', '  Chemoradiotherapy (CRT) for locally advanced esophageal cancer is based on 5FU combined with cisplatin. The anti-EGFR antibody cetuximab increases the efficacy of RT-based regimen for patients (pts) with cancer of the head and neck. This phase I/II trial was evaluating MTD, safety and pathologic complete response (pCR) rate of the combination of cetuximab with platinum-based CRT in esophageal cancer.  Methods', '  Inclusion criteria', ' squamous cell carcinoma or adenocarcinoma of the esophagus, stage II-III, WHO PS 0-1. A radiotherapy of 45 grays (1.8 Gy/25F) was given over 5 weeks. During phase I, four patients experienced limited toxicity to dose level 0, and treatment was desescalated to dose level -1', ' weekly cetuximab (400 mg/m2 one week before start of radiotherapy and 250 mg/m2 during radiotherapy), and 5 FU (500 mg/m2 per day D1-D4) combined with cisplatin (40 mg/m2 D1) on week 1 and 5. Nine pCR over 27 resections were needed to show a pCR rate>20% (=5%, power = 90% ). Thirty three patients were included in the phase II.  Results', '  From 07-2007 to 01-2011, 33 pts were enrolled, 20 squamous cell carcinoma (60.6%), 13 adenocarcinoma (39.4%), 25 (75.8%) stage III and 8 (24.2%) stage II. Among 32 pts who received CRT, the main grade 3-4 toxicities were esophagitis (4 pts), leucopenia (1 pt), anaphylaxis reaction (1 pt), rash (1 pt). Resection was achieved in 27 pts (25 R0)/31 who underwent surgery. Complete or near complete pathologic response (TRG grades 1 and 2 to Mandard) was achieved respectively in 5 (18.5%) and 6 (22.2%) pts. There were 4 deaths at 30 days post surgery. Severe postoperative complications were pulmonary complications (8), anastomotic stricture (4), gastric necrosis (1) and infection (7). The median overall survival was 15.7 months [11.01-.], and the median relapse free survival was 13.7 months [5.47-.].  Conclusions', '  Adding cetuximab to preoperative chemoradiotherapy including 5FU and cisplatin did not increase pCR. The recommended dose level of chemotherapy determined during phase I could explain those disappointing results. We wont initiate a phase III trial.']",
        "Doc_id":"ASCO_99779-114",
        "Doc_title":" Neoadjuvant chemoradiotherapy with 5-fluorouracil-cisplatin combined with cetuximab in patients with resectable locally advanced esophageal carcinoma",
        "_version_":1606189003775672320},
      {
        "Meeting_name":" Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors.",
        "Background":"['Background', ' Sym004 is a 1', '1 mixture of two chimeric IgG1 antibodies targeting non-overlapping epitopes of the epidermal growth factor receptor (EGFR). Binding of both antibodies to EGFR leads to its internalization and degradation. The resulting down-regulation of EGFR results in antitumor activity that is superior to that of cetuximab and panitumumab in preclinical models; Sym004 can also overcome acquired resistance to cetuximab in vivo. We have evaluated the safety of Sym004 in Japanese patients (pts) with advanced solid tumors. Methods', ' Japanese adults aged  20 years with refractory or recurrent late-stage solid tumors, ECOG status of 0 or 1, and life expectancy of at least 3 months were eligible for the dose-escalation part of the trial (Part A). Sym004 doses tested were 6 mg/kg weekly (n = 3+3), 9 mg/kg loading dose followed by 6 mg/kg weekly (n = 6), 12 mg/kg weekly (n = 6), and 18 mg/kg q2w (n = 6). An expansion cohort of pts with esophageal squamous cell carcinoma (ESCC) (Part B) was enrolled at the Sym004 dose recommended based on part A. The primary objective was the safety and tolerability of Sym004 in Japanese pts. Secondary objectives included antitumor activity and pharmacokinetics. Results', ' 51 pts were treated (male/female', ' 39/12; median age 62 [40-73] years; ECOG performance status 0/1', ' 32/19). No dose-limiting toxicities were observed in Part A. A Sym004 dose of 12 mg/kg weekly was selected for use in Part B (n = 30). Pts in Part B received a median of 7 weeks of Sym004 therapy. All Part B pts had treatment-related adverse events (AEs); 18 had grade  3 AEs and 5 had serious AEs (cardiac arrest, lung infection, interstitial lung disease, toxic skin eruption, blood creatinine increase). Two pts had treatment-related AEs resulting in death (cardiac arrest and blood creatinine increase). 5 pts had a best overall response of partial response, 12 stable disease, 12 disease progression (1 pt not evaluable). The objective response rate was 16.7% (95% CI', ' 5.634.7%). Conclusions', ' Sym004 therapy was well tolerated with no DLTs at any dose studied. Evidence of antitumor activity, with objective responses, was observed in the expansion cohort of pts with advanced ESCC. Clinical trial information', ' NCT01955473']",
        "Doc_id":"ASCO_166054-176",
        "Doc_title":" Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors.",
        "_version_":1606188992948076544},
      {
        "Meeting_name":" Functional analysis of family with sequence similarity 83, member B in lung adenocarcinoma",
        "Background":"['Background', 'We have reported the usefulness of Family with sequence similarity 83, member B (FAM83B) as a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma. FAM83B expresses not only in lung cancer but also in several types of solid cancer such as breast, esophageal, and so on. More recently, novel finding showing FAM83B involve to the resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in breast cancer cell lines has been shown. EGFR signaling pathway also plays an important role in lung adenocarcinoma, therefore we hypothesize that FAM83B associates to the tumor proliferation in lung adenocarcinoma, and its results in the resistance to EGFR TKI and in a novel therapeutic target in lung adenocarcinoma.Materials and methods', 'Sixty-four paired tumor and corresponding normal tissue samples obtained from patients with lung adenocarcinoma who underwent surgical resection since 2008 to 2011 were subjected. FAM83B mRNA expression were examined and analyzed relationship between the level of FAM83B and clinicopathological variables. Then, FAM83B knock down study was performed in several types of cancer cell lines (PC-14, H820, H1650, H1975, HLC-1, H2347) to understand whether FAM83B involve to cell proliferation.Results', 'Multivariate analysis show that smaller cancer(3cm vs >3cm, p = 0.044), and wild type EGFR(wild type vs. mutant, p = 0.004) tend to express higher FAM83B mRNA. There is no significant difference between FAM83B expression and progression-free survival. FAM83B knock down results in suppression of proliferation in HLC-1, H1650, which express high level of FAM83B protein.Conclusions', 'FAM83B could involve to tumor proliferation of lung adenocarcinoma in part, and could be the novel therapeutic target.']",
        "Doc_id":"AACR_2016-422",
        "Doc_title":" Functional analysis of family with sequence similarity 83, member B in lung adenocarcinoma",
        "_version_":1606189000974925824},
      {
        "Meeting_name":" Multicenter feasibility study of chemoradiation, trastuzumab and pertuzumab in resectable HER2+ esophageal carcinoma",
        "Background":"['Background', ' Despite multimodality treatment the outcome of esophageal adenocarcinoma (EAC) is poor. In EAC, human epidermal growth factor receptor 2 (HER2) is overexpressed in 19% to 43% of cases. Based on the positive results of the ToGA trial in metastatic esophagogastric cancer, HER2 targeting is currently investigated in patients treated with curative intent. Most patients, however, develop resistance to trastuzumab. Recent studies in breast cancer evaluating the effect of combined HER2/HER3 targeting with trastuzumab and pertuzumab showed improved efficacy. To explore if combined HER2 targeting added to multimodality treatment is feasible and has potential benefit in HER2 overexpressing resectable EAC, we are currently conducting the TRAP study. The primary objective is the feasibility of preoperative treatment with chemoradiation combined with pertuzumab and trastuzumab. Secondary objectives include', ' toxicity, surgery withdrawal rate, R0 resection rate, pathological reponse and pharmacokinetics. Methods', ' Patients with resectable EAC who are in a good clinical condition and considered operable are treated in one of the 9 participating centers with paclitaxel 50 mg/m2 and carboplatin AUC = 2 on days 1, 8, 15, 22 and 29. Trastuzumab is administered at a dose of 4 mg/kg on day 1, followed by 2 mg/kg at week 2-6. From week 7 onwards trastuzumab is dosed at 6 mg/kg every 3 weeks. Pertuzumab is administered on day 1, 22, 43, 64, and 85 using a fixed dose of 840 mg. Radiotherapy is delivered to a total dose of 41.4 Gy, starting the first day of chemotherapy. Surgical resection follows in week 14. Treatment with trastuzumab and pertuzumab during chemoradiation is regarded feasible if  80% of patients complete treatment. Primary analysis will be performed in all patients who received at least one dose of pertuzumab and/or trastuzumab. Currently, 21 of planned 40 patients have been enrolled. The data safety monitoring board did not find any safety concerns after the first 10 operated patients. Clinical trial information', ' NCT02120911']",
        "Doc_id":"ASCO_167707-176",
        "Doc_title":" Multicenter feasibility study of chemoradiation, trastuzumab and pertuzumab in resectable HER2+ esophageal carcinoma",
        "_version_":1606189002996580352},
      {
        "Meeting_name":" Phase II study of panitumumab plus irinotecan as second-line therapy for advanced esophageal adenocarcinoma",
        "Background":"['Background', ' Esophageal adenocarcinoma (EAC) is a lethal cancer, and the incidence is increasing. Our group demonstrated that over-expression of the epidermal growth factor receptor (EGFR) correlated with reduced survival in EAC. Panitumumab (P) is a fully human IgG2 monoclonal antibody against human EGFR. Cetuximab combined with irinotecan (I) has shown activity for second-line treatment of advanced colorectal cancer (CRC). P alone is active in EGFR expressing CRC as well. Our group has empiric evidence for the activity of cetuximab + I as third-line treatment for advanced EAC. As such, a phase II study was designed to evaluate P + I as second-line therapy for advanced EAC. Trial Design', ' The primary endpoint is overall response (OR) as measured by RECIST (cross-sectional imaging every 2 cycles). Secondary endpoints include overall survival, safety/toxicity and correlative studies. Patients with confirmed EAC with history of one prior treatment are treated with P 9 mg/m2 on day 1 and I 125 mg/m2 on days 1 and 8 of each 21 day cycle to a maximum of 6 cycles. Inclusion criteria include confirmed EAC, measurable disease, no prior I or P, PS <2 and normal organ function. A Simon two-stage design is used with power of 80% and a type I error of 0.05. 18 patients will be tested in the first stage and will terminate the trial if 2 or fewer respond. A total of 43 patients will be studied. Blood and tissue are obtained to analyse the role of FC-R receptors as well EGFR pathway components and kras mutations. Enrollment', ' The 1st patient was enrolled in May 2009. Through August 2011, 7 patients received treatment. Preliminary results', ' Of the 7 patients treated, all are white males, median age 62. 2 patients completed 6 cycles. 1 patient received 3 cycles, 3 received 2 cycles and 1 patient completed 1 cycle. 3 patients are still alive. However, only 1 patient is still in the trial. 4 patients received dose reductions due to grade 3 or 4 side effects, including GI disturbances (5), fatigue(1), skin rash(1), electrolyte imbalances(2) and hematologic abnormalities (5). Reasons for discontinuation included progressive disease (PD, 5 patients) and patient refusal (2). The longest survival was 338 days1 of the 2 patients who completed 6 cycles. The second patient who completed 6 cycles is alive at 307 days. 1 patient completed 3 cycles and survived 213 days after PD. 1 patient survived 174 days followed PD after 2 cycles. 2 patients completed 2 cycles and are still alive, surviving 151 (pt refusal) and 103 days respectively. The shortest survival was 85 days who completed only 1 cycle. Conclusion', ' Preliminary data from this Phase II trial suggests that patients with advanced EAC might benefit from P+I regimen as 2nd line therapy. 3 additional centers will open the trial. Accrual is ongoing, and correlative studies will follow. This project used the University of Pittsburgh Cancer Institute and was supported in part by award P30CA047904']",
        "Doc_id":"AACR_2012-3708",
        "Doc_title":" Phase II study of panitumumab plus irinotecan as second-line therapy for advanced esophageal adenocarcinoma",
        "_version_":1606188979024035840},
      {
        "Meeting_name":" The role of autocrine epidermal growth factor receptor (EGFR) signaling in breast cancer metastasis",
        "Background":"['The majority of breast cancer deaths are due to the development of metastatic disease. The metastatic cascade consists of a series of steps and includes primary tumor growth and angiogenesis, invasion, intravasation, cell survival in circulation, extravasation and sustained growth at secondary organ sites to form micrometastases. Previous studies have shown that overexpression of the epidermal growth factor receptor (EGFR; ErbB1; Her1) increases tumor cell motility, intravasation and motility. In addition, it has been demonstrated that the metastatic potential of cancer cells depends not only on their intrinsic characteristics but also on their cooperative interaction with the tumor microenvironment. For instance, imposed gradients of EGF or colony-stimulating factor-1 (CSF-1) can stimulate invasion via an EGF/CSF-1 paracrine loop between tumor cells and macrophages. Because breast malignancies exhibiting increased expression of the epidermal growth factor (EGF) family of receptors and their cognate ligands are associated with more biologically aggressive disease and poorer patient prognosis, we decided to study how expression of certain members of the EGF family of ligands in the context of ErbB1 overexpression can affect the processes of invasion, intravasation and metastasis using in vitro and in vivo systems. Based on initial Oncomine cancer gene expression analysis, heparin-binding epidermal growth factor-like growth factor (HB-EGF) overexpression was correlated with more rapid recurrence of disease in breast cancer and thus, we decided to focus our study this ligand. Briefly, MTLn3 rat mammary adenocarcinoma cells and human MDA-MB 231 breast adenocarcimona cells were transduced to overexpress HB-EGF. HB-EGF expression did not significantly affect in vitro or in vivo growth rate. In vitro microchemotaxis and invasion assays to study chemotaxis and invasion, respectively, in the presence and absence of EGF, demonstrated that random motility and spontaneous invasion were both enhanced in the presence of HB-EGF expression. Interestingly, EGF-induced chemotaxis and EGF-induced in vivo invasion were both suppressed. In vivo studies show that tumor cells expressing HB-EGF not only display increased metastasis to the lungs and extravasation from circulation, but also significantly enhanced macrophage recruitment and exerted an angiogenic effect. These findings suggest that a better understanding of the role of HB-EGF in breast cancer will aid in directing and modifying therapeutic approaches aimed at inactivating the ErbB ligand/EGFR system as well as developing approaches based on the EGF family of ligands as a target for the clinical treatment of breast cancer, ultimately leading to improved patient survival.']",
        "Doc_id":"AACR_2012-38",
        "Doc_title":" The role of autocrine epidermal growth factor receptor (EGFR) signaling in breast cancer metastasis",
        "_version_":1606188990785912832},
      {
        "Meeting_name":" A phase I evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advanced cancer of the esophagus and GE junction.",
        "Background":"['Background', '  Vandetanib (Vb) is an oral inhibitor that selectively targets VEGFR2, VEGFR3, RET and EGFR. Preclinical models indicate synergy with radiation and chemotherapy. We report the final results from an open-label phase I study of pre-operative Vb with carboplatin, paclitaxel, 5FU and radiation in pts with operable esophageal and GE junction (GEJ) carcinomas.  Methods', '  Pts with operable PET/CT and EUS-staged carcinoma of the esophagus and GEJ received once daily Vb with concomitant RT (1.8 Gy/d, total 45 Gy) plus carboplatin AUC5 (d1 and 29), paclitaxel (50 mg/m2, d1,8,15,22,29), and 5-FU (CI 225 mg/m2, M-F, 5 wks). The primary objective was the safety, tolerability and the maximum tolerated dose of Vb  in this combination. Planned dose escalations of Vb', ' 100, 200 and 300 mg daily with a 3+3 design.  Results', '  Nine male pts (median age 58 (35-77), stage II, T2-3N0 (2 pts), III, T2-3N+ (7 pts)) were accrued between 03/2009 and 08/2010 at Fox Chase Cancer Center', ' 2/9 pts had esophageal squamous carcinoma (SCC) and 7/9 pts had adenocarcinoma including GEJ (2 pts). All patients completed the planned induction chemoradiation and underwent esophagectomy with curative intent. Of 3 initial pts at Vb 100 mg, one with SCC died on day 99 from GI hemorrhage which was considered treatment-related. Three more pts received Vb 100 mg and 3 pts received Vb 200 mg daily. Dose limiting toxicities (DLT) occurred in 2/3 pts receiving Vb 200 mg (esophago-gastric anastomotic leak, and diarrhea requiring Vb dose reduction). Grade 3 non-hematological toxicities included diarrhea (2), anorexia (1), abdominal pain (1), hyponatremia (1), AST/ALT (1), depression (1). Dose escalation to 300 mg Vb was not attempted. 5/9 pts had a pathologic complete response (no tumor seen, 56%), 5/9 remain disease free with median followup of 23 months (13-31). 3 pts had distant recurrences at 322, 334 and 561 days.  Conclusions', '  Targeting VEGFR/RET/EGFR with Vb at 100 mg daily in combination with induction chemoradiotherapy for operable esophageal and GEJ cancer is well tolerated and with promising clinical activity warranting further phase II evaluation.']",
        "Doc_id":"ASCO_88642-115",
        "Doc_title":" A phase I evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advanced cancer of the esophagus and GE junction.",
        "_version_":1606189041004314624},
      {
        "Meeting_name":" A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC).",
        "Background":"['Background', ' Preoperative CRT improves the survival of pts with EC when compared with surgery alone. Epidermal growth factor receptor (EGFR) is overexpressed in 30-90% of EC and is associated with poor prognosis, providing the rationale for using the anti-EGFR monoclonal antibody cetuximab (C). The purpose of the study was to investigate the efficacy, toxicity and feasibility of C with FOLFOX- 4 regimen as induction CT followed by C and RT in pts with LAEC in a multicenter setting. Methods', ' Eligibility criteria', ' resectable, locally advanced (uT3 or uN1, T4 if deemed resectable) squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the esophagus; staged by EUS, CT and PET scan; age 18-70y; PS <2; normal organ functions.All pts received induction treatment with C at a starting dose of 400 mg/m2 and further weekly infusion at a maintenance dose of 250 mg/m2 and 4 cycles of FOLFOX-4 every two weeks. Post-induction EUS and CT scans were performed, while a PET scan was repeated early before second cycle of CT', ' pts without PD were given daily RT (180cGy fractions to 5040cGy) with concurrent weekly C. Post RT, EUS plus biopsies, CT scan and PET were performed. At wk 18, pts without PD had esophagectomy. Simons two stage design was used. Primary endpoint was histopathological response rate. Results', \" Up to December 2008, 40 pts, 30 men, were enrolled from 4 institutions; median age 59 y (35-70y); AC 12; SCC 28; stage II 15, stage III 25 pts. At this time 32/40 pts were evaluable. The most frequent grade 3/4 toxicity of chemoradiotherapy were skin (32%),neutropenia (29%) and esophagitis (9%); 10 pts had no resection (9 progressive disease,1 patient's refusal). Of 22 operated pts, 17 pts (77%) had RO-resection, 5 pts had palliative surgery.2 pts died due to complications after surgery (1 after > 30 days). The pathological response rate was 68 %, with a complete histopathological remission recorded in 6 pts (27%);17 pts (53%) are still alive without residual or recurrent disease. Conclusions\", ' The current findings suggest the feasibility of incorporating cetuximab into a preoperative regimen for LAEC pts and an encouraging antineoplastic activity with 68% histopathological responders.']",
        "Doc_id":"ASCO_31227-65",
        "Doc_title":" A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC).",
        "_version_":1606189020568616960},
      {
        "Meeting_name":" Phase III randomized study of elective nodal irradiation plus erlotinib combined with chemotherapy for esophageal squamous cell carcinoma.",
        "Background":"['Background', ' The addition of anti-EGFR therapy to chemoradiotherpay in the treatment of unresectable esophageal squamous cell carcinoma (ESCC) is not well defined, as well as the role of elective nodal irradiation (ENI). This phase III trial was designed to determine whether the addition of erlotinib and/or ENI to concurrent conventional chemoradiotherapy containing cisplatin/paclitaxel (CP) improved survival. Methods', ' This study was a 2x2 factorial design, with erlotinib and ENI as factors. We randomized Chinese patients with ESCC to', ' (A) ENI/CP/erlotinib; (B) ENI/CP; (C) conventional-field irradiation (CFI)/CP/erlotinib; (D) CFI/CP. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival, local-regional failure rate, and toxicity. Three hundred and forty-four patients and 242 events were needed for 85% power to detect a hazard ratio (HR) of 0.76 (2-year OS rate from 35% to 45% for each factor) if no interaction between the two factors was observed. Results', ' From December 2007 to December 2014, 352 patients were recruited. Median follow-up was 16.5 months for all patients at this analysis. There were no significant interactions between the two factors of ENI and erlotinib (P = 0.999). Two-year OS rate and median OS was 54% and 35.4 months for ENI (A+B) versus 42% and 20.5 months for CFI (C+D; HR = 0.69; 95% CI, 0.52 to 0.91; P = 0.008), respectively. Two-year OS rate and median OS was 52% and 24.9 months for erlotinib (A+C) versus 44% and 20.9 months for control (B+D; HR = 0.77; 95% CI, 0.57 to 1.00; P = 0.049), respectively. Patients treated with ENI plus erlotinib (A) achieved a 2-year OS rate of 58% and a median OS of 47.2 months. Hematologic toxicities grade 3 or above were the most common adverse events. Erlotinib was associated with a higher rate of all-grade rash events. Conclusions', ' Compared with conventional chemoradiotherapy, the addition of either ENI or erlotinib significantly improved survival among Chinese patients with ESCC, with the best of benefits in those treated with ENI plus erlotinib. The incidence rates of adverse-event were acceptable in this study. Clinical trial information', ' NCT00686114.']",
        "Doc_id":"ASCO_166662-176",
        "Doc_title":" Phase III randomized study of elective nodal irradiation plus erlotinib combined with chemotherapy for esophageal squamous cell carcinoma.",
        "_version_":1606188990147330048},
      {
        "Meeting_name":" Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer",
        "Background":"['Background', '  The aim of this present phase II study is to explore the safety and efficacy of paclitaxel (T), cisplatin (C), and nimotuzumab (N), a humanized anti-EGFR monoclonal antibody combination (TCN) as first-line treatment in advanced esophageal squamous cell cancer (ESCC).  Methods', '  Patients with histologically confirmed advanced ESCC, measureable tumor, and no prior chemotherapy and radiotherapy except adjuvant treatment were enrolled. Patients were given cisplatin 60mg/m2, paclitaxel 175mg/m2per 21 days for at least 2 cycles. The nimotuzumab was given 200mg weekly. Radiotherapy was admitted for patients with unresectable local advanced disease after 4 cycle of TCN treatment. The primary endpoints were safety and objective response rate (ORR). The secondary endpoints were progression-free survival (PFS) and over-all survival (OS). The expression of EGFR and ERCC1 were also analyzed by histoimmunochemical staining.  Results', '  Between Mar. 2011 and Dec. 2012, 55 patients with advanced ESCC were enrolled and 53 (96.4%) were eligible for evaluation. The ORR was 54.7% (29/53) and the DCR was 94.3% (50/53). The expression of EGFR and ERCC1 were detected in 46 and 31 patients respectively. The ORR had no relation to both the expression of EGFR (55.3% vs 62.5%, p=0.71) and ERCC1 (41.7% vs 58.3%, p=0.47). As a median follow-up of 15months, the median PFS was 10.5 months (95% CI 8.7 to 12.3 months).The TCN combination treatment was well tolerated and the most common adverse events were alopecia (86.8%), leukopenia (84.9%), anorexia (84.9%), vomiting (73.6%), fatigue (73.6%), pain (66.0%), and anaemia (39.6%).  And 18 (34%) patients had Grade 3 to 4 leukopenia. The median OS have not yet been reached.  Conclusions', '  In this study, the ORR, DCR and PFS are superior to previous published studies. The addition of anti-EGFR treatment of nimotuzumab to standard chemotherapy was well tolerated with no serious AEs. But the expression of EGFR by IHC could not predict the outcome of nimotuzumab treatment. A phase III study of TCN followed by radiotherapy in unresectable local advanced ESCC had been designed to explore the survival benefits. Clinical trial information', ' NCT01336049.']",
        "Doc_id":"ASCO_114497-132",
        "Doc_title":" Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer",
        "_version_":1606188991123554305},
      {
        "Meeting_name":" Overcoming intrinsic and acquired cetuximab resistance",
        "Background":"['Aberrant signalling of the epidermal growth factor receptor (EGFR) plays an integral role in the tumorigenesis of many cancer types, including head and neck squamous cell carcinoma (HNSCC), making it a compelling drug target. After the initial promising results of EGFR-targeted therapies, the problem of therapeutic resistance is emerging and new treatment options are necessary. In contrast to the first generation EGFR inhibitors, afatinib is an irreversible ErbB family blocker that inhibits EGFR as well as HER2 and HER4. The objective of this study was to investigate whether afatinib is able to overcome intrinsic and acquired cetuximab resistance in human papillomavirus (HPV) positive and negative HNSCC cell lines under normal and reduced oxygen conditions and to identify the molecular mechanisms underlying afatinibs cytotoxic effect.']",
        "Doc_id":"AACR_2017-4102",
        "Doc_title":" Overcoming intrinsic and acquired cetuximab resistance",
        "_version_":1606188972945440768},
      {
        "Meeting_name":" A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer.",
        "Background":"['Background', ' Neoadjuvant chemoradiation therapy is a standard treatment for localized esophageal cancers. The combination of carboplatin (C), paclitaxel (P), 5-FU and radiation therapy (RT) showed a path CR rate of 38% in a previous phase II study. Overexpression of VEGF and/or EGFR in esophageal cancers is associated with a poor prognosis. Both bevacizumab (B) and erlotinib (E) have antitumor activity in multiple solid tumors and are known radiosensitizers. This phase II study evaluated the combination of carboplatin, paclitaxel, 5-FU, bevacizumab, and erlotinib with RT as preoperative treatment of localized esophageal cancers. Methods', ' Eligibility included previously untreated stage I, II or III surgical candidates with histologically confirmed cancer of the esophagus or GE junction. The treatment regimen was', ' C', ' AUC 5 d 1, 22, P', ' 200 mg/m2 d 1, 22, 5-FU', ' 225 mg/m2/d IV C1 d 1-35, B', ' 15 mg/kg d 1, 22, and E', ' 100 mg PO d 1-42. RT was 1.8 Gy M-F to a total dose of 45 Gy. Patients were restaged between weeks 9-11 and had surgical resection between weeks 12-14. Results', ' 62 subjects enrolled, 59 currently available for analysis. Median age 64 (43-76), 54 M', ' 5F, ECOG PS 0 37 (63%). Adenocarcinoma 56 (95%), SCC 3 (5%). Pretreatment clinical stage', ' I 1 (2%), II 25 (42%), III 30 (51%). Common grade 3/4 toxicities', ' neutropenia (46%, 10% fever and neutropenia), mucositis (39%), diarrhea (27%), esophagitis (22%), rash (15%), and fatigue (15%). Other significant AEs', ' 1 G3 peripheral arterial thrombosis, 2 G4 wound complications. 3 treatment related deaths; 1 GI bleed and 2 post op deaths. 42 (71%) subjects have undergone surgical resection, with 3 still undergoing neo-adjuvant treatment. Path CR = 17 (30%); micro residual disease = 13 (23%); macro residual disease = 8 (14%). Conclusions', ' This multicenter phase II study of chemotherapy plus B and E with RT shows a path CR rate comparable to historical chemoradiation trials. Toxicity was not significantly increased compared to other neoadjuvant combination regimens for esophageal cancer. Given the potential difficulty to build upon this regimen with added agents, the further development of this regimen for patients with esophageal cancers is limited.']",
        "Doc_id":"ASCO_51222-74",
        "Doc_title":" A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer.",
        "_version_":1606188983655596032},
      {
        "Meeting_name":" Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Therapies directed at both the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways have been shown to improve survival in NSCLC and also have radiosensitizing properties. Methods', ' Pts receive Ind Cb (AUC 6), P (225 mg/m) and B (15 mg/kg) on d1 and 22. PET scans are done pre- and post-I. On day 43, pts receive weekly Cb (AUC 2 x 7) and P (45 mg/m x 7) with 74 Gy (2 Gy/d) of thoracic conformal radiotherapy (TCRT). Cohort I (n=5) received B at 10 mg/kg q2wks during C therapy. Cohorts II and III (both n=5) received the same dose of B as in cohort I but also received Er at 100 mg and 150 mg po Tuesday - Friday of each week of C therapy, respectively. The primary endpoint is PFS at 1 year. All histologies are allowed including squamous (SQ) (an early stopping rule is in place for pulmonary hemorrhagic (PH) complications in SQ pts). Results', ' Thus far, 31 eligible PS 0-1 pts have been accrued (med age 62 yrs, range 41-74, 19 non- squamous, 12 SQ, 63% IIIA, 37% IIIB). Ind CbP + B has been well tolerated (1 gr 3 hypertension). No PH during Ind has been seen (including the 12 SQ cell pts). Response after Ind, 37% PR, 59% SD, 4% PD. Tumor volumes and PET SUVs have significantly decreased comparing pre- and post-Ind studies (p=0.0001 and p=0.0002, respectively). Cohort II has been expanded as the phase II regimen. To date, 25 of 26 (96%) pts have achieved the dose of 74 Gy (1 pt stopped at 60 Gy due to ILD). During Conc therapy, the principal toxicity has been esophagitis (53.8% gr 2, 19.2% gr 3). One grade 3 PH occurred in 1 SQ pt. One gr 5 late (> 2 mos after treatment) PH occurred in a SQ pt. Overall response rate following treatment - 68.2% (95% CI, 45-86%). The PFS at 1 year is 58% (95% CI, 34-76%) with an estmated 1-year overall survival rate of 79% (95% CI, 53-92%) which compares favorably to our historical experience. Conclusions', ' Preliminarily, we conclude that 1) Incorporation of B and E into this treatment paradigm appears feasible, 2) Esophagitis remains the primary toxicity, 3) Phase II accrual continues but early analysis of survival appears promising. Further details regarding the TCRT parameters and toxicity will be presented.']",
        "Doc_id":"ASCO_34098-65",
        "Doc_title":" Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC).",
        "_version_":1606189015842684928},
      {
        "Meeting_name":" A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of esophagus.",
        "Background":"['Background', '  Dacomitinib is an oral irreversible tyrosine kinase inhibitor of EGFR, HER2 and HER4 signaling. The goals of this study were to investigate the clinical activity, safety and predictive biomarkers of dacomitinib in patients with advanced esophageal squamous cell carcinoma (ESCC).  Methods', '  Forty-nine patients with advanced ESCC, who had failed one line of prior platinum-based chemotherapy, were administered dacomitinib 45mg/day. The primary endpoint was objective response rate and predictive biomarkers were evaluated using tumor material obtained before dacomitinib treatment. We characterized somatic mutations using the Ion AmpliSeq platform (2,800 mutations from 50 genes), gene copy number (86 genes) and gene expression (230 genes) using NanoString nCounter.  Results', '    The median age was 64 years (range 47-83) and  the majority of patients were male (93.3%), had 0-1 ECOG performance status (91.8%). In terms of previous chemotherapy, 40 (81.3%) and 9 (18.4%) patients received 1 and 2 prior chemotherapy, respectively. Of the 48 evaluable patients, 10 (20.8%) achieved partial responses (PR), of these, 6 (12.2%) showed confirmed PRs. Twenty-nine patients (61.2%) had stable disease. The median treatment duration is 82 days (range 16-335 days), and main reason of treatment discontinuation was progression (n=34, 69.4%) and toxicity (n=4, 8.2%). Seven (14.3%) patients are on treatment and they are all progression free more than 120 days. Among the 34 patients with progression, the median time to progression was 80 days (95% CI, 59-102 days). With a median 169 days of follow up, the median overall survival was 4.5 months (95% CI, 3.1-6 months). Nineteen patients (38.8%) had treatment interruption due to toxicity, and 14 (28.5%) of them had dose reduction. The most common dacomitinib-related adverse effects were diarrhea (69.4%) followed by rash (57.1%).  Conclusions', '  Dacomitinib demonstrated promising efficacy with manageable toxicity in platinum-failed ESCC patients. We attempted to identify predictive biomarker for dacomitinib treatment. Updated clinical outcome and final biomarker data will be presented at ASCO 2014. Clinical trial information', ' NCT01608022.']",
        "Doc_id":"ASCO_133500-144",
        "Doc_title":" A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of esophagus.",
        "_version_":1606189033379069952},
      {
        "Meeting_name":" Phase II study of afatinib in recurrent and/or metastatic esophageal squamous cell carcinoma (R/M ESCC) (KCSG HN14-18).",
        "Background":"['Background', ' Afatinib, an irreversible pan-ErbB kinase inhibitor showed anti-tumor activity against esophageal cancer in phase I trial. In this multicenter, open-label, single arm phase II study, we aimed to evaluate the activity and safety of afatinib in R/M ESCC. Methods', ' Patients (pts) who had ECOG PS 0-2 and had progressed on platinum-based chemotherapy for R/M ESCC were enrolled. Pts were treated with afatinib 40mg/day until disease progression, unacceptable toxicity, or patients refusal. Primary endpoint was objective response rate (ORR) per RECIST 1.1. The estimated sample size was 49, using a two-stage minimax design to evaluate incremental response rate from 5 to 15%. Secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety profile. Additionally, we try to identify biomarker to predict efficacy of afatinib with target capture sequencing and gene expression profile as exploratory endpoints. Results', ' In a total of 49 enrolled pts (median age 60; range 44 -84), ORR and DCR were 14.3 % and 73.3%, respectively. With a median follow-up of 6.6 months, median PFS and OS was 3.4 months (95% CI 2.2-4.6) and 6.6 months (95% CI 5.2-8.0). Median treatment duration and duration of response were 2.8 months (range, 0.4-15.3) and 7.1 months (range, 2.5-13.9), respectively. Dose reduction and interruption occurred in 19 (38.8%) and 15 (30.6 %) pts. Treatment-related adverse events (TRAE) occurred in 33 pts (67.3%) with most common TRAEs being diarrhea (n=22, 44.9%) and acneiform rash (n=12, 24.5%). G3-4 TRAEs were rare, occurring in 7 pts (14.3 %). Conclusions', ' Afatinib demonstrated modest efficacy with manageable toxicity in platinum-resistant R/M ESCC patients. Given the modest response rate, identification of predictive biomarkers is essential for further clinical investigation of afatinib in R/M ESCC. Those biomarkers are being analyzed and will be presented in the conference (NCT02353936). Clinical trial information', ' NCT02353936EfficacyTotal  (n=49)%Best responseComplete response00.0Partial response (confirmed)714.2Stable disease2959.1Progressive disease1122.4Not evaluable24.0ORR (95% CI)14.2 (4.4  24.0)DCR (95% CI)73.3 (61.1  85.9)']",
        "Doc_id":"ASCO_184943-199",
        "Doc_title":" Phase II study of afatinib in recurrent and/or metastatic esophageal squamous cell carcinoma (R/M ESCC) (KCSG HN14-18).",
        "_version_":1606189016742363136},
      {
        "Meeting_name":" A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer.",
        "Background":"['Background', ' Neoadjuvant chemoradiation therapy is a standard treatment for localized esophageal cancers. The combination of carboplatin, paclitaxel, 5-FU and radiation therapy (RT) showed a path CR rate of 38% in a previous phase II study. Overexpression of VEGF and/or EGFR in esophageal cancers is associated with a poor prognosis. Both bevacizumab and erlotinib have antitumor activity in multiple solid tumors and are known radiosensitizers. This phase II study evaluated the combination of carboplatin, paclitaxel, 5-FU, bevacizumab, and erlotinib with RT as preoperative treatment of localized esophageal cancers. Methods', ' Eligibility included previously untreated stage I, II, or III surgical candidates with histologically confirmed cancer of the esophagus or gastroesophageal junction. The treatment regimen was', ' carboplatin AUC 5.0 d 1, 22, paclitaxel 200mg/m2 d 1, 22, 5-FU 225 mg/m2/d IVCI d 1-35, bevacizumab 15 mg/Kg d 1, 22, and erlotinib 100 mg PO d-42. RT was 1.8 Gy M-F to a total dose of 45 Gy. Patients were restaged between weeks 9-11 and had surgical resection between weeks 12-14. Results', ' 60 subjects enrolled, 57 currently available for analysis. Median age 64 (43-76), 52 M', ' 5 F, ECOG PS 0 35 (61%). Adenocarcinoma 54 (95%), SCC 3 (5%). Pretreatment clinical stage', ' I 1 (2%), II 24 (42%), III 29 (51%). Common grade 3/4 toxicities', \" neutropenia (39%, 9% fever and neutropenia), mucositis (39%), diarrhea (26%), esophagitis (22%), rash (14%), and fatigue (14%). Other significant AE's\", ' 1 G3 peripheral arterial thrombosis, 1 G4 wound dehiscence. 2 subjects died, 1 multisystem organ failure, 1 found unresponsive. 37 (65%) subjects have undergone surgical resection, with 7 still undergoing neoadjuvant treatment. Path CR = 15 (30%); microresidual disease = 10 (20%); macroresidual disease = 8 (16%). Conclusions', ' This multicenter phase II study of chemotherapy plus bevacizumab and erlotinib with RT shows a path CR rate comparable to historical chemoradiation trials. Toxicity was not significantly increased compared to other neoadjuvant combination regimens for esophageal cancer. Survival data is forthcoming.']",
        "Doc_id":"ASCO_2030-72",
        "Doc_title":" A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer.",
        "_version_":1606189021401186304},
      {
        "Meeting_name":" Identification of driver mutations and gene amplifications in resected asophageal adenocarcinoma",
        "Background":"['BACKGROUND', 'Adenocarcinoma of the distal esophagus and esophagogastric junction (EGJ) have received much attention because of increasing frequency and poor outcome despite multimodality therapy. Driver mutations and gene amplifications in resected esophageal adenocarcinoma are not widely investigated. Opportunity exists to discover actionable mutations in resected esophageal adenocarcinoma.METHODS', 'We analyzed driver mutations harbored in coding regions of 25 selected genes (95 point mutations) using a multiplex PCR-based assay. EGFR, HER2, MET, and PI3K amplifications were tested using fluorescent in situ hybridization in patients who underwent esophagectomy for distal esophagus and EGJ adenocarcinoma from 2009 to 2013. Disease free survival (DFS) and overall survival (OS) were compared between patients with TP53, KRAS, PI3K, BRAF, APC mutant and wild-type tumors using Kaplan-Meier methods and Cox regression models. The impact of HER2 expression and outcomes were also analyzed.RESULTS', 'Of 54 distal esophagus and EGJ adenocarcinoma patients, 5 different driver mutations were observed in 39 patients, including TP53 (11/39, 28.2%), KRAS (6/39,15.4%), PI3K (2/11,5.1%), BRAF(1/39, 2.6%) and APC (2/39,5.1%). Double driver mutations (3/39, 7.9%) were shared in 3 patients with TP53 and KRAS (1/39, 2.6%), TP53 and PI3K (1/39, 2.6%), KRAS and PI3K (1/39, 2.6%), respectively. Amplifications in HER2 (10/45, 22.2%), MET (1/34, 2.9%) and EGFR (2/17, 11.8%) were observed where directed therapy was altered in 5 patients (1 patient received induction herceptin and 4 patients received adjuvant herceptin). In the targeted patients with HER2 amplification who received herceptin, mean progression-free survival was 18.8 (range 7-41 months) vs. 8.9 (1-28 months) [p=0.089] and OS was 35.7 (range 26-46 months) vs. 24.2 (range 20-29 months) [p=0.053], compared to herceptin naive patients. We did not identify any significant difference in DFS and OS (inclusive of all stages) between TP53, KRAS or any mutation compared to wild type patients.DISCUSSION', 'Oncogenic driver mutations are under-investigated in resected distal esophageal and EGJ adenocarcinoma. Different therapeutic opportunities may become available if routine tumor genotyping is employed in the treatment of esophageal adenocarcinoma. We recommend the routine use of driver mutation and gene amplification analysis for esophageal cancer.']",
        "Doc_id":"AACR_2014-4696",
        "Doc_title":" Identification of driver mutations and gene amplifications in resected asophageal adenocarcinoma",
        "_version_":1606188973831487488},
      {
        "Meeting_name":" Comparative immunohistochemical study of basaloid and usual squamous cell carcinoma of the esophagus",
        "Background":"['Basaloid squamous cell carcinoma (BSCC) is a rare epithelial malignancy variant of the typical SCC, and it has been associated to an aggressive behavior, with a high capacity for developing metastasis and low survival rates. It has been reported that less than 12% of the primary esophageal carcinoma have been diagnosed as BSCC. The study aimed to compare the protein expression of HER-2, EGFR, Ki-67, Cyclins A, B1 and D1 between usual SCC and BSCC. Immunohistochemistry of 94 usual ESCC and 17 EBSCC cases were carried out using Tissue Microarray technique. Immunohistochemical analysis of cyclins and growth factors receptors was based on frequency and intensity of tumor cells in each sample; Ki-67 analysis was based on the frequency of tumor cells showing strong nuclear positive staining. When the clinicopathological data were compared, only histological grade (p=0.000) showed a significant difference between the usual and basaloid SCC groups. No significant difference was found in gender, age, lymphatic, venous, and perineural invasion, pT, pN, pM and TNM staging when the two groups were compared. No significant difference was found between the overall survival rates of both groups. In EBSCC cases, cyclin A expression was positive in 94.1% of the cases, while 5.9% showed no expression. Cyclin B1 expression showed positivity in 23.6% of cases and 76.4% showed no staining. Most of the cases (70.6%) showed no cyclin D1 expression, while 29.4% were considered positive. EGFR expression was positive in 52.9% and negative in 47.1% of the cases. Expression of HER2 was observed in a small proportion of the cases (29.4%), when compared to those (70.6%) with no expression. Considering the KI-67 labeling index, most of the cases (76.4%) were classified as Low Proliferation, while only 11.8% were considered as High Proliferation. Among the ESCC cases, 30.0% were considered negative for cyclin A expression and 70.0% cases were positive. For cyclin B1, 18.4% were positive and 81.6% showed no expression. Cyclin D1 showed no staining in 85.4% of the cases, while 14.6% were positive. EGFR expression was positive in 80.9% and negative in 19.1% of the cases. HER2 expression was negative in 52.8% and 44.7% were considered positive. Analysis of Ki-67 expression showed that most of the cases (70.8%) were classified as Low Proliferation, while 29.2% were considered as High Proliferation. Comparing the markers expression between the two groups, EGFR (p=0.025) and cyclin A (p=0.029) showed significant differences. Positive EGFR expression was more frequent in the usual ESCC than in the EBSCC group. For cyclin A, positivity was more frequent in the EBSCC group, when compared to the usual ESCC cases. Regarding the other markers, there was no significant difference between the two groups. Although some observed differences did not achieve statistical significance, this work has further highlighted possible differences between the molecular pathogenesis of BSCC and SCC.']",
        "Doc_id":"AACR_2014-571",
        "Doc_title":" Comparative immunohistochemical study of basaloid and usual squamous cell carcinoma of the esophagus",
        "_version_":1606188999747043328},
      {
        "Meeting_name":" Biological basis of pan-ErbB receptor targeting for malignant melanoma treatment",
        "Background":"['Dysregulated activation of the epidermal growth factor receptor (ErbB) family (EGFR, ErBB2, ErbB3, and ErbB4) is involved in promoting the cellular growth of human melanoma. EGFR, ErbB3, and ErbB4 are promising targets of malignant melanoma for new molecular drug development. However, the biology of ErbB family signaling pathways indicates that functional redundancy and heterodimerization among ErbB family members can greatly compromise the therapeutic efficacy of single ErbB targeting tyrosine kinase inhibitors (TKIs). In fact, Phase II clinical trials have already shown that EGFR (ErbB1) targeting TKIs provide limited benefits to melanoma patients. Here, this study has compared single vs. multiple ErbB targeting TKIs for inhibiting the growth of melanoma cells with different ErbB family protein expression profiles. We examined the expression of ErbB family members in 14 different human melanoma cell lines (MEL-526, M14, UPCI-MEL 527.1 and 11 SK-MEL cells). EGFR was expressed in 5 of the cell lines examined (35.7 %). ErbB2 was present in 13 lines (92.9 %); ErbB3 was found in 12 lines (85.7 %); and ErbB4 was found in all the cell lines. Furthermore, individual cell lines had a particular dominant form of ErbB protein. This differential expression pattern of ErbB family proteins was also seen in melanoma tissues from patients. Out of 14 melanoma cases examined by immunohistochemistry, 8 samples (61.5 %) were positive for ErbB1 and ErbB4 expression while ErbB2 was detected in 11 samples (84.6 %). We also found that Neuregulin 3 (which ranged from 500 to 76500 pg/ml) and Neuregulin 4 (which ranged from 26-300 pg/ml), which activate ErbB3 and/or ErbB4, are the major ErbB ligands released by the human melanoma cell lines. TGF and Amphiregulin, which mainly bind to EGFR, were released in relatively lower levels by the majority of the cell lines, but high levels of these ligands were distinctly found in individual cell lines. Among all the cell lines examined, HB-EGF was barely undetectable. In addition, different sensitivities towards single ErbB targeting tyrosine kinase inhibitors (TKIs) and pan-ErbB targeting TKIs were seen among the melanoma cells. For example, the TKI sensitivities of MEL526 which expressed no EGFR but high ErbB2, 3, and 4 proteins, was found to be', ' lapatinib (IC50', ' 6.7 M) > canertinib (IC50', ' 12.4 M) = erlotinib (IC50', ' 12.9 M) > gefitinib (IC50', ' 23 M). Similarly, M14 and UPCI-MEL527.1, which also have no EGFR expression but express ErbB 2, 3, 4, also responded better to lapatinib and canertinib respectively than to gefitinib or erlotinib. Our study is the first to suggest that the pan-ErbB targeting approach may be more effective in treatment malignant melanoma. Our findings also suggest that future screening of melanoma patients for their dominantly expressed ErbB protein types can potentially serve as a guide for the choice of effective ErbB TKI in treating malignant melanoma.']",
        "Doc_id":"AACR_2012-3864",
        "Doc_title":" Biological basis of pan-ErbB receptor targeting for malignant melanoma treatment",
        "_version_":1606189011491094528},
      {
        "Meeting_name":" Mutual transformation between adenocarcinoma and squamous carcinoma after EGFR tyrosine kinase inhibitors treatment in lung cancer.",
        "Background":"['Background', ' Knowledge on the epidermal growth factor receptor (EGFR) has improved survival of non-small cell lung cancer (NSCLC). Several mechanisms underlying have been discovered, here we would report a rare resistant mechanism of histology mutual transformations. Methods', ' From July 2013 to June 2015, we retrospectively collected 135 NSCLC patients who were in resistance with TKI treatments. Patients clinical data including pathologic result, gene status, demographic information, clinical staging, and treatment were recorded.[YL1]Results', ' Among the 135 NSCLC patients, we found two cases of lung cancer with histological transformation from adenocarcinoma to squamous cell carcinoma, one case from squamous cell carcinoma to adenocarcima after TKI treatment. These cases still harbored sensitive epidermal growth factor gene mutations and developed acquired resistance T790M mutation. Conclusions', ' Histologic evolution may be a mechanism associated with TKI resistance .']",
        "Doc_id":"ASCO_191749-199",
        "Doc_title":" Mutual transformation between adenocarcinoma and squamous carcinoma after EGFR tyrosine kinase inhibitors treatment in lung cancer.",
        "_version_":1606188975087681536},
      {
        "Meeting_name":" Molecular profiling of resected esophageal cancer and its correlation with clinical outcome.",
        "Background":"['Background', '  The tumor related gene profiling in esophageal cancer remains unknown and requires further investigation in order to promote efficient and rapid development of molecular-target agents. The aim of this study was to evaluate the expression level and mutations of tumor related genes in resected esophageal cancer and to assess correlation of the profiling with clinical outcome.  Methods', '  135 consecutive patients with esophageal cancer who underwent esophagectomy at Shizuoka Cancer Center and Toyama University between October 2002 and November 2011 were analyzed. Protein expression of MET, EGFR, ALK and HGF was determined by Automated QUantification Analysis. Copy number of EGFR, PIK3CA, MET and FGFR1/2 was analyzed by real time PCR. The translocation of ALK gene and mutations of tumor related genes were evaluated by fluorescence in situ hybridisation and TruSeq Amplicon Cancer Panel, respectively. Prognostic factors associated with survival were identified by multivariate analyses using the Cox proportional hazards model.  Results', '  Overall, heavy smoking was significantly associated with high HGF expression (p=0.03938), but was not an independent prognostic factor. After adjustment for clinical features by multivariate Cox regression analysis, high expression of ALK was associated with poor OS in patients without neoadjuvant therapy (HR 4.589, p=0.0102). The translocation of ALK gene was present only in 1 patient. High expression of MET was associated with poor OS in patients with neoadjuvant therapy (HR 5.68, p=0.043). Mutations in p53 and PIK3CA were present in 73% and 13%, respectively. The frequency of mutations in APC, BRAF, ERBB4, VHL, KRAS and EGFR was less than 10%. PIK3CA amplification was observed in 2%.  Conclusions', '  High expression of ALK and MET may be prognostic factors for resected esophageal cancer. Esophageal cancers with high expression level of ALK and MET might be possible candidates for ALK and MET targeting therapies.']",
        "Doc_id":"ASCO_127367-144",
        "Doc_title":" Molecular profiling of resected esophageal cancer and its correlation with clinical outcome.",
        "_version_":1606188998240239617},
      {
        "Meeting_name":" Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinomas patients with EGFR mutations.",
        "Background":"['Background', '   The criterion for defining clinical subtype of lung cancer is gradually transiting from histopathology to genetic variations in driver genes. Targeting these driver mutations such as sensitizing EGFR mutations has dramatically improved the prognosis of advanced non-small lung cancer (NSCLC), however the therapeutic benefit of this regimen on NSCLC seemed to be different between lung adenocarcinomas and squamous cell carcinomas (SqCC).  Methods', '   Two cohorts of SqCC patients with or without EGFR mutations and cell lines are used for this study. The methods included gene aberrance detection, IHC, ICC, cell viability test, western-blot analysis, soft agar foci formation, RNA sequencing analysis, protein chip and subcutaneous in vivo experiments.  Results', '   Report here that lung SqCC harboring EGFR mutations show resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) was correlated with the activation of BMP-BMPR-Smad1/5-p70S6K. The combinational treatment of these tumor cells with EGFR-TKI together with the inhibitors specific to BMPR or downstream mTOR effectively reversed the resistance to EGFR-TKI. Moreover, blocking the whole pathway of PI3K-AKT-mTOR with PI3K/mTOR dual inhibitor BEZ235 also showed efficacy toward this subtype of lung SqCC in animal models.  Conclusions', '  This study details the scientific basis for a feasible clinical solution for squamous cell carcinomas with EGFR mutations.']",
        "Doc_id":"ASCO_151589-156",
        "Doc_title":" Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinomas patients with EGFR mutations.",
        "_version_":1606189012342538240},
      {
        "Meeting_name":" Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin",
        "Background":"['Squamous cell carcinoma (SCC) is a common subtype of lung cancer and is strongly associated with smoking. In contrast to adenocarcinomas of the lung, SCCs do not significantly harbor epidermal growth factor (EGFR) mutations or ALK, ROS1 or RET translocations, which are therapeutically tractable. SCC of the lung and SCC of the head and neck region and esophagus not only share risk factors, morphologic features and mechanisms of tumorigenesis but also frequent fibroblast growth factor receptor 1 (FGFR1) gene alterations. In addition, we found that FGFR2 and FGFR3 expression were also altered in patient derived models of SCC of various origins. FGFRs may thus represent viable therapeutic targets for the treatment of SCC.BAY 1163877, an orally available and potent inhibitor of FGFR1, FGFR2 and FGFR3, inhibited SCC cell proliferation as well as downstream FGFR signaling in vitro. When applied in vivo, BAY 1163877 was able to reduce growth of a FGFR1-overexpressing lung SCC xenograft model, a FGFR1-overexpressing esophageal SCC xenograft model, and a FGFR3-overexpressing head and neck SCC xenograft model, achieving reductions in tumor growth by 67 to 92% as compared to the vehicle control. BAY 1163877 was very well tolerated in all models performed.These data suggest that selective inhibition of FGFR1 to 3 with BAY 1163877 might have therapeutic potential for the treatment of SCC malignancies. A phase I clinical trial (NCT01976741) to determine the safety, tolerability and recommended Phase 2 dose in advanced cancer patients is ongoing.']",
        "Doc_id":"AACR_2015-772",
        "Doc_title":" Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin",
        "_version_":1606189016049254401},
      {
        "Meeting_name":" A genetic mouse model of head-and-neck squamous cell carcinoma using targeted deletion of E-cadherin and TGF receptor II.",
        "Background":"['We previously observed that 70% of esophageal tumors demonstrated coordinated loss of E-cadherin and TGFRII. When grown in three-dimensional organotypic reconstruct cultures, cells lacking E-cadherin and TGFRII demonstrate fibroblast-dependent invasion into the underlying matrix. Therefore, we hypothesized that coordinated loss of CDH1 (E-cadherin) and TGFBR2 (TGFRII) will induce tumorigenesis in vivo. We developed a mouse model targeting CDH1 and TGFBR2 loss in the oral-esophageal epithelium using the Epstein-Barr virus L2 promoter, ED-L2. For spatio-temporal control of CDH1- and TGFBR2 gene expression, we also generated an inducible mouse model using Cre-ERT(tam) under the control of the keratin 14 promoter. Few mouse models focusing on genetic alterations of oral and head-and-neck cancer exist. We show that the loss of E-cadherin and TGF receptor II without carcinogen treatment is sufficient to induce invasive HNSCC and forestomach tumors. Double knock-out animals succumb to the disease between 1 and 1.5 years of age and show invasive tumors in the oral cavity and tongue, as well as the forestomach. Advanced tumors metastasize to the lung. The tumors are characterized by Ki67-positive and p63-positive staining and show disruption of adherens junctions with loss of -catenin and mislocalisation of p120 to the cytoplasm. Additional genetic modifications frequently described for HNSCC are the upregulation of c-myc and cyclin D1. We could show that the oral mouse tumors are positive for these markers allowing us to conclude that this animal model recapitulates HNSCC at the pathologic and molecular levels. Furthermore, the forestomach is an extension of the squamous epithelium of the esophagus in the mouse. Known genetic alterations causing esophageal squamous cancer are amplification of EGFR, cyclin D1 and mutations in p53 in addition to the loss of E-cadherin and TGFRII. The analysis of the forestomach tumors recapitulates these events in the mouse model as a result of CDH1 and TGFBR2 loss. This tumor model will provide us with a unique tool for testing therapeutic approaches.']",
        "Doc_id":"AACR_2013-335",
        "Doc_title":" A genetic mouse model of head-and-neck squamous cell carcinoma using targeted deletion of E-cadherin and TGF receptor II.",
        "_version_":1606189018441056256},
      {
        "Meeting_name":" Targeting HER3 and EGFR in NRG1 positive and HER3 mutated lung squamous cell carcinoma",
        "Background":"['HER3 is a member of the ErbB family of receptor tyrosine kinases. Aberrant activation of HER3 as a result of HER2 amplification or neuregulin 1 (NRG1) over-expression has been demonstrated to mediate constitutive activation of downstream oncogenic signals. LJM716 is a fully human IgG1 anti-HER3 monoclonal antibody. It locks HER3 in an inactive conformation and prevents HER3 dimerization with other ErbB family members. This unique mode of action enables LJM716 to block both ligand dependent and ligand independent HER3 activation. In search of new indications that may benefit from anti-HER3 therapies, we noted that squamous cell carcinomas (SCC) tend to have relatively higher NRG1 expression as compared to their adenocarcinoma counterparts. Highest NRG1 expression was observed in the lung SCC cell lines in cell line encyclopedia (CLE). A subset of the lung SCC cell lines with high NRG1 expression are moderately sensitive to LJM716, with HER3 activation detected in all of the sensitive lines. Additionally, EGFR activation is consistently observed in our panel of squamous lung carcinoma models. In some cases, activation of HER2 and/or HER3 is also noted. We hypothesize that squamous lung carcinomas may be dependent on signaling through EGFR, HER2 and HER3. To completely block EGFR, HER2-HER3 signaling, we set to test the treatment of LJM716 and Cetixumab in a number of NGR 1 positive squamous lung carcinomas tumor models. Enhanced anti tumor activity of LJM716 and Cetixumab is observed in four out nine tumor models. Analysis of broad activation status of receptor tyrosine kinases (RTK) reveals that a subset of responsive models have activated pEGFR, pHER2 and pHER3. These data suggest that activated HER3 signaling may be important in a subset of lung squamous cell carcinoma. Combination of anti-HER3 and anti EGFR treatment is effective at inhibiting growth in these tumors.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2015-5320",
        "Doc_title":" Targeting HER3 and EGFR in NRG1 positive and HER3 mutated lung squamous cell carcinoma",
        "_version_":1606189020383019009},
      {
        "Meeting_name":" A phase 1b trial of mFOLFOX6 and everolimus (NSC-733504) in patients with metastatic gastroesophageal adenocarcinoma (NCT01231399).",
        "Background":"['Background', '  Gastric cancer remains a significant problem worldwide with approximately 870,000 new cases and 650,000 deaths per year.  Although the Granite trial did not show any benefit of everolimus over best supportive care in patients with advanced gastric cancer, preclinical combinations of platinum chemotherapy and mTOR inhibition have shown a synergistic effect.  We conducted a phase 1 trial combining mFOLFOX6 with everolimus.  Methods', '  Patients with metastatic gastric, gastroesophageal and esophageal adenocarcinoma were eligible.  A standard 3+3 design was employed and patients received standard dose mFOLFOX6 and escalating doses of everolimus ranging from 2.5 to10 mg/day.  Patients were evaluated for dose limiting toxicities during the first 4 weeks of treatment.  Tumor tissue was collected for next generation sequencing.  Results', '  Six patients were accrued to the first dose level of everolimus at 2.5 mg daily, four with metastatic gastric cancer and 2 with metastatic esophageal cancer.  Two dose limiting toxicities (DLTs) were observed at the first dose level with one patient being hospitalized for fever secondary to a possible infection.  The second patient developed grade 2 neutropenia that resulted in a treatment delay greater than 7 days.  Toxicities were manageable with mucositis, nausea, neutropenia, fatigue and rash being the most common.  Five patients required everolimus dose reduction during their course of treatment.  The median time to treatment failure was 8.9 months.  Next generation sequencing revealed mutations in APC, EGFR, FGFR3, FLT3, KDR, KIT, PDGFRA, PIK3CA, RET, STK11 and TP53.  Conclusions', '  The immunosuppressive effect of chemotherapy in combination with everolimus resulted in two DLTs at the first dose level.  One patient that required dose reductions due to mucositis had a FLT3 mutation which more commonly occurs in acute myelogenous leukemia.  A FLT3 genotype variant associated with the development of pneumonitis in renal cell carcinoma patients treated with mTOR inhibitors was previously reported (Y. Urun, et al, ASCO 2013).  Further research is needed to identify biomarkers of treatment response and toxicity. Clinical trial information', ' NCT01231399.']",
        "Doc_id":"ASCO_131904-144",
        "Doc_title":" A phase 1b trial of mFOLFOX6 and everolimus (NSC-733504) in patients with metastatic gastroesophageal adenocarcinoma (NCT01231399).",
        "_version_":1606189018212466688},
      {
        "Meeting_name":" Assessment of EGFR mutations in patients diagnosed of squamous non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '    Mutations in the Epidermal Growth Factor Receptor (EGFR) predict a better outcome to EGFR tyrosine kinase inhibitors than platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Previous studies with Caucasian patients have shown a prevalence of EGFR mutation of 10-15%. The aim of this study is to analyze the prevalence of EGFR mutations in squamous-cell NSCLC patients from an area of influence of 500,000 habitants.    Methods', '    Prospective mutation testing in NSCLC patients included in our institution since October 2010 to January 2012 was performed on DNA obtained from available tumor tissue and cytologic samples, using ARMS-scorpion TheraScreen EGFR 29 Mutation Test Kit (Qiagen).  Results', '    From 218 consecutive NSCLC diagnoses, 18 (8.25%) patients showed EGFR mutations', ' 6 (33.3%) exon 19 deletion, 9 (50%) exon 21 mutations (7 L858R and 2 L861Q) and 3 (16.6%) cases exon 20 insertion. In the EGFR mutated population, 16 (88.88%) patients were diagnosed as adenocarcinoma and 2 (11.11%) as squamous cell carcinoma. The characteristics of these squamous cell cancer patients were', ' 2 male; 1 non-smoker, 1 former-smoker; 1 stage IV and 1 stage IB at diagnosis; one case exon 20 insertion and one exon 21 mutation (L858R).  Conclusions', '    The EGFR mutation rate in squamous-cell NSCLC patients in our referral area is superior (11.17%) than previously reported, reinforcing the importance of including EGFR mutation testing in squamous-cell NSCLC population for selecting optimal therapy for these patients.']",
        "Doc_id":"ASCO_100581-114",
        "Doc_title":" Assessment of EGFR mutations in patients diagnosed of squamous non-small cell lung cancer (NSCLC).",
        "_version_":1606188996711415808},
      {
        "Meeting_name":" Phase II study of neoadjuvant and adjuvant gefitinib (G) with neoadjuvant chemoradiotherapy (CRT) in operable esophageal adenocarcinoma (EAC).",
        "Background":"['Background', ' Esophageal cancer offers an intriguing and accessible model for studying novel inhibitors of cancer-related pathways. EGFR is expressed in 30%-70% of EAC. Given the need in EAC for improved therapies and better predictors of outcome, we proposed to study the effectiveness of EGFR targeted therapy in EAC. Methods', ' Patients (pts) included PS 0-1 adults with untreated, resectable stage II-IVa EAC and with normal organ function. A Simon 2 stage design used a power of 90% and 2-sided alpha of 5%. The null was a pathologic complete response rate (pCR) = 25% and the alternative was a pCR = 45%. Stage 1 had 17 pts with expansion to 36 pts if > 4 had pCR. Pts were treated with a 2 week run-in of G at 250 mg daily. Paclitaxel (50 mg/m2) and cisplatin (30 mg/m2) were given IV wkly x 5 doses along with 4,500 cGy of XRT. G continued daily until 1 week prior to surgery. Surgery was performed wks 9 or 10 from CRT start date. Adjuvant G began 2-8 wks post-op and continued 1 year. Specimens were collected for pharmacokinetic (PK) and pharmacodynamic (PD) analyses. Results', ' 17 pts were treated. Demographics include', ' mean age (range)-57 (38-73); M', 'F-9', '1; 95% White, 5% Hispanic; Stages', ' 3 IIA; 2 IIB; 10 III; 2 IVa. 90% of pts received all the CRT. 10% missed 1 or 2 doses of CT due to myelosuppresion or renal insufficiency. All pts completed > 90% of pre-operative G. Side effects of the G included grade 1 rash and diarrhea. All 17 pts had surgery. 1 pt died during surgery. Pathologic response was', ' 3 pts pCR (18%); 1 stage 0 (Tis); 2 stage I; 2 IIA; 4 IIB; 4 III; 1 IVa; 1 undetermined. 11 total pts downstaged; 4 pts were unchanged; 1 pt upstaged; 1 was undetermined. 13 pts started the adjuvant G. Of these, 5 completed 1 year. 1 stopped for knee surgery. 1 stopped due to a heart attack. 6 stopped due to progression. Median TTP was 15.7 mos. Median OS for the 17 pts was 31.5 mos. Median follow-up was 30 months. PK and PD studies are being analyzed. Conclusions', ' The addition of G to standard neoadjuvant CRT is feasible but does not improve the pCR rate. Exploratory analyses are being done to see if a subset of pts may benefit from EGFR therapy.']",
        "Doc_id":"ASCO_48328-74",
        "Doc_title":" Phase II study of neoadjuvant and adjuvant gefitinib (G) with neoadjuvant chemoradiotherapy (CRT) in operable esophageal adenocarcinoma (EAC).",
        "_version_":1606188997264015360},
      {
        "Meeting_name":" EGFR expression and phosphorylation in HNSCC predict response to EGFR inhibition but cell lines are not representative for the clinical situation.",
        "Background":"['Introduction Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Survival rates have not been improved for decades and conventional therapy is effective in only 50% of the patients. Based on broad expression in up to 80-90% of the HNSCC cases, epidermal growth factor receptor emerged as drug target but clinical efficacy of EGFR inhibitors in HNSCC is very limited. We therefore reinvestigated the EGFR expression levels necessary for response in cell lines and clinical samples.']",
        "Doc_id":"AACR_2017-2786",
        "Doc_title":" EGFR expression and phosphorylation in HNSCC predict response to EGFR inhibition but cell lines are not representative for the clinical situation.",
        "_version_":1606189010002116608},
      {
        "Meeting_name":" Menacalc as an independent prognostic factor and predictor of metastasis in Non-Small Cell Lung Cancer",
        "Background":"['The Mena protein has been shown to be critical for breast cancer metastasis, and, in pre-clinical models two of its isoforms MenaINV and Mena11a are expressed in invasive and non-invasive tumor cell subpopulations, respectively. We have previously developed a quantitative immunofluorescence approach to assess the fraction of Mena protein lacking Mena11a called Menacalc as a method to infer presence of invasive tumor cells. Menacalc is determined by subtracting the population-based Z-score (quantifies the relationship to the mean) for Mena11a quantitative expression score from the population-based Z-score for total Mena quantitative expression score. The resulting Menacalc scores range from -4 to +4 with high scores reflecting tumors with relatively high total Mena (all isoforms) but low Mena11a. We showed that high MENAcalc scores associated significantly with poor disease-specific survival in breast cancer patients, including node-negative and positive cases. A recent study reported that a semi-quantitative approached to Mena assessment shows prognostic value in early Non-Small Cell Lung Cancer (NSCLC) (Bria et. al 2014). Here, we asked whether the quantitative Menacalc assay has prognostic value in NSCLC and if it can predict metastatic disease. We determined Menacalc on a cohort of 201 predominantly early-stage NSCLC cases using multiplexed quantitative immunofluorescence (MQIF) and then assessed Menacalc with respect to clinical and pathological features, as well as disease-specific survival. There was no significant difference in Menacalc by stage, sex, or age. However, Menacalc was significantly higher (P = 0.001) in squamous cell carcinoma (N = 32) as compared to other histological subtypes. High levels of Menacalc were associated (10% significance level) with decrease 5-year disease specific survival in all patients [HR = 1.78 (95%CI', ' 0.92-3.43); P = 0.08], and were significantly associated with survival when either corrected for histological subtype [HR = 2.10 (95%CI', ' 1.04-4.26); P = 0.04] or in the squamous-only population [HR = 6.60 (95%CI', ' 1.22-53.75); P = 0.04]. There was no difference in survival as a function of stage nor in adenocarcinomas. Furthermore, consistent with Mena isoform status being associated with the metastatic phenotype, Menacalc was 2-fold higher (P = 0.09) in metastatic patients, but the sample size with available clinical data was limited (N = 9). Taken together, these data demonstrate that Menacalc has potential prognostic value especially in squamous cell carcinoma patients. These data also preliminarily suggest that Menacalc can predict the metastatic phenotype. Further studies examining Mena isoform expression in squamous and later-stage metastatic NSCLC patients is thus warranted and currently ongoing.']",
        "Doc_id":"AACR_2015-4331",
        "Doc_title":" Menacalc as an independent prognostic factor and predictor of metastasis in Non-Small Cell Lung Cancer",
        "_version_":1606188978778669056},
      {
        "Meeting_name":" Discovery of orally active 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes with dual EGFR and HER2 inhibitory activity.",
        "Background":"['Growth factor receptors of the ErbB family, especially ErbB1 (EGFR) and ErbB2 (HER2), have attracted considerable attention in recent years as therapeutic targets for the treatment of numerous malignancies including cancers of the lung, colon, and breast, either through blockade of the extracellular ligand binding site by monoclonal antibodies (e.g. anti-EGFR antibodies cetuximab and panitumumab, and anti-HER2 antibody trastuzumab) or inhibition of the intracellular tyrosine kinase domain by small molecule inhibitors (e.g. EGFR kinase inhibitors gefitinib and erlotinib, and dual EGFR/HER2 inhibitor lapatinib). The abundance of small molecule kinase inhibitors in clinical development or on the market attests to the acceptance of ErbB inhibition as a clinically relevant paradigm. Nevertheless, the emergence of resistance mechanisms in ErbB driven or dependent tumors indicates that continued research is required to discover more effective drugs. We previously reported the discovery of JNJ-28871063, a potent inhibitor of EGFR and HER2 kinases in vitro that also showed excellent antitumor efficacy in EGFR (A431 epidermoid carcinoma) and HER2 (N87 gastric carcinoma) overexpressing xenograft models and significant extension of survival in a mouse intracranial tumor model. This compound is a 4-amino-6-arylaminopyrimidine-5-carbaldehyde oxime, a monocyclic chemotype that mimics the traditional bicyclic quinazoline scaffold via an intramolecular hydrogen-bonded pseudocycle involving the adjacent 4-amino and 5-oximino groups. In this study, we present results of a structure-guided analog program designed to optimize in vitro kinase potency and in vivo antitumor efficacy of the pyrimidine-oximes. While substituents on the 6-arylamino group are critical for ErbB inhibitory potency and kinase selectivity, substitution on the oxime oxygen may be changed to modify physico-chemical properties and bioavailability. We will discuss structure-activity relationships for the 5-oximino and 6-arylamino groups as well as the important role played by O-aminoalkyl oxime substituents in improving in vivo activity.']",
        "Doc_id":"AACR_2013-2456",
        "Doc_title":" Discovery of orally active 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes with dual EGFR and HER2 inhibitory activity.",
        "_version_":1606188971905253376},
      {
        "Meeting_name":" PID, a novel immunofluorescence nanotechnology, as a histopathology-based EGFR biomarker assay enhances predictive power for the Erbitux response in subsets of PDXs.",
        "Background":"['Immunohistochemistry (IHC) is the most common used assay for detecting/quantifying defined protein biomarkers in specific tissue location in clinical/preclinical settings as prognostic/drug-predictive biomarker assays. However, IHC suffers from several key drawbacks, limiting its applications, including semi-quantitative nature, inconsistence, low sensitivity, narrow dynamic detection range and inadequacy for multi-target analysis, etc. An alternative method is immunofluorescence (IF), but with even lower usage for its disadvantageous photo-instability. A sensitive, quantitative and robust assay is thus an urgent/unmet need. We have recently developed a novel fluorescence nanoparticle (PID, phosphor integrated dye) with highly compact phosphor inside. PID has several key advanced features', ' 1) enhanced fluorescence (30,000x brighter over the conventional fluorescence and significantly above tissue auto-fluorescence), 2) enhanced photo-stability (stained slide is stable for >2 years); 3) highly quantitative by broadened detection dynamic range through enumeration of the bright fluorescent dots (nanoparticles) instead of signal amplification as in IHC (digital vs. analog); 4) fine subcellular imaging; 5) potentials for multi-color and H&E/bright light imaging. PDX is a well-accepted experimental cancer model mimicking original patients in histo- & molecular pathology(1), as well as drug response. We previously conducted a series of mouse clinical trial (MCT) of Erbitux on PDX cohorts of NSCLC, CRC, gastric and esophageal cancers (2,3), showing specific subsets of high-EGRF-expressing PDXs responded to the drug, where EGFR expression was measured by either RNAseq (mRNA) or IHC (protein). To assess PID-EGFR as a new biomarker assay platform, we analysed and compared its quantification to RNAseq and IHC, particularly in terms of the correlation to the drug efficacy. Our data demonstrates a greatly enhanced correlation of PID scores to mRNA levels in all cancer types, and to the tumor growth inhibition of gastric (3) and esophageal (4) carcinoma, but not in CRC (2) and NSCLC (Li et al., unpublished) as anticipated. The results demonstrated that PID-EGFR is a significantly improved histopathology based EGFR protein quantification assay over IHC-EGFR assay, warranting further clinical confirmation.']",
        "Doc_id":"AACR_2017-2789",
        "Doc_title":" PID, a novel immunofluorescence nanotechnology, as a histopathology-based EGFR biomarker assay enhances predictive power for the Erbitux response in subsets of PDXs.",
        "_version_":1606189002387357696},
      {
        "Meeting_name":" Mutation analysis using next-generation sequencing in histologically heterogeneous of primary lung cancers.",
        "Background":"['Rare cases of primary lung cancer are known to have different histological types. Recently, small cell carcinoma was reported to be developed in adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations after EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment. The purposes of this study are to evaluate mutational status in two different histological types separately, and to further understand the molecular pathogenesis. Twelve tumor samples from 6 patients were collected in our institution. 4 patients had primary adenocarcinoma and small cell carcinoma transformed after EGFR-TKI. One patient had primary adenocarcinoma and squamous cell carcinoma transformed after EGFR-TKI. The other one patient had carcinosarcoma in a surgically resected tumor. Two samples per patient were collected from histologically different areas within a resected tumor or the 2 distinct metastatic sites. DNA was extracted from formalin-fixed, paraffin-embedded tumor tissues. Next-generation sequencings in the 12 samples were performed on 160 cancer-related genes using GeneRead DNAseq Targeted Panels V2 Human comprehensive Cancer Panel (QIAGEN). In a carcinosarcoma case with deletional mutation in EGFR gene, a total 504 in adenocarcinoma and 595 in sarcoma variants in 160 genes were detected with high confidence. The gene of identical alterations, as truncal alterations, were EGFR, CBLB, TP53 and MEN1 and the number of that as an unique alteration corresponding to each histology is 25 for adenocarcinoma and 85 for sarcoma. We show relations between the histological types and the genomic alterations, identical alterations and unique alterations, in each patient. Furthermore, we raise essential factors for the histological transformation.']",
        "Doc_id":"AACR_2017-2467",
        "Doc_title":" Mutation analysis using next-generation sequencing in histologically heterogeneous of primary lung cancers.",
        "_version_":1606189035910332417},
      {
        "Meeting_name":" Distinctive phospho-proteome signatures in non-small cell lung carcinoma tumors",
        "Background":"['Non-small cell lung carcinoma (NSCLC) is a major, lethal cancer worldwide. Various molecular and cellular abnormalities are found in NSCLC, and an established theme is the alteration of protein phosphotyrosine (pY), as exemplified by elevated epidermal growth factor receptor (EGFR) activity recognized in a subset of NSCLC. In order to gain a broad perspective of pY-mediated signaling networks in NSCLC, mass spectrometry was used to analyze pY-containing peptides affinity purified from protease-digested xenograft tumors. Seventeen tumors representing the major NSCLC subtypes adenocarcinoma (ADC) and squamous cell carcinoma (SCC) were characterized. The major classes of pY proteins detected were cytoskeletal, protein kinases, and adhesion proteins. Pathways and cellular functions enriched in the data set included focal adhesion, adherens junction, and ErbB signaling. Five receptor tyrosine kinases (RTKs) were detected, with EGFR and EPHA2 most prevalent. Src-family kinases (YES, LYN, FRK and LCK) and focal adhesion kinase (FAK) comprised the majority of non-receptor tyrosine kinases measured. Analysis of individual pY sites on 14 tyrosine kinases indicates their activation by kinase domain activation loop phosphorylation, but also revealed additional pY sites suggestive of regulation by trafficking/endocytosis and inter- and intra-molecular protein-protein interactions involving, for example, SH2 and SH3 domains, and extra-kinase domain regions. Analysis of tumors based on protein-pY suggested subtypes distinguished by their activated tyrosine kinase networks. Genetic analysis of 3 tumors that displayed EGFR-associated phospho-proteome signatures confirmed that they carried either EGFR activating mutations (in two ADCs) or increased gene copy number (in one SCC). Western blot analysis of protein pY confirmed different patterns of cellular protein pY among the tumor phospho-types in agreement with the phospho-proteomic analysis. Quantification of kinase and substrate pY sites, according to their integrated extracted ion currents, revealed a set of phosphorylations that constituted a molecular signature that differentiated between the ADC and SCC subtypes. In summary, quantitative phospho-proteomic profiling of NSCLC tumors is feasible and may have utility in the categorization of individual tumors according to their networks of activated tyrosine kinases and substrates.']",
        "Doc_id":"AACR_2012-4805",
        "Doc_title":" Distinctive phospho-proteome signatures in non-small cell lung carcinoma tumors",
        "_version_":1606189024789135360},
      {
        "Meeting_name":" First-in-human phase I study of CetuGEX, a novel anti-EGFR monoclonal antibody (mAb) with optimized glycosylation and antibody dependent cellular cytotoxicity.",
        "Background":"['Background', '  Epidermal growth factor receptor (EGFR) is a validated target in cancer. EGFR antagonists in clinical use do not exploit the full potential of this target. CetuGEX is an IgG1 mAb against EGFR. Fully human and optimized glycosylation lead to a 10- to 250-fold improvement of ADCC-mediated tumor cell killing in all FcRIIIa allotypes and lack of immunogenic carbohydrate-chains, compared to cetuximab.  Methods', '  Eligible patients with advanced solid tumors, progressing after standard treatment, were enrolled into this phase I, first-in-human, multicenter, single agent dose escalation trial. PK, PD and immunological parameters were assessed. Endpoints were safety and tolerability and secondarily pharmacokinetics, immunogenicity and anti-tumor activity.  Results', '  41 patients were treated on a q1w (8 dose levels from 12 to 1,370 mg flat dose), or q2w (990 mg flat) schedule. 25 pts had received at least 8 weekly doses (per protocol population [PP]).The most frequently observed drug-related AE were nausea (20%), vomiting (20%), hypertension (20%), almost all low grade and acneiform dermatitis (25%), only grade 1 or 2. Infusion-related reactions (IRR), virtually restricted to the first infusion, were associated with cytokine secretion', ' IL-6, IL-8, TNF, IFN and IP-10 as marker of macrophage activation. Optimization of infusion scheme and premedication reduced IRRs in severity and frequency from 76% to 57% mainly of low grade. Blood NK cells were reduced as sign of redistribution. Activity was seen over all dose levels. One patient with NSCLC achieved a complete response. One patient with metastatic colorectal cancer had a partial response, another 2  patients with esophageal and gastric cancer without measurable disease at study entry had marked improvement of symptoms and normalization of tumor markers. Additional 15 pts had stable disease lasting from 8 weeks to over a year, including several minor responses, leading to a clinical benefit rate of 46% (19/41) in the overall and 76% (19/25) in the PP population. PK supports q1w and q2w dosing.   Conclusions', '  CetuGEX shows clear signs of activity and acceptable toxicity. Phase II will soon be initiated. Clinical trial information', ' NCT01222637.']",
        "Doc_id":"ASCO_116312-132",
        "Doc_title":" First-in-human phase I study of CetuGEX, a novel anti-EGFR monoclonal antibody (mAb) with optimized glycosylation and antibody dependent cellular cytotoxicity.",
        "_version_":1606189035108171777},
      {
        "Meeting_name":" EGFR as a marker for head and neck squamous cell carcinoma-derived small extracellular vesicles.",
        "Background":"['Head and neck cancer will account for an estimated 61,760 new cancer cases and 13,190 cancer-related deaths in the United States in 2016, the majority of which (> 90%) will be squamous cell carcinoma (HNSCC). The prognosis for HNSCC is relatively poor, with an overall 5-year survival around 60%, and the outlook worsens with increasing stage at diagnosis, which is problematic since about two-thirds of patients present with advanced stage disease. This underscores the urgent need for discovery, development and translation of novel biomarkers to facilitate early detection of HNSCC and bolster the chance for positive patient outcomes. Exosomes are nano-sized (40-150 nm) membrane-encapsulated vesicles that may offer a new avenue for discovery and development of novel HNSCC biomarkers. However, they are released by essentially all cells, both normal and malignant, into the extracellular space, resulting in a noisy environment in biofluids from the perspective of biomarker measurement. As such, a membrane-bound surface marker that allows for enrichment for cancer-derived exosomes in patient samples would provide a clear benefit. Epidermal growth factor receptor (EGFR), which belongs to the ErbB/HER family of receptor tyrosine kinases, localizes to the plasma membrane and is over-expressed in as much as 90% of HNSCC tumors. Therefore, we hypothesized that EGFR will be over-represented on membranes of HNSCC-derived exosomes and thus may offer utility as a surface marker for detection and/or enrichment. To test this, we cultured an HNSCC cell line that over-expresses EGFR (FaDu), EGFR-deficient SW620 colorectal adenocarcinoma cells, and primary human oral epithelial cells pooled from 3 healthy donors. Cells were cultivated in supplier-recommended media with 10% fetal bovine serum (FBS) that was super-depleted of exosomes via 18 hour ultracentrifugation at 100,000g and 1% penicillin/streptomycin at 37C with 5% CO2 in 150 cm2 flasks with 25mL media. After reaching 80-90% confluence, media was harvested, and exosomes were isolated and purified via differential ultracentrifugation. Exosome isolates were whole-mounted on carbon grids, Immuno-Gold labeled with anti-EGFR, and imaged on a JEOL JEM-1230 transmission electron microscope (Immuno-EM); anti-nucleoporin 153 (NUP-153), which localizes to the nucleus, was used as a negative control. Immuno-EM images indicate abundant EGFR expression on exosomes secreted by FaDu HNSCC cells, but EGFR is not detectable on the exosomes secreted by the oral epithelial cells from healthy donors. These results indicate that EGFR may offer utility for enrichment for HNSCC-derived exosomes in human biofluid isolates using magnetic beads or flow cytometry.']",
        "Doc_id":"AACR_2017-1797",
        "Doc_title":" EGFR as a marker for head and neck squamous cell carcinoma-derived small extracellular vesicles.",
        "_version_":1606188989260234752},
      {
        "Meeting_name":" KRAS and EGFR gene mutation status in anal canal carcinoma.",
        "Background":"['Background', ' Squamous cell anal carcinoma is a rare gastrointestinal tumor whose treatment remains unchanged since the institution of chemoradiation four decades ago. Recently, clinical trials testing cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, with simultaneous radiation therapy have begun in this patient population. The discovery of Kristen-ras (KRAS) wild type status and EGFR gene mutation as markers of response to EGFR inhibitor monotherapy has allowed individualized cancer treatment in colorectal and lung cancer respectively. Neither of these markers is present in squamous cell carcinoma of the head and neck (SCCHN), the only tumor proven to be radiosensitized by Cetuximab. It is not yet known what mutations predict sensitivity to cetuximab with concurrent radiation. The objective of this study was to assess the KRAS and EGFR mutation status in squamous cell carcinoma of the anal canal. Methods', ' Mutation status of KRAS exon 2 and EGFR exon 19 and 21 was evaluated in 95 pretreatment formalin-fixed paraffin-embedded anal cancer tumor biopsies from patients treated between 1990 and 2009. DNA was extracted from verified tumor samples. Gene segments were amplified, their mutational status was assessed by High Resolution Melting (HRM) analysis, and variants were confirmed by sequencing. Samples were tested in duplicate along with positive and negative controls that consisted of lung or colorectal cancer samples known to either contain the sought after mutation or to be wild-type. Results', ' KRAS exon 2 mutations were identified in 0/95 samples. EGFR exon 19 mutations were likewise absent in all 95 samples. Only three of the 95 samples scored positive by HRM for EGFR exon 21; however, sequencing revealed a single nucleotide polymorphism (rs17290559) in all three samples. Conclusions', ' These results imply that, like SCCHN, squamous cell anal canal carcinoma lacks the most common mutations in KRAS and EGFR; suggesting anal cancer patients may likewise be radiosensitized by cetuximab.']",
        "Doc_id":"ASCO_2056-72",
        "Doc_title":" KRAS and EGFR gene mutation status in anal canal carcinoma.",
        "_version_":1606188982612262912},
      {
        "Meeting_name":" Application of the EGFR in squamous lung cancer and its relationship between p63",
        "Background":"['OBJECTIVE', ' Epidermal growth factor receptor (EGFR) mutations are rarely found in squamous cell carcinoma (SQC).METHODS', ' Between J February 2010 and March 2013, we investigated the incidence of EGFR activating mutations in SQC of the lung using the automated direct sequencing of polymerase chain reaction products method. The efficacies of formal therapy, observation, targeting therapy (EGFR-tyrosine kinase inhibitors [TKIs]) were retrospectively evaluated in patients with EGFR-mutated SQC. Further pathologic analyses were performed using immunohistochemistry.RESULTS', \" Sixteen of the 282 patients with SQC (5.67%) had EGFR mutations, including exon 19 deletion (7 of 16 patients, 44%), L858R point mutation in exon 21 (9 of 16, 56%). The patients' median progression-free survival (PFS) and median overall survival (OS) in formal therapy, observation and targeting therapy were 6.28 and 9.03, 5.23 and 6.17, and 4.20 and 10.57 months. The median OS of 4 EGFR-mutated patients received p63 (partly +) was 11.28 months (95% confidence interval [CI], 6.33-16.23months) verse that of 11 EGFR-mutated patients received p63 (+) was 3.57 months (95%CI, 1.75- 5.39 months) (p=0.039).CONCLUSION\", ' EGFR-TKIs for EGFR-mutated SQC are generally inferior to that for EGFR-mutated ADC. Chemotherapy or radiation therapy seemed to be less inferior to TKI therapy considering the PFS and OS results and the economy when patients are in good status. Patients presenting partly + of p63 had longer OS than p63 + patients. EGFR and p63 might be two separate factors which affected the proliferation of squamous tumor cells and result remained to be confirmed by large samples.KEYWORDS', ' squamous lung cancer, SQC,epidermal growth factor receptor, EGFR, P63Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2014-4678",
        "Doc_title":" Application of the EGFR in squamous lung cancer and its relationship between p63",
        "_version_":1606188972341460992},
      {
        "Meeting_name":" Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in patients with solid tumors",
        "Background":"['Background', ' Neratinib (HKI-272) is a potent irreversible pan-ErbB inhibitor of the tyrosine kinase receptors ErbB1, -2, and -4. In this phase 1 study, a tolerable combination dose of neratinib plus paclitaxel was determined in patients (pts) with solid tumors, and safety and preliminary efficacy were assessed in pts with ErbB2+ metastatic breast cancer (BC). Methods', ' In this open label, 2-part study, ascending multiple daily oral doses of neratinib (160 mg, 240 mg) were administered in combination with IV paclitaxel 80 mg/m2, if tolerable, or 70 mg/m2 on days 1, 8, and 15. Pts with solid tumors and pts with ErbB2+ metastatic BC were enrolled in parts 1 and 2, respectively. Tumor measurements were made at screening and at every 8 weeks (2 cycles) by modified RECIST criteria. Timed blood samples were collected for neratinib and paclitaxel plasma concentration determination, and PK analyses were performed using a noncompartmental method. Results', ' Data for 54 pts as of 30 Oct 2008 are presented (median age [range] of 51.5 [20-74] years; 91% female; 26% with prior trastuzumab treatment of median duration [range] 32.5 [10-52] weeks; 15% with prior lapatinib treatment). Tumor types in part 1 included breast, endometrial, cervical, colorectal, and esophageal cancer. Dose escalation beyond standard doses was not necessary; there were no dose-limiting toxicities (DLTs) at the neratinib 240 mg/paclitaxel 80 mg/m2 dose. Neratinib-related AEs, any grade in 10% of pts included diarrhea (50%), neutropenia (17%), rash (13%), nausea (11%), and vomiting (11%). Neratinib-related AEs, grade 3 in 2% of patients were diarrhea (20%), neutropenia (9%), and dehydration (4%). Only 2 pts (at the neratinib 240 mg/paclitaxel 80 mg/m2 dose) had dose reductions due to diarrhea. In 35 pts evaluable for efficacy, 5 had confirmed partial response (PR). Confirmed clinical benefit (PR and prolonged disease stabilization) was seen in 2 pts in part 1, 1 pt with endometrial cancer and 1 pt with cervical cancer. Conclusions', ' The combination of neratinib 240 mg and paclitaxel 80 mg/m2 was tolerable with a toxicity profile similar to that observed for neratinib and had promising antitumor activity in pts with solid tumors and ErbB2+ BC.']",
        "Doc_id":"ASCO_40440-70",
        "Doc_title":" Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in patients with solid tumors",
        "_version_":1606188985493749760},
      {
        "Meeting_name":" Impact of epidermal growth factor receptor (EGFR) gene intron 1 dinucleotide CA repeat polymorphism on protein expression and clinical outcome in oral cavity squamous cell carcinoma.",
        "Background":"['Epidermal growth factor receptor (EGFR) is one of the four members of the ErbB receptor family and has been shown to play a key role in tumorigenesis of many human cancers including oral cavity squamous cell carcinoma (OSCC). Previous studies have observed a significant relationship between EGFR overexpression and poor outcomes in head and neck squamous cell carcinoma (HNSCC) including OSCC. Elevated EGFR levels have primarily been attributed to enhanced transcriptional activity, rather than amplification of the gene. Since the EGFR intron 1 polymorphic CA dinucleotide repeats has been suggested to affect EGFR transcription efficiency, the present study was designed to explore the relationship between this CA repeats polymorphism, gene copy number and protein levels in Taiwanese OSCC. A total of 194 OSCCs were examined for EGFR protein overexpression using immunohistochemistry and for copy number using a fluorescence in situ hybridization (FISH) assay. DNAs from peripheral blood of 164 OSCC patients were also available for EGFR intron 1 CA dinucleotide repeats analysis. Overexpression and increased gene copy numbers of EGFR were found in 101 (52.06%) and 59 (30.41%) cases, respectively. The length of EGFR CA repeats were not associated with EGFR protein expression (p = 0.261) while the copy number was strongly related to protein overexpression (p < 0.001). EGFR protein overexpression was associated with young age (p = 0.036), tumor differentiation (p < 0.001) and lymph node metastasis (p = 0.028). EGFR gene copy number was also associated with young age (p = 0.009), tumor cell differentiation (p = 0.002), tumor depth (p = 0.001), lymph node metastasis (p = 0.051) and bone invasion (p = 0.003). However, the length of EGFR CA repeats was not associated with clinicopathologic factors. Patients with EGFR overexpression in their tumors were found to have significant poorer disease-free survival (DFS) (p = 0.026, log-rank test) and overall survival (OS) (p = 0.019, log-rank test) than those without overexpression. Patients with CA repeats SS form (both alleles < 19 repeats) had significantly shorter DFS and OS than those with SL and LL forms (both alleles  19 repeats) (p = 0.039 and 0.018 for DFS and OS, respectively). On the other hand, the association between an increase in EGFR gene copies and DFS or OS was insignificant. In summary, our current findings confirm that EGFR protein overexpression is closely related to EGFR copy number; but, do not support the role of CA repeats as an EGFR expression regulator. On the other hand, the length of CA repeats was significantly associated with both DFS and OS.']",
        "Doc_id":"AACR_2013-2394",
        "Doc_title":" Impact of epidermal growth factor receptor (EGFR) gene intron 1 dinucleotide CA repeat polymorphism on protein expression and clinical outcome in oral cavity squamous cell carcinoma.",
        "_version_":1606189024068763648},
      {
        "Meeting_name":" Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced cancers of the GI tract and anus.",
        "Background":"['Background', ' The treatment of GI carcinomas (CA) is influenced by the presence or absence of prognostic and predictive genomic alterations (GA). Tissue sampling is the historical platform for genomic biomarker assessment, but non-invasive ctDNA assay provides an alternative when tissue is unavailable or cannot be safely obtained. Methods', ' Hybrid-capture based genomic profiling using a ctDNA assay (FoundationACT) was performed on blood samples from 82 consecutive pts with lower alimentary canal CA. Results', ' Median age was 62 (range 28-92) and 61% were male. Anatomic breakdown included CRC (n = 51), esophageal (n = 9), gastric (n = 8), gastroesophageal (n = 3) and small bowel adenoCA (SBA, n = 2), anus squamous cell CA (n = 5), and other GI CA (n = 4). At least one GA was reported in 72% of cases. In 23 cases with no GA reported, the average maximum somatic allele frequency was 0.17% (95% CI', ' 0-0.6%) vs. 16.7% (95% CI', ' 0-54.4%) for the 59 cases with GAs (P < 0.0001). For the 3 of 18 patients with both blood and tissue testing performed and samples collected within a 30-day interval, 8/9 (89%) GA detected in tissue were also detected in ctDNA. An average of 1.7 GA/sample were detected in ctDNA. The most commonly altered genes were TP53 (61%), KRAS (24%), BRAF (10%) and PIK3CA (10%). Comparative analysis using the tissue-based Foundation Core database showed a similar trend with overall slightly higher frequencies of GAs in individual genes. RAF and RAS short variants (SV) were exclusive to lower GI and anal CA. KRAS and RAF1 amplification (amp) occurred only in esophageal CA (4/11, 36%). FGFR SV or amp was identified in 3 cases across the cohort. Of CRC, 4 (8%) had  1 ERBB2 activating SV or amp, 2 (4%) had IDH1/2 hotspot SV, and 2 (4%) had BRCA2 inactivating alterations. ERBB2 activating SV and EGFR amp were found in a SBA and an esophagus CA, respectively. A kinase fusion was identified as the sole driver in 1 CRC (STRN-ALK) and 1 SBA (GOPC-ROS1). Outcomes to targeted therapies will be presented for the available subset of patients. Conclusions', ' Our results provide early clinical support and confirm that hybrid-capture based ctDNA testing can reliably detect all 4 classes of GA and provide a molecular profiling option for patients with GI CA.']",
        "Doc_id":"ASCO_177110-195",
        "Doc_title":" Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced cancers of the GI tract and anus.",
        "_version_":1606189003224121344},
      {
        "Meeting_name":" Vorinostat (V) intratumoral levels and biomarker response in a window of opportunity trial in patients with resectable aerodigestive tract cancer.",
        "Background":"['Background', '  Aerodigestive tract cancer (ADT) is the leading cause of cancer-related death in the US. New effective treatments are needed. Among a panel of drugs causing growth inhibition of lung cancer cells and repression of cyclin D1, the histone deacetylase inhibitor V was found most potent. To translate studies into the clinic, a window of opportunity trial of V was conducted.  Methods', '  Pts with resectable ADT received 400 mg V once daily orally for 7 days prior to surgical resection. Serum samples were obtained before the last V dose and at the time of biopsy. Tumor tissue was immediately snap-frozen in liquid nitrogen, stored at -70C, homogenized in three parts PBS (1', '3g/v). V was quantitated with a LC-MS/MS assay. Post- versus pre-treatment tumor biopsies were scored for necrosis, acute and chronic inflammation, and immunohistochemical changes in Ki-67, cyclin E, cyclin D1, EGFR, phospho-EGFR, p21, p27 and caspase.  Results', '  15 pts enrolled, 9 pts took V for a median of 7 days (3-9), underwent resection and had adequate pretreatment samples. Median age 66, 4 women, 4 former, 5 current smokers, 1 squamous cell lung carcinoma, 8 adenocarcinoma (1 esophageal).  PK analyses confirmed plasma (8pts) and tumor (7pts) concentrations above the detection limits. There was considerable interindividual variation in plasma V concentrations (7.3-192.4 ng/ml; CV 95%), at 178-500 min from last V dose, and in intratumoral V levels (15.0-80.3 ng/g; CV 59%). All pts had wild-type EGFR, 4 pts had KRAS codon 12 mutations, 78% showed reduced Ki-67 expression, 50% had decreased cyclin E, 78% exhibited necrosis, chronic or acute inflammation in the post-treatment biopsies. Most cases with KRAS mutations had biomarker responses. Changes in multiple biomarkers were observed across the range of intratumoral V levels.  Conclusions', '  This is the first report of V concentrations in human tumors. Preoperative treatment with V achieved intratumoral concentrations comparable to serum with evidence of necrosis, decreased Ki-67 and cyclin E, and other biomarker responses in resected ADT. The results demonstrate the value of window of opportunity trials in the investigation of novel cancer therapeutics.']",
        "Doc_id":"ASCO_94024-114",
        "Doc_title":" Vorinostat (V) intratumoral levels and biomarker response in a window of opportunity trial in patients with resectable aerodigestive tract cancer.",
        "_version_":1606189006171668481},
      {
        "Meeting_name":" Activated EGFR and PPAR regulate MUC1 expression in human uterine and pancreatic cancer cell lines",
        "Background":"['The high molecular weight, transmembrane mucin, MUC1 is expressed at high levels in many epithelial tumors including endometrial and pancreatic cancers. Aberrant glcosylation and overexpression of MUC1 make tumor cells poorly adherent, protect tumor cells from the host immune system, promote metastases from primary sites and enhance resistance to chemotherapeutic drugs. MUC1 has three distinct domains', ' an extracellular domain (ECD) composed of a tandem repeat region rich in serine, threonine and proline; a transmembrane domain (TM) and; a short cytoplasmic tail domain (CT) involved in a variety of signal transduction events. Epidermal Growth Factor Receptor (EGFR/erbB) family members regulate cell growth and survival in both normal and cancer cells. MUC1 interacts with erbB receptors and also affects downstream signaling pathways in a EGFR-ligand dependent manner. We previously demonstrated that the Peroxisome Proliferator Activated Receptor  (PPAR) agonist rosiglitazone severely inhibits progesterone stimulated MUC1 expression (Wang et al. 2010. Mol. Endocrinol. 24', ' 1368-1379). Two independent approaches were used to determine if rosiglitazone as well as EGFR tyrosine kinase inhibitor, AG1478 reduced MUC1 expression in a high MUC1-expressing cell line, HES; the uterine adenocarcinoma cell line, HEC-1A; and in the human pancreatic adenocarcinoma cell lines, HPAFII and CAPAN2. EGFR activation by Epidermal Growth Factor (EGF) stimulated MUC1 protein expression (1.5-2 fold) in both uterine and pancreatic cancer cells. The PPAR agonist, rosiglitatzone, markedly (> 90%) reduced EGFR-driven MUC1 expression detected by antibodies directed against the MUC1 ECD and CT. Preliminary studies indicate that rosiglitazone effects on EGFR-driven MUC1 expression is indirect. Furthermore, rosiglitazone treatments enhanced EGFR degradation via the lysosomal degradation pathway in the presence of EGF-family ligands in both uterine and pancreatic cancer cell lines. A combination of biochemical and molecular biological assays have been used to identify the transcriptional and signal transduction pathways activated by EGFR, leading to increased MUC1 expression and the impact of AG1478 and rosiglitazone on these events. Understanding the molecular basis of how these agents reduce MUC1 expression may offer novel therapeutic avenues to improve cancer chemotherapies.']",
        "Doc_id":"AACR_2012-3070",
        "Doc_title":" Activated EGFR and PPAR regulate MUC1 expression in human uterine and pancreatic cancer cell lines",
        "_version_":1606188981197733888},
      {
        "Meeting_name":" Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '    c Met expression is common in NSCLC tumors and has been implicated in the development of resistance to EGFR inhibitors. CRIZ is an ALK and MET/HGF receptor tyrosine kinase inhibitor (TKI). In pre-clinical studies, combining CRIZ with an EGFR inhibitor enhanced anti-tumor activity in NSCLC cell lines that were either sensitive or resistant to EGFR inhibition. The phase I portion of a phase I/II study (A8081002; NCT00965731) investigated the combination of E (EGFR TKI) and CRIZ in pts with advanced NSCLC.    Methods', '    Pts had advanced NSCLC, 1 or 2 prior chemotherapy regimens, and no previous MET-directed therapy. Endpoints included maximum tolerated dose (MTD) determination, safety, and pharmacokinetics (PK). Pts received CRIZ 150 or 200 mg BID combined with E 100 mg QD (150/100 and 200/100, respectively).  Results', '    Twenty-five pts have been treated to date. Median duration of combination therapy in 150/100 (n=18) was 6.6 weeks (0.125.3); for 200/100 (n=7) was 6.9 weeks (3.064.7). Five pts had dose-limiting toxicities (grade [G] 2 and unable to receive at least 80% of the planned dose or G3), all of which resolved', ' 3 pts at 150/100, G2 vomiting, G2 esophagitis and dysphagia, G3 diarrhea and dehydration; and at 200/100, G3 dry eye (1 pt) and G3 esophagitis (1 pt). Most pts (92%) experienced treatment-related adverse events (TRAEs), mainly of G1 or 2 severity. Common TRAEs were diarrhea (72%), rash (56%) and fatigue (44%). Six pts discontinued therapy due to TRAEs (150/100', ' G3 diarrhea, G3 dehydration, and G2 rash in 1 pt, G2 asthenia, G2 vomiting, G2 esophagitis, n=1 each; 200/100', ' G3 dry eyes, G1 esophagitis, n=1 each). One partial response (200/100; duration 61 weeks) and 9 stable diseases (n=7 150/100, n=2 200/100; duration 754 weeks) were observed overall. Co-administration of both doses of CRIZ with E increased E AUC by 1.8 fold, while CRIZ PK parameters appeared to be unaffected. Plasma exposure to E 100 mg QD with CRIZ was comparable to that of 150 mg QD from historical data.  Conclusions', '    E plus CRIZ at the MTD was well tolerated, with no unexpected AEs, and showed signs of activity in a pre-treated population. E 100 mg QD plus CRIZ 150 mg BID was defined as MTD.']",
        "Doc_id":"ASCO_96412-114",
        "Doc_title":" Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606189038199373824},
      {
        "Meeting_name":" WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.",
        "Background":"['While multiple post-translational modifications have been reported to regulate the function of epidermal growth factor receptor (EGFR), the effect of protein methylation on its function has not been well characterized. In this study, we show that WHSC1L1 mono-methylates lysine 721 in the tyrosine kinase domain of EGFR, and that this methylation leads to enhanced activation of its downstream ERK cascade without EGF stimulation. We also show that EGFR K721 mono-methylation not only affects the function of cytoplasmic EGFR, but also that of nuclear EGFR. WHSC1L1-mediated methylation of EGFR in the nucleus enhanced its interaction with PCNA in squamous cell carcinoma of the head and neck (SCCHN) cells and resulted in enhanced DNA synthesis and cell cycle progression. Overall, our study demonstrates the multifaceted oncogenic function of the protein lysine methyltransferase WHSC1L1 in SCCHN, which is mediated through direct non-histone methylation of the EGFR protein with effects both in its cytoplasmic and nuclear functions.']",
        "Doc_id":"AACR_2017-342",
        "Doc_title":" WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.",
        "_version_":1606188990450368512},
      {
        "Meeting_name":" A study on EGFR gene amplification and protein expression in Chinese esophagus cancer patients and antitumor effect of an EGFR inhibitor in patient-derived esophagus cancer models",
        "Background":"['Esophagus cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality in China. According to Chinese cancer registry annual report in 2012, esophagus cancer accounts for nearly 1 in 10 of all cancer deaths. Despite the fact that much progress has been made in diagnosis and systemic chemotherapy regimens, the overall prognosis of esophagus cancer is disappointing. The 5-year survival rate, all stages included, is around 1525%. There remains a significant unmet medical need for esophagus cancer treatment.EGFR expression was reported in 3090% esophagus cancers and overexpression of EGFR was found to be associated with poorer survival. Unlike colon cancer, K-ras mutation was less frequently found in esophagus cancer (510%), suggesting EGFR pathway blockade might bring therapeutic benefit to those patients with EGFR activation or overexpression. In this study, as of November 2013, 35 surgical esophagus tumor samples were collected from a local hospital in Shanghai. 31 of the 35 samples were identified as squamous cell carcinoma. EGFR gene amplification, protein expression and K-ras mutation were studied. In addition, 9 patient derived esophagus cancer xenograft models (PDX) were developed and anti-tumor effect of a novel and highly potent EGFR inhibitor was evaluated in 6 PDX models.Positive EGFR protein expression was found in 66% (23/35) of esophageal cancer samples. EGFR gene amplifications were observed in 9% patients (3/35). In 9 established PDX models, 7 of them showed EGFR expression and 2 with EGFR gene amplification. No K-ras mutation was observed in the 9 models. A novel and highly potent EGFR inhibitor (EGFRi), developed by Hutchison and currently being evaluated in phase I clinical trials in China, demonstrated potent anti-tumor activity in several PDX models with tumor growth inhibition in a range of 70% to >100%. One PDX model with EGFR gene amplification and overexpression exhibited the highest sensitivity to EGFRi with remarkable tumor regression. EGFR signaling transduction was evaluated and the EGFRi inhibited phosphorylation of EGFR and downstream signaling molecules AKT and ERK.In conclusion, EGFR expression and/or gene amplification was frequently found in Chinese esophagus cancer. EGFR inhibition resulted in potent anti-tumor effect in multiple patient derived esophagus cancer models carrying EGFR amplifications or high expression, suggesting the potential benefit that anti-EGFR agents might bring to esophagus cancer patients with abnormal EGFR activation.']",
        "Doc_id":"AACR_2014-1730",
        "Doc_title":" A study on EGFR gene amplification and protein expression in Chinese esophagus cancer patients and antitumor effect of an EGFR inhibitor in patient-derived esophagus cancer models",
        "_version_":1606189008467001344},
      {
        "Meeting_name":" Prevalence of EGFR mutations in non-small cell lung cancer (NSCLC) smoker patients.",
        "Background":"['Background', '    Mutations in the Epidermal Growth Factor Receptor (EGFR) predict a better response to tyrosine kinase inhibitors compared to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Previous studies in caucasian population have reported a frequency of EGFR mutation of 10-15%. The aim of this study is to analyze the prevalence of EGFR mutations in caucasian smoker patients with NSCLC.  Methods', '    Prospective mutation testing in NSCLC patients included in our institution since October 2010 to January 2012 was performed on DNA obtained from available tumor tissue and cytologic samples, using ARMS-scorpion TheraScreen EGFR 29 Mutation Test Kit (Qiagen).  Results', '    From 218 consecutive NSCLC diagnoses, 18 (8.25%) patients showed EGFR mutations', ' 6 (33.3%) exon 19 deletions, 9 (50%) exon 21 mutations (7 cases L858R and 2 cases L861Q) and 3 (16.6%) exon 20 insertions. In the EGFR-mutated patients, 13 (72.25%) were never-smoker and 5 (27.7%) were smoker (3 current-smoker and 2 former-smoker). The EGFR-mutated smoker population showed the following characteristics', ' 3 female, 2 male; 4 adenocarcinoma, one squamous cell carcinoma; 3 stage IV, 2 stage IA at diagnosis; 1 (20%) case EGFR deletion exon 19, 1 (20%) case insertion exon 20 and 3 patients (60%) mutation exon 21 (2, L858R and 1, L861Q).  Conclusions', '    The EGFR mutation rate in NSCLC smoking patients in our referral area is superior (27.7%) than previously reported, reinforcing the importance of including EGFR mutation testing in NSCLC smoking population for the correct management of these patients.']",
        "Doc_id":"ASCO_100169-114",
        "Doc_title":" Prevalence of EGFR mutations in non-small cell lung cancer (NSCLC) smoker patients.",
        "_version_":1606188997367824384},
      {
        "Meeting_name":" A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations.",
        "Background":"['Background', '  Efficacy of gefitinib therapy strongly depends on epidermal growth factor receptor (EGFR)-mutation status in patients with non-small cell lung cancer (NSCLC). However, cumulative data from many clinical studies demonstrated that some patients with wild-type (WT) EGFR also responded to gefitinib and remained stable. The aim of this trial was to evaluate the efficacy and toxicity of gefitiinb in NSCLC patients who failed previous chemotherapy with WT EGFR tumors.  Methods', '  Patients with advanced or recurrent NSCLC whose tumors have WT EGFR were eligible. Gefitinib (250 mg/day) was administered until disease progression or unacceptable toxicity occurred. The primary end point was disease control rate (DCR) at 8 weeks.  Results', '  Eighty-five patients (53 men and 32 women; median age, 60 years; range, 30-86) were enrolled between October 2010 and May 2013. Seventy-four (87.1%) had adenocarcinoma, nine (10.6%) had squamous cell carcinoma. Forty-one patients (48.2%) were treated with gefitinib as second-line chemotherapy and 34 patients (40.0%) as third-line chemotherapy. Eleven patients showed partial response, and twenty-one had stable disease. Thus, response rate was 12.9%, and DCR was 37.6%. Skin rash was the most common side effect. One patient developed interstitial lung disease (grade 2). The median progression-free survival and overall survival times were 1.9 and 10.9 months, respectively.  Conclusions', '  Gefitinib might be an alternative option for pretreated patients even in those with WT EGFR NSCLC.']",
        "Doc_id":"ASCO_133299-144",
        "Doc_title":" A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations.",
        "_version_":1606189024623460352},
      {
        "Meeting_name":" Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases.",
        "Background":"['Background', '  S-222611 is an oral, reversible ErbB tyrosine kinase inhibitor of EGFR and HER2 with potent pre-clinical activity. MTD was not reached during dose-escalation, even at the maximum dose of 1600mg QD. PK and efficacy data supported a daily dose of 800mg. A further cohort has been treated to further explore safety and efficacy. Methods', '  Subjects with advanced solid tumors expressing EGFR and/or overexpressing HER2 were enrolled. S-222611 was administered until disease progression or unacceptable toxicity. Results', '  76 patients (33 male/43 female; median age 62 years [range 31-81], ECOG PS 0/1/2', ' 24/51/1), were included in this expansion phase, including breast (27), esophago-gastric (30), head & neck (12) and renal (7). Dose reduction was required because of adverse events in 11 patients (14%); the most frequent of such being diarrhea and elevated bilirubin. Only 2 patients discontinued treatment due to drug-related adverse events.  Of the 41 patients with HER2-positive cancers (26 breast, 13 esophago-gastric, 2 head & neck), 1 complete response (gastric-esophageal junction cancer) and 5 partial responses (4 breast cancer, 1 gastric cancer) were observed; all these patients had received prior HER2-directed therapy. Prolonged stable disease (  6 months) was observed in 3 additional patients with breast cancer. 6 of the 25 breast patients had brain metastases, in whom 1 intracranial response and 2 prolonged SD (  6mo) were observed.  In the EGFR+ve/HER2-ve cohort (n = 35), no RECIST responses were seen, however 4 patients had prolonged stable disease (  6mo).  Conclusions', '  S-222621 was well tolerated at a dose of 800mg once daily. Anti-tumour activity, including shrinkage of brain metastases, was evident in a heavily pre-treated population of patients with HER2-positive breast and esophago-gastric cancers.  Clinical trial information', ' 2009-017817-31.']",
        "Doc_id":"ASCO_148414-156",
        "Doc_title":" Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases.",
        "_version_":1606189004909182976},
      {
        "Meeting_name":" Genotypic agreement between histological specimen and preoperative cytology in small lung adenocarcinoma.",
        "Background":"['Background. Histological subtype and genotype is critical for making treatment decisions and improving patient outcomes in non-small cell lung cancer (NSCLC). Approximately 70% of lung cancers are diagnosed in advanced stages where small biopsies and cytological specimens are the only source of material for both diagnosis and genotyping. Patients with specific gene alterations in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) likely receive more benefit from EGFR TKI or ALK TKI therapy, respectively. Although, genotyping agreement from cytological and histological samples is critical, more investigational studies need to be explored to assess the concordance of genotype. Purpose. We performed a comparing investigation on concordance rate for pathological diagnosis and EGFR gene mutation status between surgical specimen and preoperative cytological specimen in small lung cancer. Additionally we reviewed immunohistochemical (IHC) staining with two different ALK specific antibodies. Materials and Methods. 55 patients who had surgically resected small (3cm) lung adenocarcinoma with known preoperative bronchial brushing cytology were examined retrospectively. IHC staining was conducted by mutation-specific antibodies using E746-A750 deletion and L858R for EGFR or 5A4 and D5F3 for ALK. DNA analysis was performed by PNA-RNA PCR clamp assay. Results. 1) Diagnostic concordance rate between cytological and histological specimen was 90.9%. Disagreement cases were included one case of squamous cell carcinoma, two cases of small cell carcinoma, one case of melanoma and one case of mucoepidermoid carcinoma by cytology. 2) In IHC positive for mutation-specific EGFR antibodies, the sensitivity was 83% in E746-A750 and 100% in L858R, respectively. In EGFR IHC positive cases, well to moderate differentiation were dominant. 3) In ALK IHC, one case was observed stronger cytoplasmic staining in D5F3 than 5A4. Furthermore, the cribriform pattern was observed in H&E staining. Distinctive cytological feature was not observed. Conclusion. Our results showed that high genotype concordance rates of histology and cytology agreement in small lung adenocarcinoma.']",
        "Doc_id":"AACR_2013-4209",
        "Doc_title":" Genotypic agreement between histological specimen and preoperative cytology in small lung adenocarcinoma.",
        "_version_":1606188998834782208},
      {
        "Meeting_name":" Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Pertuzumab (P) is a fully humanised, murine monoclonal antibody that targets the dimerisation epitope of human epidermal growth factor receptor (HER) 2, preventing dimerisation between HER2 and other HER receptors and inducing antibody-dependent cell-mediated cytotoxicity. P as a single agent is not associated with meaningful activity against NSCLC, though stable disease (SD) has been observed in a phase II study (Herbst et al. Clin Cancer Res 2007;13', '6175). Erlotinib (E) inhibits HER1 tyrosine kinase signalling and is widely registered for treatment of relapsed NSCLC. By inhibiting extracellular receptor dimerisation, as well as internal signal transduction through HER1, the combination of E and P would be expected to result in extensive blockade of HER signalling. Preclinical and initial response data seem to confirm this (Felip et al. ESMO 2008, abs 269P). Methods', ' 15 pts in 2 cohorts were treated in this Phase I, dose-escalating study. There was no evidence of pharmacokinetic interaction and the majority of treatment-related adverse events were CTC grade 1 or 2; full doses of each drug were recommended for further phase II evaluation. Potential biomarkers possibly associated with antitumour activity of P and E were measured in tumour tissue and evaluated against clinical disease status. Proteins of potential significance were measured by immunohistochemistry (IHC) and mRNA by reverse transcriptase real-time quantitative polymerase chain reaction (RT qPCR). The panel of biomarkers measured included HER1 (epidermal growth factor receptor [EGFR]), HER2 and HER3. Results', ' Progression-free survival and tumour response were evaluated in all 15 pts. There were 3 partial responses (20%), with 1 further pt experiencing SD of  6 months. 13 pts had tumour samples that were suitable for full quantification of EGFR, HER2 and HER3 by RT qPCR as well as other markers by IHC. Interestingly, higher levels of mRNA for some HER receptors, as well as IHC markers, may correlate with treatment response. Conclusions', ' The biomarker analyses may provide some initial insight into markers of efficacy, although the data are limited by small numbers. Full data will be presented.']",
        "Doc_id":"ASCO_52735-74",
        "Doc_title":" Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).",
        "_version_":1606189034293428225},
      {
        "Meeting_name":" Prognostic value of epidermal growth factor receptor gene amplification in surgically resected non-adenocarcinoma lung cancer patients.",
        "Background":"['Background', '    The purpose of this study is to investigate the prognostic role of genomoic gain and expression for epidermal growth factor receptor (EGFR) gene in surgically resected non-adenocarcinoma of non-small-cell lung cancer (NA-NSCLC).  Methods', '    This retrospective study included 115 NA-NSCLC consecutive patients with available tumor tissue and survival data, median follow up period of 6.4 years. EGFR gene copy number and protein expression was evaluated using by fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) in tissue microarray sections, respectively.  Results', '    Among 115 patients, 99 patients (86.1 %) were with squamous cell carcinoma histology. EGFR gene amplification and high polysomy (EGFR FISH+) were observed in 57 (49.6%) and 45 (39.1%) patients, respectively. Patients with EGFR FISH+ had significantly shorter overall survival [median, 41 months vs. not reached (>70 months), P = 0.011]. Multivariable model confirmed that patients with EGFR FISH+ had a significantly greater risk of death than those with EGFR FISH-negative after adjusting pathologic staging, presence of pleural invasion, venous invasion and adjuvant chemotherapy (hazard ratio = 2.11, 95% confidence interval 1.23-3.61, P = 0.006). EGFR IHC expression did not associate with overall survival in same group.  Conclusions', '  EGFR increased gene copy number is an independent negative prognostic factor in surgically resected NA-NSCLC.']",
        "Doc_id":"ASCO_116120-132",
        "Doc_title":" Prognostic value of epidermal growth factor receptor gene amplification in surgically resected non-adenocarcinoma lung cancer patients.",
        "_version_":1606189030642286592},
      {
        "Meeting_name":" Metabolic stress played a role in dasatinib-induced EGFR degradation and apoptosis in head and neck cancer.",
        "Background":"['Head and neck squamous cell carcinoma (HNSCC) is a worldwide disease with aggressive course and dismal outcome. Dasatinib, a Bcr-abl and Src in hibitor, has been approved clinically for CML and shown activities against solid tumors in vitro. In our recent work, degradation of epidermal growth factor receptor (EGFR) plays a role in dasatinib-induced apoptosis in HNSCC cells. We further revealed the role of metabolic stress in dasatinib-induced EGFR degradation and apoptosis. Dasatinib decreased cellular ATP, and activated AMPK activation and induced endoplasmic reticulum stress (ER stress) as well. Inhibition or knockdown of AMPK reversed dasatinib-induced EGFR degradation, and pharmacological activation of AMPK led to ER stress and EGFR degradation. Addition of ER stress inhibitor to dasatinib reversed EGFR degradation and apoptosis, and pharmacologic activation of ER stress resulted in EGFR degradation. In conclusion, metabolic stress may play a role in dasatinib-induced EGFR degradation and apoptosis in HNSCC cells.']",
        "Doc_id":"AACR_2013-5404",
        "Doc_title":" Metabolic stress played a role in dasatinib-induced EGFR degradation and apoptosis in head and neck cancer.",
        "_version_":1606189020758409216},
      {
        "Meeting_name":" Molecular profiling in patients (pts) with upper gastrointestinal (UGI) cancers correlated with clinical outcome.",
        "Background":"['Background', ' Recent efforts have expanded our understanding of the molecular pathogenesis of UGI cancers and how oncogenes and tumor suppressor genes play a role in both carcinogenic and metastatic processes. These markers may serve as prognostic and/or predictive factors for recurrence following resection and resistance to radiotherapy and chemotherapy. Gene expression levels of thymidylate synthase (TS), thymidylate phosphorylase (TP), epidermal growth factor receptor (EGFR) and excision repair cross complementing (ERCC-1) have been shown to be associated with outcomes in lung, gastric and colon cancer. We evaluated TS, ERCC-1, EGFR and TP gene expression levels in patients with UGI cancers. Methods', ' This was a retrospective study of 80 pts with UGI cancers evaluated at USC who underwent molecular profiling. The primary objective was to determine a correlation between TS, TP, ERCC1 and EGFR and correlate with clinical outcome. Characteristics of these 80 pts', ' (16 females, 64 males ); median age 61 years (range 34-85); tumor types evaluated - 32 (40%) esophageal, 24(30%) gastric, 24(30%) GE junction; stages- 53 % IV, 21% III, 12% II, 2% I were evaluated for intratumoral gene expression of TS, TP, ERCC-1, & EGFR by real time quantitative PCR using Taqman technology from microdisected paraffin-embedded tumor sections. Results', ' High TS expression was associated with shorter OS (12.8 months vs. 23.7 months p=0.036). A significant correlation was found between TP & ERCC-1 (p=0.0078, r=0.37); TP & TS (p=0.0128, r=0.35); TP & EGFR (p=0.0065, r=0.39); TS & ERCC-1 (p=0.0004, r=0.39); ERCC-1 & EGFR (p=0.025, r=0.30). No statistically significant relationship was found between TS & EGFR (p=0.06 ,r=0.25). There was no correlation of ERCC-1, TP, & EGFR with OS that reached statistical significance. Conclusions', ' TS mRNA levels were shown to be associated with OS in UGI tumors, consistent with data reported in colon cancer. TS gene expression was significantly associated with expression levels of ERCC-1. In addition, ERCC1 was associated with EGFR. These data show for the first time that molecular pathways of cytotoxic agents are linked to the EGFR pathway suggesting that sensitivity to fluoropyrimidines, oxaliplatin, and EGFR inhibitors may be associated.']",
        "Doc_id":"ASCO_35374-65",
        "Doc_title":" Molecular profiling in patients (pts) with upper gastrointestinal (UGI) cancers correlated with clinical outcome.",
        "_version_":1606188991958220801},
      {
        "Meeting_name":" Clinical and therapeutic impact of family with sequence similarity 83, member B in EGFR gene wild type-lung adenocarcinoma.",
        "Background":"['Background', ' We have reported the usefulness of Family with sequence similarity 83, member B (FAM83B) as a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma. FAM83B expresses not only in lung cancer but also in several types of solid cancer. More recently, novel finding showing FAM83B involve to tumor growth, oncogenesis, and resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in breast cancer cell lines has been shown. EGFR signaling pathway also plays an important role in lung adenocarcinoma, therefore, we hypothesize that FAM83B associates with tumor proliferation in lung adenocarcinoma (ADC), results in resistance to EGFR-TKI and in a novel therapeutic target in a part of lung ADC. Here we show that correlation between FAM83B expression and clinicopathological features. Methods', ' This study was conducted with approval of ethics committee in our institute, and informed consent was obtained from all the participants. We identified 216 participants underwent for primary lung ADC between 2008 and 2015. Paired tumor and corresponding normal tissue samples obtained from patients were subjected. FAM83B mRNA expression were examined by cDNA microarray, and analyzed relationship between the level of FAM83B and clinicopathological variables including survival analysis. Further, FAM83B knock down study was performed in several types of cancer cell lines (H1975, HLC-1, H2347) to validate whether FAM83B involve to cell proliferation. Results', ' FAM83B highly expressed in male (p = 0.007), or smoker (p = 0.007), or EGFR wild type tumor (p<0.001). Multivariate analyses also showed that EGFR wild type-tumor correlate with FAM83B expression. In survival analysis, multivariate analysis showed FAM83B correlated with poor outcome in both disease free survival and overall survival (p = 0.011 and p = 0.001), especially stratified by EGFR wild type-tumor (p = 0.017, p = 0.008). Gene silencing with FAM83B siRNA showed growth suppression of HLC-1 and H1975 cell lines. Conclusions', ' FAM83B could involve to tumor proliferation of lung ADC in part, and expected to be the novel therapeutic target of EGFR wild type-ADC.']",
        "Doc_id":"ASCO_185567-199",
        "Doc_title":" Clinical and therapeutic impact of family with sequence similarity 83, member B in EGFR gene wild type-lung adenocarcinoma.",
        "_version_":1606189019763310592},
      {
        "Meeting_name":" Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH)",
        "Background":"['MET amplification has been implicated in signaling pathways that promote cell proliferation, invasion, and survival. It has been identified as an oncogenic driver in various malignancies and is currently being investigated as a potential therapeutic target. To date, MET exon 14 skipping by sequencing and MET amplification by FISH have been found to have potential clinical utility in predicting those patients who may derive benefit from MET-targeted therapy. However, little research has been conducted on alternative technologies to FISH such as CISH, which does not require a dark room and can be interpreted by a board-certified pathologist. The purpose of this study is to report our experience with MET amplification across solid tumors using CISH.A retrospective analysis was done on 26,619 specimens analyzed for MET amplification by CISH at a CLIA-certified lab (Caris Life Sciences). The validated CISH assay, previously validated against a FISH assay, utilized a gene copy number > 5 to assess amplification. Concordance and correlative studies were done in MET-amplified, non-small cell lung cancer (NSCLC) specimens analyzed using a cMET IHC (SP44, 2+ or 3+ staining intensity in 50% or more tumor cell membrane) analyzing protein expression. Correlative studies involving co-existing aberrations, including PD-L1 (SP142, any intensity in at least 50% of tumor cells), in this MET-amplified, NSCLC cohort were also performed.MET amplification utilizing CISH was 0.7% (188/26,619) overall. MET-amplified solid tumors included carcinomas such as NSCLC (3.1%, 87/2767), gastric adenocarcinoma (3.8%, 11/293), esophageal and esophagogastric junction adenocarcinoma (3.3%, 11/338), and endometrial carcinoma (0.4%, 9/2020) along with non-carcinomas, including glioblastoma multiforme (1.0%, 5/510), uterine sarcoma (1.3%, 5/400), melanoma (0.4%, 2/538), and rare tumors such as placental-site trophoblastic tumor (100%, 1/1) and prostatic neuroendocrine tumor (100%, 1/1). A sub-analysis of MET-amplified, NSCLC specimens demonstrated co-occurring protein overexpression in 92.6% (75/81) of cases. These same MET-amplified, NSCLC specimens were found to have EGFR pathogenic/presumed pathogenic mutations (19.7%, 15/76), ALK rearrangements (2.5%, 2/80), and PD-L1 overexpression (27.5%, 14/51). ROS1 rearrangements were not detected in this NSCLC cohort (0%, 0/76).Our data suggest MET amplification detection utilizing CISH is a viable option for identifying MET-driven cancers. The presence of MET across various solid tumors contrasts with biomarkers like HER2, which are exclusive to carcinomas. A sub-analysis of our NSCLC population shows MET-amplified tumors contains a similar molecular distribution to the general NSCLC population. Future studies should incorporate MET CISH in clinical trials utilizing MET-targeted agents to determine its potential as a predictive test for evaluating who may derive the most benefit.']",
        "Doc_id":"AACR_2016-396",
        "Doc_title":" Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH)",
        "_version_":1606188983115579392},
      {
        "Meeting_name":" Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer.",
        "Background":"['Background', '    Majority of non-small cell lung cancer (NSCLC) overexpress EGFR. Our prospective phase II trial investigated EGFR-TKI (erlotinib) as a radiosensitizer for inoperable stage III NSCLC patients (pts) who also received standard chemoradiotherapy (ChT/RT).  Methods', '    48 stage III NSCLC pts were enrolled from 3/2008 through 6/2010. ChT/RT was given every Monday followed by erlotinib/RT on Tuesday-Friday and erlotinib alone over the weekend. RT (63 Gy in 35 fractions) with weekly paclitaxel (45mg/m2)/carboplatin (AUC=2) and erlotinib (150 mg p.o. daily except on the day of chemotherapy) were given for 7 weeks. After one month break, pts received two cycles consolidation of paclitaxel (AUC=6) and carboplatin (200mg/m2). EGFR mutation analysis was performed for 41 pts. The response was evaluated by CT scan three months after completion of ChT/RT based on RECIST criteria. Fishers exact and Kaplan-Meiers tests were used for the statistical analysis.  Results', '    46 pts completed the entire treatment are evaluable for response. All had PS KPS 80, 17 (37%) were female, 23 adenocarcinoma, and 87% former or current smokers, with median age 63 year-old (range', ' 46-81). Responses showed 14 (30%) CR, 23 (50%) PR and 9 (20%) stable or progressive disease. Five in 41 pts (12%) had EGFR mutation (EGFR-M), all adenocarcinoma with 2 females, compared to none of squamous histology (p=0.05). CR and non-CR were 3 and 2 in the EGFR-M group compared to 11 and 25 in the EGFR-wild group (p=0.32), respectively. The median OS and PFS were 25.8 mons & 13.6 mons, respectively. 1-year & 2-year OS were 84% & 75% and PFS 54% & 32%, respectively.  Toxicity showed 2 grade 3 acne, 1 Grade 3 esophagitis, 3 Grade 3 pneumonitis and no Grade 4-5.  Conclusions', '    This prospective phase II clinical study demonstrated an excellent 1-year OS 84 % and median OS 25.8 mons. All EGFR-M were seen in adenocarcinomas. Erlotinib demonstrated a radiosensitization effect.']",
        "Doc_id":"ASCO_80301-102",
        "Doc_title":" Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer.",
        "_version_":1606188997535596544},
      {
        "Meeting_name":" Specific binding of modified ZD 6474 (Vandetanib) monomer and its dimer with VEGF receptor 2",
        "Background":"['Introduction', ' Tumor angiogenesis is an important component of cancer biology driven in part by the thesis that tumor vessel growth is a necessary requirement for tumor growth. Angiogenesis does not only depend on endothelial cell invasion and proliferation', ' it also requires pericyte coverage of vascular sprouts for vessel stabilization. These processes are coordinated by vascular endothelial growth factor (VEGF). A significant portion of research on tumor angiogenesis has focused on VEGF and its blockage with the expectation that dramatic results would be demonstrated in cancer patients as previously documented in animal models. Vandetanib, also known as ZD6474, is an antagonist of the vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2) and the epidermal growth factor receptor (EGFR or HER1 or ErbB1). It is an orally bioavailable small molecule tyrosine kinase inhibitor of multiple growth factors, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC). Methods', ' ZD 6474 monomer was purchased modified to add a fluorescent dye (6-FAM). Its coupled ZD 6474 dimer was also prepared using a PEG linker, similarly with FAM fluorescent dye. The two compounds were compared in a series of in vitro studies using human endothelial cell (HUVECs) and several cancer cell lines. We first looked at VEGFR binding affinity and specificity with cell uptake and blocking study. Then, the effects on cellular viability and angiogenesis were compared using with tubular formation of HUVECs in vitro, also matrigel plug assay, and bio-distribution test on VEGF over expressed U87 human glioma tumor model in vivo. Results', ' Imaging of ZD 6474 dimer showed much better binding and uptake in HUVECs and other VEGFR expressing cells than ZD 6474 monomer, including during systemic delivery to tumors. However, the therapeutic and anti-angiogenic effects were mixed, with most tests showing the dimer to have same or weaker effects than the monomer. Conclusion', ' This study provides a rational for the evaluation of dimeric ZD 6474 as a potential imaging agent. Paradoxically, it also demonstrates that the enhanced receptor binding achieved by multivalency does not always translate into enhanced therapeutic effectiveness. Keyword', ' Vandetanib (ZD 6474), anti-angiogenesis, VEGFR']",
        "Doc_id":"AACR_2012-2339",
        "Doc_title":" Specific binding of modified ZD 6474 (Vandetanib) monomer and its dimer with VEGF receptor 2",
        "_version_":1606189005796278272},
      {
        "Meeting_name":" Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma.",
        "Background":"['Head and neck squamous cell carcinoma (HNSCC), the sixth most common cancer worldwide, has a five-year survival rate of only 50%. The first targeted agent FDA approved for treatment of HNSCC was cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Despite EGFR overexpression in up to 90% of HNSCC tumors and ample evidence supporting EGFR as a therapeutic target in HNSCC, the response rate for single-agent cetuximab is below 20%, and resistance to cetuximab-containing therapy remains a major obstacle in the effective treatment of HNSCC. Identification and targeting of mediators of cetuximab resistance is needed to improve patient outcomes.']",
        "Doc_id":"AACR_2017-4108",
        "Doc_title":" Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma.",
        "_version_":1606188977002381313},
      {
        "Meeting_name":" Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations",
        "Background":"['Background', '  Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show great efficacy in patients with advanced non-small cell lung cancer (NSCLC)  with EGFR mutations. The BR.19 trial exploring the role of adjuvant gefitinib in resected early stage NSCLC (stage IB 49%, II 38%, III 13%) did not show significant progression-free survival (PFS) or overall survival (OS) improvement in all patients. The efficacy of gefitinib following adjuvant chemotherapy in patients with EGFR mutation is unknown.  Methods', '    In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned to receive pemetrexed (500mg/m2) and carboplatin (AUC=5), administered every 21 days for 4 cycles, followed with (n=30) or without (n=30) gefitinib (250mg per day) for 6 months. The primary end point was PFS. The second end point was OS. Results', '  From August 2008 toSeptember 2011, 60 patients (35 males and 25 females) were included in our center. Of the 60 patients (56 adenocarcinomas, 2 squamous cell carcinomas, 2 adenosquamous carcinomas), 20 patients (33.3%) had exon 19 deletion mutation, 40 (66.7%) patients had exon 21 L858R point mutation. The most common adverse event was rash (43.3%, 13 of 30) in the pemetrexed and carboplatin (PC)-gefitinib group and the addition of gefitinib to chemotherapy was well tolerated. The PFS was significantly longer among those who received PC-gefitinib than among those who received PC alone (median,39.8 months vs 27.0 months; hazard ratio [HR],0.369; 95% confidence interval [CI], 0.161-0.847; P=0.014). There was no significant difference in OS between the two group(median,41.6 months vs 32.6 months,P=0.066). The rates of 2-year PFS and OS were 78.9% and 92.4% in PC-gefitinib group, and 54.2% and 77.4% in PC alone group, respectively.  Conclusions', ' The addition of gefitinib to pemetrexed and carboplatin adjuvant therapy showed significant improvement in PFS for patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations.']",
        "Doc_id":"ASCO_110355-132",
        "Doc_title":" Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations",
        "_version_":1606189002547789824},
      {
        "Meeting_name":" Patient-derived xenograft models reveal a subset of clinically relevant squamous non-small cell lung cancers that respond to targeted EGFR inhibition.",
        "Background":"['BACKGROUND', ' Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, carries a poor prognosis and remains an area of high unmet need. Despite recent advances in treating NSCLC adenocarcinomas with targeted epidermal growth factor receptor (EGFR) kinase inhibitors, few advances have been made in the treatment of squamous cell carcinoma (SCC), which accounts for 25% of NSCLC. Although the incidence of EGFR mutations in SCC is low, a retrospective clinical study of erlotinib in SCC suggested that a proportion of SCC patients would benefit from treatment with an EGFR inhibitor (Tseng et al., 2012).METHODS', ' NSCLC samples obtained from untreated patients undergoing surgery were collected with ethical consent, disaggregated and implanted subcutaneously in MF-1 nude mice (Harlan UK) admixed with a human stromal cell component to generate patient-derived xenograft (PDX) models (LION PDX models). Tumour material was diagnosed on the basis of operative histology and immunohistochemistry (IHC) used to confirm histological subtype. IHC was also used to evaluate EGFR expression and tumours characterised for mutations in p53, LKB1, EGFR and K-RAS by direct DNA sequencing. Patient-derived xenografts were maintained in vivo and study cohorts of mice dosed when tumours reached 100-200mm3 with either erlotinib or gefitinib or vehicle placebo. Response to treatment was evaluated by tumour growth inhibition and waterfall plots.RESULTS', ' We have identified a subset of tumours with squamous histology in our LION panel of patient-derived NSCLC xenografts that respond to treatment with a targeted EGFR inhibitor. Four out of 11 SCC models tested (36%) responded to treatment with either erlotinib or gefitinib with greater than 50% growth inhibition and two SCC models responded with 30% growth inhibition. Responses correlated well with EGFR expression. Work to characterise a further 8 LION SCC PDX models is also underway.CONCLUSIONS', ' These data support the proposition that a significant subset of NSCLC patients with squamous histology may benefit from treatment with targeted EGFR inhibitors. Our LION SCC models could be valuable for biomarker studies to identify the basis of the EGFR inhibitor responder subset and for evaluating new agents in a more clinically relevant setting.']",
        "Doc_id":"AACR_2013-2796",
        "Doc_title":" Patient-derived xenograft models reveal a subset of clinically relevant squamous non-small cell lung cancers that respond to targeted EGFR inhibition.",
        "_version_":1606188999730266113},
      {
        "Meeting_name":" EGFR expression in T1/T2 oral tongue and floor of the mouth carcinoma",
        "Background":"['Epidermal growth factor receptor (EGFR) is a molecular maker that regulates the cell growth and plays an important role in tumor proliferation, invasion and metastasis formation. Objective', ' In this study we examined the association of immunohistochemical expression of EGFR with clinicopathological parameters, lymph node metastasis, regional recurrence and survival in selected cases of early squamous cell carcinoma (SCC) of the oral tongue and floor of the mouth. Methods', ' Patients with early stage SCC of oral tongue and floor of the mouth were treated surgically at a single institution from 1980 to 2010. Specimens from 139 patients were analyzed for EGFR expression using monoclonal antibody. Results', ' This study included 139 patients, 96 men (69%), with ages ranging from 21 to 85 years old (mean, 58 years). The tumor site was the tongue in 105 cases (75.5%) and the floor of the mouth in 34 (24.5%). With regard to pathological T-stage, 69 cases were pT1 (52.7%) and 62 were pT2 (47.3%). EGFR was overexpressed in 18 cases (13%) and was significantly associated with pT (p=0.017), thickness greater than 4mm (p=0.017), muscular invasion (p=0.014), desmoplastic reaction (p=0.021), inflammatory infiltrate (p=0.029), lymphatic embolization (p=0.016), mode of invasion (p=0.027) and perineural invasion (p=0.007). The overexpression of EGFR was also associated with lymph node metastasis (p=0.038) and regional recurrence (p=0.014). The cancer-specific survival in 5 years decreased from 90% in the group without EGFR expression to 75.3% in the EGFR overexpression group (p=0.019). Conclusion', ' The EGFR overexpression was associated with more aggressive pathological features, lymph node metastasis and regional recurrence in patients with early oral tongue and floor of the mouth squamous cell carcinoma.']",
        "Doc_id":"AACR_2014-2867",
        "Doc_title":" EGFR expression in T1/T2 oral tongue and floor of the mouth carcinoma",
        "_version_":1606189009274404864},
      {
        "Meeting_name":" Polyisoprenylated methylated protein methyl esterase as a potential therapeutic target and biomarker in lung cancer.",
        "Background":"['PURPOSE', ' Excessive epidermal growth factor receptor (EGFR) signaling and/or hyperactivities of polyisoprenylated monomeric G-proteins of the Ras superfamily are frequently associated with various human cancers including lung cancer. While mutations or overexpression of these proteins are responsible for their tumorigenic effects, secondary modifications of the monomeric G-proteins involving polyisoprenylation and eventual methylation are required for their normal as well as the pathological activities. Despite the use of anti-EGFR targeted therapies, prognosis is still poor for patients whose tumors harbor the defective receptor. The need to find novel biomarkers for early/companion diagnosis and targets for the development of novel therapies remains strong. Since polyisoprenylated methylated protein methyl esterase (PMPMEase) is a critical enzyme of the polyisoprenylation pathway whose inhibition causes cancer cell death, the objective was to determine whether it is overexpressed and/or hyperactive in lung cancers in which case, it might serve as a possible diagnostic biomarker or drug target.METHODS', ' Tissue microarrays (TMAs) consisting of 416 cores from 416 separate normal lung and lung cancer cases were analyzed for PMPMEase expression. Also, PMPMEase activities in fresh frozen lung cancer tissues were determined. PMPMEase expression and activities in normal lung fibroblasts (WI-38) as well as lung cancer A549 and H460 cells were also determined. The effect of specific PMPMEase inhibition with L-28 on cell viability was also tested.RESULTS', ' Significantly more intense PMPMEase immunoreactivity was observed in 88.3% of the 416 cases in the lung cancer compared to the normal controls (p < 0.0001). The mean scores  SEM were 118.87.7 (normal), 232.125.1 (small-cell lung carcinomas), 352.19.4 (squamous cell carcinomas), 311.79.8 (adenocarcinomas), 350.024.2 (papillary adenocarcinomas), 334.730.1 (adenosquamous carcinomas), 321.939.7 (bronchioloalveolar carcinomas), and 331.385.0 (large-cell carcinomas). PMPMEase was significantly more active in five of the ten lung cancer cases compared to normal adjacent tissues (p < 0.001). The specific PMPMEase activity in A549 (5.2  0.10 mmol/h/mg of protein) and H460 (4.8  0.05 mmol/h/mg of protein) cells was 1.6- and 1.5-fold higher than in WI-38 cells (3.2  0.04 mmol/h/mg of protein), respectively. Exposure of the cells to L-28, led to lung cancer cell death, with EC50 of 8.5 x 10-6 M for A549 and 2.8 x 10-5 M for H460 cells.CONCLUSION', ' These results implicate PMPMEase overexpression and hyperactivity in lung cancer progression, implying that PMPMEase could serve as a marker for diagnosis and target for lung cancer therapy.']",
        "Doc_id":"AACR_2013-4357",
        "Doc_title":" Polyisoprenylated methylated protein methyl esterase as a potential therapeutic target and biomarker in lung cancer.",
        "_version_":1606188974817148928},
      {
        "Meeting_name":" The effects of dacomitinib (PF-299) on pancreatic ductal adenocarcinoma (PDAC) and cancer-associated fibroblasts (CAFs).",
        "Background":"['Background', ' PF-299 is an oral irreversible small molecule that is an effective inhibitor of the ErbB pathway, which has been shown to play a critical role in pancreatic ductal adenocarcinoma (PDAC) pathogenesis. Indirect activation of Epidermal Growth Factor Receptor (EGFR) signaling through ErbB3 heterodimerization and stromal ligand production has been shown to act as an escape mechanism for EGFR directed therapies. This phenomenon may explain the modest clinical benefit of anti-EGFR drugs in PDAC. We have previously shown that CAFs are responsible for the secretion of ErbB pathway ligands. The addition of CAFs to PDAC xenografts improves the tumor modeling and adds testing stringency to novel targeted therapies. We hypothesize that PF-299 inhibition of multiple ErbB receptors results in effective inhibition of PDAC tumor progression.Materials', ' AsPC-1, BxPC-3, C3, Panc-1 and Panc-1+ErbB3 (stable ErbB3 transfected cell line) PDAC cells were treated with different concentrations of PF-299. PDAC cell proliferation and ErbB signaling was analyzed in vitro. Subcutaneous xenografts were developed using the AsPC-1 and BxPC-3 cell lines alone and in combination with CAFs. CAFs were obtained from surgically resected PDAC tissue. Xenografts were analyzed for tumor growth and tumor-associated ErbB signaling after treatment with PF-299.Results', ' In vitro, PF-299 effectively inhibited AsPC-1, BxPC-3, C3, Panc-1 and Panc-1+ErbB3 cell proliferation in a dose-dependent manner (1-10 M). PF-299 decreased migration of AsPC-1 cells by 54%, while the addition of CAFs (in co-culture) increased cell migration by 13% in the PF-299 treated group compared to an increase of 273% in the control group. In vivo, tumor proliferation of AsPC-1 and BxPC-3 xenografts was significantly inhibited by PF-299 treatment (p=0.04 and p=0.002, respectively). Combination of AsPC-1/BxPC-3+CAFs xenografts increased initial tumor size by 22.5% (p=0.17) for the AsPC-1 cell line and by 11.6% (p=0.46) for the BxPC-3 cell line compared to cells without CAFs. The AsPC-1+CAFs PF-299 treated tumors were 4.1% smaller than placebo treated tumors (p=0.99), while BxPC-3+CAFs PF-299 treated tumor were 26% smaller than the placebo treated group (p=0.05). Immunoblot analysis of AsPC-1/BxPC-3+CAFs xenografts confirmed PF-299 mediated inhibition of both EGFR and ErbB3 mediated signaling.Conclusion', ' We demonstrated that PF-299 targets multiple ErbB receptors, including ErbB3. PF-299 significantly inhibited PDAC cell proliferation, migration and tumor progression by targeting EGFR and ErbB3 signaling. CAFs may provide a novel addition to current models by increasing tumor virulence while pan-ErbB receptor targeting may improve therapeutic approaches to PDAC.']",
        "Doc_id":"AACR_2013-2446",
        "Doc_title":" The effects of dacomitinib (PF-299) on pancreatic ductal adenocarcinoma (PDAC) and cancer-associated fibroblasts (CAFs).",
        "_version_":1606188976712974336},
      {
        "Meeting_name":" Cetuximab in combination with concurrent chemoradiotherapy (CRT) in locally advanced non-small cell lung carcinoma (NSCLC)",
        "Background":"['Background', ' Despite modest benefits from CRT regimens in patients with locally advanced NSCLC, more efficacious treatment options are needed. Cetuximab, a monoclonal antibody that selectively binds to the epidermal growth factor receptor, has demonstrated activity in patients with metastatic NSCLC. This trial was initiated to assess the feasibility of combining cetuximab with concurrent CRT. Methods', ' Patients with non-operable locally advanced NSCLC received cetuximab (400 mg/m2 on day 1, 250 mg/m2 q1w from weeks 2-6) in combination with cisplatin (6 mg/m2 q1d from weeks 2-6), and RT (66 Gy in 24 fractions from weeks 2-6). Results', ' Between April and July 2008, 12 consecutive, eligible patients entered the study. The mean age was 61 years (range', ' 43-77) and 50% were male. Baseline NSCLC staging was', ' IIb (1 patient), IIIa (5 patients), and IIIb (6 patients). Treatment was generally well tolerated. Acne-like rash and radiation esophagitis were the most common side effects (grade 3 according to CTCAE v 3.0) (see table). No unexpected toxicities were observed. Early-response monitoring using PET-CT scans was performed 4 weeks after the last fraction of RT in 10/12 patients. A metabolic response was seen in 50% (complete', ' 3 patients; partial', ' 2 patients) of patients. One patient showed progressive disease. Conclusions', ' Cetuximab added to CRT in patients with NSCLC was generally well tolerated and produced promising early clinical responses. A randomized phase II study comparing CRT with CRT and cetuximab is ongoing. Frequency of reported toxicity by worst grade (CTCAE, version 3.0) Toxicity1234Total Acne-like rash074011 Anorexia30115 Constipation50106 Cough811010 Dysphagia713011 Fatigue51208 Nausea71109 Pain70108 Weight loss22004The most frequent and/or relevant toxicity is shown.']",
        "Doc_id":"ASCO_31293-65",
        "Doc_title":" Cetuximab in combination with concurrent chemoradiotherapy (CRT) in locally advanced non-small cell lung carcinoma (NSCLC)",
        "_version_":1606188974031765504},
      {
        "Meeting_name":" Mechanisms of resistance to trastuzumab emtansine in gastric cancer",
        "Background":"['Background', ' Overexpression of Human Epidermal growth factor Receptor 2 (HER2) in cancer was associated with poor outcome and high chances of recurrence before the development of anti-HER2 agents. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate targeting HER2 based on its antibody component trastuzumab. After internalization of T-DM1/HER2, Lys-MCC-DM1, a tubulin binding agent is released in the cytoplasm. In spite of therapeutic advances, acquired resistance to treatment remains a major obstacle. A better understanding of the mechanisms of resistance to T-DM1 is necessary to improve treatment regimens for HER2-overexpressing cancer patients. We have developed and characterized resistance models to T-DM1 in order to describe underlying resistance mechanisms and develop alternative strategies.Methods', ' To develop in vitro T-DM1 resistance models, HER2-overexpressing esophageal adenocarcinoma cell line OE-19 was exposed to increasing doses of T-DM1 several months in the absence or presence of cyclosporin A (CsA, an inhibitor of MDR1 transporter). Resistance models were called OE-19 TR (exposed to T-DM1) and OE-19 TCR (exposed to T-DM1 and CsA). To characterize the resistance models, sensitivity to T-DM1 was assessed by MTT assay, Annexin V-PI staining and xCELLigence. Cell cycle distribution was assessed by propidium iodide using flow cytometry. Cross-resistance was studied by MTT assay. Expression of HER2, ABC transporters and tubulin was studied by rt-qPCR, flow cytometry and/or Western Blot. An expression profile of sensitive and resistant cells to T-DM1 was performed using a pan-genomic Illumina cDNA array.Results', ' After prolonged exposure of OE-19 cells to T-DM1, IC50 value is 18-fold higher in TR cells and 21-fold higher in TCR cells and both models become less sensitive to T-DM1-induced apoptosis. T-DM1 induced G2/M arrest in OE-19 sensitive cells but not in resistant cells. We found that resistant cells become less sensitive to trastuzumab but remain sensitive to other HER2-targeted therapies such as lapatinib, as well as to a variety of chemotherapy agents. Among the resistant cells, a subpopulation with increased expression MDR1 was identified in OE-19 TR and TCR. Concerning the expression of the main targets of T-DM1 (HER2 and tubulin); we found that HER2 expression and total  and  tubulin expression and content remained unchanged. However the isoforms 2 and 3 were overexpressed in both resistant models. A transcriptomic approach of T-DM1 resistant cells showed modification in adhesion junctions and focal adhesions.Conclusion', ' Prolonged exposure of the OE-19 cell line to T-DM1 resulted in resistance to this immunoconjugate. We are working on describing the resistance mechanisms to T-DM1, which are important to understand cancer progression in patients receiving this therapy. In the long term, we hope this study will allow proposing agents that benefit T-DM1-refractory cancer patients.']",
        "Doc_id":"AACR_2016-309",
        "Doc_title":" Mechanisms of resistance to trastuzumab emtansine in gastric cancer",
        "_version_":1606188973711949824},
      {
        "Meeting_name":" Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3 receptor signaling, in combination with paclitaxel (P).",
        "Background":"['Background', ' AZD8931 is an oral, equipotent inhibitor of ErbB1, ErbB2 and ErbB3 receptor signaling. Methods', ' This open-label (3+3 design) study (NCT00900627) evaluated the MTD, safety, tolerability and PK of AZD8931 (40160 mg bid) combined with P (90 mg/m2 on days 1, 8 and 15 of a 28-day cycle). DLTs were evaluated during Cycle 1. AZD8931 dosing started at 160 mg bid (based on monotherapy study results; NCT00637039). Results', ' 20 pts with advanced refractory tumors (16 breast) received AZD8931. Median exposure to AZD8931 was 52 days and to P was 3 cycles. In the 160 mg bid cohort, DLTs occurred in 2/6 pts (Gr 3 rash; Gr 3 keratitis and Gr 3 photophobia), leading to lower dose cohorts. DLTs occurred in 1/2 pts at 120 mg bid (Gr 3 diarrhea) and 2/6 pts at 80 mg bid (Gr 3 rash; Gr 3 esophagitis). AZD8931 40 mg bid was the protocol-defined MTD. At AZD8931 40 mg bid + P, skin rash (n=6) and diarrhea (n=5) were the most common dermatology and GI-related AEs; the majority were of short duration, and responded to appropriate management and/or temporary AZD8931 interruption. At 40 mg bid, AZD8931 steady-state concentrations exceeded preclinical IC50s for target receptors. Combination treatment did not alter exposure of AZD8931 or P (preliminary data). Conclusions', ' AZD8931 40 mg bid was generally well tolerated, considered suitable for chronic administration, and is progressing into phase II. Experience in this study has highlighted the importance of early rash management and robust guidelines have been adopted. The difference in AZD8931 MTD between this and the monotherapy study most probably reflects differences in clinical interpretation of DLT criteria as they pertained to non life-threatening and subjective events such as rash, more long-term exposure in the present study, and the possible augmentation of rash when EGFR inhibition is combined with P.']",
        "Doc_id":"ASCO_78752-102",
        "Doc_title":" Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3 receptor signaling, in combination with paclitaxel (P).",
        "_version_":1606189001202466816},
      {
        "Meeting_name":" Regulation of p53 function by KLF5",
        "Background":"['Background', ' The transcription factor Krppel-like factor 5 (KLF5) is essential for normal homeostasis, stemness, and tumorigenesis. Typically, KLF5 functions as a transcriptional activator, including in esophageal epithelia where KLF5 promotes keratinocyte proliferation and migration by activating EGFR and ILK, respectively, and prevents transformation by activating Notch1. Yet, the function of KLF5 is context dependent, and mutation of the tumor suppressor p53 switches KLF5 from a transcriptional activator to a repressor of p21Waf1/Cip1 and from pro-proliferative to anti-proliferative. Interestingly, KLF5 also inhibits p53 itself, though the mechanism of this inhibition is unknown. We hypothesized that the functional switch of KLF5 from transcriptional activator to repressor involves the recruitment of a co-repressor.Methods', ' Primary human esophageal keratinocytes immortalized with hTERT were stably infected with inducible lentivirus containing shRNA against KLF5 or Sin3A. p53 mRNA and protein levels were assessed by real-time quantitative PCR and Western blotting, respectively, and p53 protein stability was evaluated by pulse-chase experiments. We employed ChIP across a 4 kb region on the p53 gene, from 2 kb upstream to 2 kb downstream of the transcription start site, to identify the region of KLF5 binding on p53. Promoter activity was assessed with a series of luciferase reporters containing varying lengths of p53 and its upstream regulatory region. Protein-protein interaction was examined by co-IP.Results', ' KLF5 knockdown significantly increased p53 both at the mRNA and protein levels. In unstressed cells p53 protein undergoes rapid degradation such that p53 levels are typically low. Yet, with KLF5 knockdown, despite increased p53 protein levels, we saw no changes in p53 protein stability. By ChIP, we identified a region of KLF5 binding to p53 between -600 to -356 bp upstream of the transcription start site. Several other KLF family members can interact with the co-repressor Sin3A, and we found that Sin3A also complexed with KLF5 in human primary esophageal keratinocytes. Knockdown of Sin3A abolished the inhibitory effect of KLF5 on p53, resulting in elevated p53 expression, growth inhibition, and increased apoptosis.Conclusion', ' KLF5 transcriptionally represses p53 via the co-repressor Sin3A. Thus, KLF5 promotes cell proliferation in normal keratinocytes by both activating pro-growth signals and inhibiting the brake machinery of the cell cycle.']",
        "Doc_id":"AACR_2015-2087",
        "Doc_title":" Regulation of p53 function by KLF5",
        "_version_":1606189006487289856},
      {
        "Meeting_name":" Combining forces",
        "Background":"['Oncogenic drivers are often overexpressed in adenocarcinoma non-small cell lung cancer (NSCLC) patients, so this tumor type is often sensitive to targeted therapies. Sensitizing mutations in the epidermal growth factor receptor (EGFR) are good predictive biomarkers for response to EGFR-small molecule inhibitors, eg erlotinib. Amplification or exon 14 skipping of cMET are good biomarkers for cMET-small molecule inhibitors, eg crizotinib. In other subtypes of NSCLC, eg squamous, targeted therapy is not considered to be active.']",
        "Doc_id":"AACR_2017-1074",
        "Doc_title":" Combining forces",
        "_version_":1606189022635360256},
      {
        "Meeting_name":" How sensitive are epidermal growth factor receptor tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring epidermal growth factor receptor genesensitive mutations-",
        "Background":"['Background', '  The efficacy of epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs; gefitinib and erlotinib) has been demonstrated in patients with non-small cell lung cancers (NSCLC) harboring EGFR sensitive mutations. EGFR mutations are found in 30-40% of adenocarcinoma, but rarely in other histologic subtypes. EGFR mutations are occasionally found in squamous cell carcinoma (SCC) in our clinical practice.  However, there is little data demonstrating the efficacy of EGFR-TKIs in SCC harboring EGFR mutations.  Methods', '  We investigated the frequency of EGFR mutation positive SCC of the lung between April 2006 and October 2010. The efficacy of EGFR-TKIs in lung cancer patients with SCC harboring EGFR mutations was retrospectively evaluated.  Results', '  Thirty of 249 patients with SCC (13.3%) had EGFR mutations. The types of EGFR mutation were exon 19 deletion (19/33, 58%), L858R point mutation in exon 21 (12/33, 36%), and G719S point mutation in exon 18 (2/33, 6%). Twenty of these 33 patients were treated with EGFR-TKIs (gefitinib 18; erlotinib 2). Five of 20 EGFR mutation positive patients responded to EGFR-TKIs with the response rate of 25.0% (95% confidence interval [CI], 8.7 to 49.1%). Median progression-free survival (PFS) and median overall survival were 1.4 months (95% CI, 0.7 to 5.8 months), and 14.6 months (95% CI, 2.9 months to undeterminable), respectively. Approximately one third of EGFR mutation positive SCC patients obtained PFS greater than six months.  Conclusions', '  Although EGFR-TKIs seem to be less effective in EGFR mutation positive SCC than EGFR mutation positive adenocarcinoma, some EGFR mutation positive patients with SCC can obtain clinical benefit from EGFR-TKIs. EGFR mutational analysis is recommended even in patients with SCC to select and treat patients properly.']",
        "Doc_id":"ASCO_78226-102",
        "Doc_title":" How sensitive are epidermal growth factor receptor tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring epidermal growth factor receptor genesensitive mutations-",
        "_version_":1606188978125406209},
      {
        "Meeting_name":" A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors.",
        "Background":"['Background', ' KBP-5209 is a novel potent and irreversible inhibitor of tyrosine kinases of the human epidermal growth factor receptor (EGFR) family that preclinically has demonstrated potent antitumor activities in esophageal and gastric cancers and NSCLC. Methods', ' This first-in-human study (NCT02442414) was conducted to determine tolerability, safety, pharmacokinetics and antitumor activity of KBP-5209 administered QD or BID in patients (pts) with advanced solid tumors. Dose escalation (DE) initially was based on a modified accelerated titration plan and then shifted to a standard 3+3 design. The starting dose was 20 mg QD. Eligible patients were adults with advanced, refractory solid tumors with ECOG PS < 1. A cycle was 28 days. DLTs were evaluated for during the first cycle. DE enriched for patients with tumors having molecular alterations in EGFR or HER2/3. Dose escalation continues so dose expansion has not initiated. Results', ' As of 26 Nov, 2016, 23 pts (15 females, 8 males) are a part of the evaluable population with a median age 57 (37-79) treated at doses of 20mg (1), 40mg (3), 60mg (7), 70mg (4), 80mg (6) QD and 20mg BID (2).Tumor types included breast (6), CRC (4), ovarian (3), H&N (2), sarcoma (2), and NSCLC, sinus, gastric, gallbladder, pancreas, CUP tumor (1 each). Tumor genetic profiles were available for 20 pts. DLTs were G3 diarrhea, nausea, and vomiting, which occurred in 1 pt at 80mg QD and G3 Diarrhea, occurring in 1pt at 80mg QD. The most common adverse events related to study drug were diarrhea (60.9%), nausea (47.8%), vomiting (43.5%), fatigue (21.7%), decreased appetite (17.4%) and lipase increased (17.4%). Serious adverse events (SAEs) related to study drug were reported in 4pts', ' diarrhea (1 pt, 70mg QD; 1pt, 80mg QD), nausea and vomiting (1pt, 70mg QD), and diarrhea, nausea and vomiting (1 pt, 80mg QD). Stable disease has been observed in 7pts up to 24 weeks, in which 2/28 pts (7%) achieved tumor shrinkage. Conclusions', ' Based on the present data, KBP-5209 has been well tolerated with a safety profile similar to other pan-HER inhibitors. For QD dosing, maximum tolerated dose has been identified as 70mg QD. The BID dose escalation continues. Clinical trial information', ' NCT02442414']",
        "Doc_id":"ASCO_194183-199",
        "Doc_title":" A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors.",
        "_version_":1606189027021553664},
      {
        "Meeting_name":" A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.",
        "Background":"['Background', ' S-222611 is a novel oral, potent, reversible tyrosine kinase inhibitor with antiproliferative activity in human tumor cell lines expressing EGFR and/or HER2 in vitro and in mouse xenograft models. We conducted the first study in patients (pts) with solid tumors expressing EGFR or HER2.  Methods', ' Daily oral doses of S-222611 were escalated in successive cohorts from 100 mg to a maximum 1600 mg, using a 3 + 3 design. Full plasma pharmacokinetic (PK) profiles were obtained in all pts for 7 days after a single dose on Day 1 and for 24 h following 21 days of once daily dosing (Cycle 1). Trough PK samples were drawn weekly during the first 3 weeks of daily dosing. A CT scan was performed at baseline and every 8 weeks post-dose to assess response (RECIST).  Results', ' Of 23 treated pts (16 male) aged 24-77y, 19 completed Cycle 1. One dose-limiting toxicity (DLT) has been seen to date, a rash at 1200 mg, which resolved on interruption and dose reduction. Other adverse events related to drug, diarrhea, rash, and nausea, were mild (grade 1 or 2) but more frequent at higher doses. Tumor responses have been seen over a wide range of doses. One complete clinical response was observed at 1200 mg in a pt with HER2 positive breast carcinoma previously treated with lapatinib and trastuzumab. Two pts showed confirmed partial responses (one with EGFR positive renal cell carcinoma at 200 mg daily and one with EGFR and HER2 positive esophageal carcinoma at 400 mg daily); 2 pts showed unconfirmed partial responses and 3 pts (with vaginal, gastric and pancreatic adenoCa) showed stable disease for >6 months (mo); 2 pts have been treated for >12 mo. Plasma Cmax, AUC and steady state concentrations increased with dose up to 1200 mg, exceeding those eliciting maximal responses in mice. The plasma t is >24 h.   Conclusions', '  S-222611 was generally tolerated well in doses up to 1200 mg, with only one DLT; rash, diarrhea and nausea have been readily manageable. PK data support once daily dosing to achieve highly effective concentrations. A substantial proportion of patients with HER2 or EGFR expressing tumors have shown partial responses or stable disease (>6 mo) and one patient has shown a complete clinical response.']",
        "Doc_id":"ASCO_93825-114",
        "Doc_title":" A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.",
        "_version_":1606188975543812096},
      {
        "Meeting_name":" C-MET overexpression as a resistance biomarker to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.",
        "Background":"['Background', ' Multiple mechanisms of C-MET activation have been reported in non-small cell lung cancer (NSCLC) including amplification and mutation. C-MET protein overexpression also occurs in 25%-75% of NSCLC and is associated with poor prognosis of NSCLC. This study aimed to evaluate whether C-MET protein expression is associated with the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in EGFR-mutant NSCLC. Methods', ' We retrospectively analyzed 1199 consecutive NSCLC patients, who were tested for C-MET expression by immunohistochemistry (IHC) between Nov 2013 and Sep 2015. The staining intensity within tumor tissue was graded on a scale of 0 (negative), 1+ (weak), 2+ (moderate), and 3+ (strong). C-MET positivity was defined as C-MET expression with strong staining intensity (grade 3+) in more than 50% of tumor cells. Among 262 patients with EGFR exon 19 deletions or exon 21 L858R mutation, 83 EGFR-mutant patients received EGFR-TKI as a first line therapy. Results', ' In total of 1199 tumors, the frequency of each tumor with C-MET grade 0 to grade 3+ was 10.8%, 41.0%, 32.5%, and 15.7%, respectively. C-MET expression was significantly stronger in the tumors with adenocarcinoma than those with squamous cell carcinoma (P< 0.001). In the tumors with adenocarcinoma, EGFR-mutant tumors showed stronger expression of C-MET than EGFR-wild type tumors (P< 0.001) but no difference in C-MET expression by mutation types was observed (P= 0.248). In the first-line EGFR-TKI treatment group, there was no significant difference in response rate to EGFR-TKI between the patients with C-MET positivity (n = 7) and those with C-MET negativity (n = 76) (71% vs. 88%, P= 0.231). However, the median progression-free survival (PFS) to EGFR-TKI was significantly shorter in the C-MET positive group compared with the C-MET negative group (4.3 months vs. 11.9 months, P= 0.015). Conclusions', ' C-MET overexpression was associated with shorter PFS to EGFR-TKI in the patients with EGFR-mutant NSCLC. C-MET overexpression might be as a biomarker to resistance to EGFR-TKI therapy in this population.']",
        "Doc_id":"ASCO_171477-176",
        "Doc_title":" C-MET overexpression as a resistance biomarker to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.",
        "_version_":1606189011917864960},
      {
        "Meeting_name":" ErbB/Pi3K signaling contributes to EGFR ligand expression in colorectal cancer cells",
        "Background":"['Background', ' Cellular expression of EGFR ligands is tightly regulated and is thought to be maintained by an autocrine signaling component in colorectal cancer cells. More importantly, the expression levels of individual ligands have gained recent interest since their expression of their mRNA was found to be linked to anti-EGFR therapy response. Since the expression of these ligands can be regulated by EGFR signaling elicited by EGF, we decided to investigate the contribution of MAPK as well as the PI3K axis, to EREG expression, in K-Ras wild-type colon cancer cells. Methods Colon cancer cells were used to interrogate EGFR downstream signaling. Several inhibitors targeting the ErbBs and the MAPK and PI3K/Akt pathways were used to dissect the pathways downstream of EGFR maintaining ligand mRNA levels in the lim1215 colon cancer cell line. Additionally, we used ER and AR reporter assays to selectively evaluate involvement of the EGFR pathway in transcriptional regulation of the pathway. Consequently, blockade and activation of EGFR pathway members was assessed by Western Blot. Results We show that Ereg and Areg mRNA levels are specifically maintained by erbb1 signaling. Treatment of lim1215 cells with inhibitors blocking Erbb1 (cetuximab) or ErbB1/Erbb2 (lapatinib) did results in near complete inhibition of Ereg and Areg expression in Kras/pi3K wild-type cells, while blockade of ErbB2 alone (which is activated in these cells) with Trastuzumab did not decrease Ereg nor Areg mRNA levels. Downstream of EGFR, we show that MEK signaling is not required for maintenance of EREG and AREG levels in lim1215 cells. Conversely, blockade of PI3K signaling by Akt inhibitors or PI3K inhibitors abolished EREG mRNA levels in these cells. This was reflected by the ability of overexpressed Akt to induce EREG and AREG reporter activity in 293T cells. In contrast, this activation could be rescued by the addition of Akt and PI3K inhibitors, but not MEK inhibitors in cellular media. Conclusions In this work we show that PI3K signaling is required for the transcription of EGFR ligands in colon cancer cells. In this regard, this provides additional insights to the recent findings that link PI3K/Akt signaling to Receptor Tyrosine Kinase expression and activation in cancer cells. Therefore, a global understanding of the signaling networks that control ligand availability and receptor abundance will be crucial in combining ErbB pathway inhibitors in the treatment of kras wild-type colon cancers.']",
        "Doc_id":"AACR_2012-1078",
        "Doc_title":" ErbB/Pi3K signaling contributes to EGFR ligand expression in colorectal cancer cells",
        "_version_":1606188996502749184},
      {
        "Meeting_name":" The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-screen",
        "Background":"['Background', ' We have conducted the Nationwide Cancer Genome Screening Project in Japan since April 2015 using Next Generation Sequencing in advanced non-colorectal gastrointestinal (GI) cancer (aNon-CRC), called as the SCRUM-Japan GI-SCREEN. The objective is to evaluate the frequency of cancer genome alterations in aNon-CRC and to identify patients who are candidate for clinical trial for corresponding targeting agents. Methods', ' This study is ongoing with the participation of 20 major cancer centers. Patients with aNon-CRC, including advanced esophageal cancer (aEC), who plan to or receive chemotherapy were eligible. DNA and RNA were extracted from FFPE tumor samples and were analyzed by the Oncomine Cancer Research Panel (OCP) which allows to detect gene mutation, copy number variant (CNV) and fusions across 143 genes in a CLIA certified CAP accredited laboratory. The detected genomic variant data were classified according to genetic drivers of cancer including gain- and loss-of-function or single nucleotide variant based on the Oncomine Knowledgebase. In this presentation, we show the results of aEC cohort. Results', ' As of October 31st in 2016, a total of 180 aEC samples were analyzed. The sequence with the OCP was successfully performed in 121 (67.2%). Out of 157 patients except for the 23 patients in which precise data is not collected, the proportion of sample and histology type is followed; surgical specimen 58.0%, squamous cell carcinoma 92.4%. The frequently detected mutations in 114 samples of which results were available were TP53 (77.2%), NFE2L2 (23.7%), CDKN2A (9.6%), PIK3CA (7.0%), RB1 (6.1%), and CNVs were CCND1 (37.7%), EGFR (7.9%), MYC (7.9%), SOX2 (6.1%), ATP11B (5.3%), NKX2-1 (5.3%). ERBB2 amplification was identified in 3 cases (2.6%) and FGFR3-TACC3fusion was identified in one case (0.9%). Conclusions', ' This nationwide screening system is efficient to detect rare gene alterations in aEC. This novel knowledge provides an intriguing background to investigate new target approaches and represents a progress toward more precision medicine. Clinical trial information', ' UMIN000016344.']",
        "Doc_id":"ASCO_189409-199",
        "Doc_title":" The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-screen",
        "_version_":1606188984715706368},
      {
        "Meeting_name":" Nuclear Y-box binding protein-1 expression as a prognostic marker and correlation with epidermal growth factor receptor expression in cervical cancer.",
        "Background":"['Background', '  Y-box binding protein-1 (YB-1) is a member of the cold shock protein family and functions in transcription and translation. Many reports indicate that YB-1 is highly expressed in tumor cells and is a marker of tumor aggressiveness and clinical prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been associated with poor outcomes in cervical cancer (CC). Clinical trials have shown that EGFR inhibitors are effective against CC (JCO 2011). Nuclear YB-1 expression correlates with EGFR expression in various types of cancer.  Methods', '  Nuclear YB-1 expression was immunohistochemically analyzed in tissue specimens obtained from 204 CC patients who underwent surgery. Associations of nuclear YB-1 expression with clinicopathological factors such as survival and EGFR (HER1 and HER2) expression were investigated.   Results', '  Nuclear YB-1 expression was observed in 41 (20%) of 204 cases and correlated with stage, tumor diameter, stromal invasion, and lymph-node metastasis. Nuclear YB-1 expression also correlated with both HER1 expression (p=0.0114) and HER2 expression (p=0.0053). Kaplan-Meier survival analysis showed that nuclear YB-1 expression was significantly associated with poor outcomes in terms of progression-free survival (p=0.0033) and overall survival (p=0.0003). On multivariate analysis, stromal invasion, parametrial invasion, and  nuclear YB-1 expression were independent predictors of survival.  Conclusions', '  Nuclear YB-1 expression is a prognostic marker and correlates with EGFR expression in CC.']",
        "Doc_id":"ASCO_92786-114",
        "Doc_title":" Nuclear Y-box binding protein-1 expression as a prognostic marker and correlation with epidermal growth factor receptor expression in cervical cancer.",
        "_version_":1606189006766211072},
      {
        "Meeting_name":" LUX-Lung 6",
        "Background":"['Background', '  Afatinib (A) is an oral, irreversible, ErbB Family Blocker, blocking signaling from EGFR (ErbB1), human epidermal growth factor receptor 2 (HER2; ErbB2) and ErbB4. In LUX-Lung 6, A was significantly better than gemcitabine/cisplatin (GC) in terms of progression free survival (PFS) and tumor response, with a more favorable safety profile. Here, we report the PRO results.  Methods', '  364 pts were randomized (2', '1) to receive A or GC. PROs were measured using EORTC questionnaires QLQ-C30/LC13 at baseline and q3w until progression. Changes of 10 points (scale 0100) were considered clinically significant. Analyses of cough, dyspnea and pain were prespecified. Time to deterioration (1st 10-point worsening from baseline) was analyzed using a stratified log-rank test. Percentage improved/worsened by 10 points or stable was determined. Mean scores over time were estimated using longitudinal (mixed-effects growth curve) models.  Results', '  Compliance on treatment with questionnaires was >90%. Baseline symptom burden was low (cough', ' 35; dyspnea', ' 25; pain', ' 24). Compared with GC, therapy with A significantly delayed time to deterioration for cough (HR=0.45; p=0.0001), dyspnea (HR=0.54; p<0.0001) and pain (HR=0.70; p=0.03). A higher proportion of A-treated pts had 10-point improvements in cough (76% vs 55%; p=0.0003), dyspnea (71% vs 48%; p<0.0001) and pain (64% vs 47%; p=0.003) compared with GC, particularly among pts with baseline symptoms. Mean scores over time for cough, dyspnea and pain also significantly favored A. Consistent with their safety profiles, a significantly higher proportion of A-treated pts had worsening of diarrhea, sore mouth and dysphagia, while fatigue, nausea, and vomiting were significantly worse with GC. Overall, therapy with A significantly improved global health-related quality of life (HRQoL; p<0.0001), physical (p<0.0001), role (p=0.01) and social (p<0.001) functioning compared with GC.  Conclusions', '  In LUX-Lung 6, prolongation of PFS with A was associated with significantly better HRQoL and significantly longer control of lung cancer-related symptoms compared with GC. Clinical trial information', ' NCT01121393.']",
        "Doc_id":"ASCO_112338-132",
        "Doc_title":" LUX-Lung 6",
        "_version_":1606188974643085312},
      {
        "Meeting_name":" Inhibition of SHP2 impairs oncogenic activity of EGFR mutants in non-small cell lung cancer.",
        "Background":"['Activating mutations of epidermal growth factor receptor (EGFR) are found in 5-15% of non small cell lung carcinomas (NSCLC) and are targets of NSCLC treatment. However, most patients treated with EGFR tyrosine kinase inhibitors eventually acquire drug resistance, pointing to the need of evaluating other molecules as potential targets for developing new therapy for NSCLC. The protein tyrosine phosphatase (PTP) SHP2 mediates signaling of growth factor receptors including that of EGFR. SHP2 is activated by EGFR mutants in lung adenocarcinoma. Inhibition of SHP2 with the SHP2 PTP inhibitor SPI-112Me or SHP2 knockdown suppressed proliferation of EGFR-dependent HCC827 and H1975 cells. To assess the role of Shp2 in the transgenic mouse model of EGFR mutant-driven lung cancer, we generated transgenic mice carrying a doxycycline (dox)-inducible, PTP-defective SHP2 (tetO-SHP2CSDA). Bitransgenic CCSP-rtTA/tetO-SHP2CSDA mice were crossed with tetO-EGFRL858R mice. F1 offspring of dox-induced transgenic mice were analyzed. Erk1/2 and Src were activated by EGFRL858R in bitransgenic CCSP-rtTA/tetO-EGFRL858R mice. Both of them were suppressed by SHP2CSDA in CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA tritransgenic mice. Importantly, expression of SHP2CSDA significantly inhibited EGFRL858R-induced lung tumor in the tritransgenic mice. These results suggest that SHP2 is critical for lung tumorigenesis mediated by EGFR mutations.']",
        "Doc_id":"AACR_2013-350",
        "Doc_title":" Inhibition of SHP2 impairs oncogenic activity of EGFR mutants in non-small cell lung cancer.",
        "_version_":1606189027123265536},
      {
        "Meeting_name":" Eps8",
        "Background":"['In this study we investigate the mechanisms regulating myofibroblast differentiation and function, and identify the adapter protein Epidermal growth factor receptor kinase substrate 8 (Eps8) as a negative regulator of the cancer-associated myofibroblast phenotype.Cancer-associated fibroblasts (CAFs) are a heterogenous, poorly defined cell population. Most commonly CAFs are identified by de novo expression of -smooth muscle actin (SMA) incorporated into stress fibres generating enhanced contractility, which is associated with an enhanced secretory profile. Myofibroblasts promote a number of the hallmarks of malignancy, and clinical studies have shown that the presence of an SMA-rich stroma is associated with poor outcome in several cancers, suggesting that stromal targeting may be a useful therapeutic adjunct. The aim of this study was to investigate the mechanisms regulating differentiation of the myofibroblastic CAF phenotype.Fibroblasts (HFFF2 and primary fibroblasts extracted and cultured from normal skin, esophageal and oral mucosa) were treated with TGF-1 to induce myofibroblast transdifferentiation. Target genes were suppressed using siRNA. Gene expression was examined using RNA-seq and qRT-PCR, and protein expression by Western blotting and immunofluorescence microscopy. Myofibroblast function was examined using gel contraction assays while the effect of the myofibroblast secretion profile on cancer cell migration was assessed using Transwell migration assays.RNA-seq confirmed the upregulation of myofibroblast-associated genes (FN1, COL1A1, CTGF, ACTA2) in TGF-1-treated fibroblasts. Conversely, we found that the adaptor protein Eps8 was significantly down-regulated, and this occurred early in the transdifferentiation process. Eps8 sits at the heart of a complex system regulating reorganization of the actin cytoskeleton, and interacts with numerous intracellular proteins including palladin, F-actin and integrins. We found that siRNA knockdown of Eps8 in fibroblasts promoted myofibroblast differentiation, resulting in increased expression of SMA, stress fibre formation and cell contractility and promotion of cancer cell motility. Suppression of Eps8 expression sensitized fibroblasts to TGF-1 treatment and potentiated TGF-1 signalling, in part through transcriptional upregulation and increased phosphorylation of SMAD2.These data suggest that Eps8 expression provides tonic inhibition of myofibroblast transdifferentiation, at least in part by desensitization of cells to TGF-1 mediated by the regulation of SMAD2 expression. Loss of Eps8 expression may play an important role in the generation of an SMA-positive myofibroblastic CAF population.']",
        "Doc_id":"AACR_2015-2389",
        "Doc_title":" Eps8",
        "_version_":1606189031017676800},
      {
        "Meeting_name":" Integrin 64 promotes autocrine EGFR signaling to stimulate migration and invasion toward HGF",
        "Background":"['Integrin 64 is upregulated in pancreatic adenocarcinomas where it contributes to carcinoma cell invasion, in part, through its coordinated modulation of the transcriptome. Here, we find that integrin 64 signaling dramatically upregulates the expression of several genes involved in the epidermal growth factor receptor (EGFR) pathway, including amphiregulin (Areg), epiregulin (Ereg), and ectodomain cleavage protease MMP1. Notably, these genes correlate well with integrin 64 expression in publicly available pancreatic cancer databases. We previously reported that integrin 64 promotes HGF-stimulated migration and invasion; therefore, we tested the role of autocrine EGFR signaling in these processes. We discovered that blocking EGFR signaling with EGFR-specific blocking antibodies or an EGFR tyrosine kinase inhibitor hindered HGF-stimulated pancreatic carcinoma cell chemotaxis and invasive growth in three-dimensional culture. Furthermore, we found that both Areg and Ereg are required for these autocrine effects, as knocking down either ligand prevented migration and invasion. Notably, AsPC1 cells, isolated from abdominal metastases, are not dependent on EGFR signaling for migration or invasion; thus suggesting a mechanism exists for circumventing EGFR dependency. We also demonstrated that HGF stimulates the secretion of Areg, which is dependent on integrin signaling pathways including MAPK, PI3K and PKC and that Areg was transported to the leading edge of cells treated with HGF. Moreover, MMP activity and integrin 64 signaling are required for Areg secretion. Finally, we found that EGFR is phosphorylated in response to HGF stimulation which was dependent on EGFR protein kinase activity; however, Met phosphorylation in response to HGF was unaffected by EGFR signaling. Taken together, we show that integrin 64 stimulates invasion by promoting autocrine EGFR signaling through the upregulation of key genes and facilitating HGF-stimulated EGFR ligand secretion.']",
        "Doc_id":"AACR_2015-1943",
        "Doc_title":" Integrin 64 promotes autocrine EGFR signaling to stimulate migration and invasion toward HGF",
        "_version_":1606188981191442432},
      {
        "Meeting_name":" Human epidermal growth factor 3 (HER3) blockade with U3-1287/AMG888 modulates radiosensitivity in the lung and head and neck carcinomas",
        "Background":"['The epidermal growth factor receptor (EGFR) family consists of four members including HER1 (EGFR), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). Collectively this family of receptor tyrosine kinases (RTKs) play critical roles in the etiology of several human cancers as well as a role in resistance to radiation therapy. In 2006, a study in head and neck squamous cell carcinoma (HNSCC) indicated that using the anti-EGFR antibody cetuximab in combination with radiation resulted in a 10% advantage of 3-year overall survival rate when compared to radiotherapy alone. This study highlighted the therapeutic utility of RTK blockade in combination with radiation. Studies investigating the role of HER3 in radiation response are limited. In the present study, we investigated whether or not HER3 blockade could enhance radiation therapy using the HER3 antibody U3-1287/AMG888. We screened a battery of cell lines from lung, HNSCC and colorectal tumor lines for HER3 expression. The results indicated that all 15 cell lines tested showed expression of HER3. In addition, U3-1287/AMG888 was able to block basal HER3 activity and radiation induced HER3 activation. Further, proliferation assays, using U3-1287/AMG888, indicated that HER3 blockade could block proliferation in SCC6, SCC1483, H226 cell lines, highlighting the importance of HER3 in these tumor cells. Clonogenic assays showed that U3-1287/AMG888 could sensitize these lines to radiation. Furthermore, -H2AX analyses, detected by immunofluorescence, lead to a statistically significant increase in apoptotic cells. Cell cycle analysis, 24 and 48 hours after U3-1287/AMG888 and radiation treatments resulted in a significant G1 and G2 cell cycle arrest. Annexin-V binding assays showed a significant increase in apoptosis in the U3-1287/AMG888 plus radiation group as compared to either agent alone. To determine if HER3 blockade using U3-1287/AMG888 could enhance radiation therapy in vivo we performed tumor growth delay experiments using SCC6, SCC1483 and H226 xenografts in nude mice. Mice were inoculated and treated with 1) IgG, 2) U3-1287/AMG888, 3) radiation or 4) the combination. The results of these experiments indicated that the combination of U3-1287/AMG888 and radiation had a strong impact on tumor growth in studies using single dose or fractionated dosing. Tumor analysis indicated that radiation treatment activated HER3 in vivo and U3-1287/AMG888 could abrogate this activation. Collectively our findings in vitro and in vivo suggest that U3-1287/AMG888 in combination with radiation has an impact on cell and tumor growth by impacting cell cycle progression, increasing apoptosis and increasing DNA damage. These findings suggest that HER3 may play a critical role in response to radiation therapy and blocking its activity may be of strong therapeutic benefit in human tumors.']",
        "Doc_id":"AACR_2012-5726",
        "Doc_title":" Human epidermal growth factor 3 (HER3) blockade with U3-1287/AMG888 modulates radiosensitivity in the lung and head and neck carcinomas",
        "_version_":1606189040234659840},
      {
        "Meeting_name":" Evaluation of Mena isoforms as a surrogate for epithelial mesenchymal transformation and erlotinib resistance in breast carcinoma.",
        "Background":"['Background', ' Epithelial to mesenchymal transition (EMT) is an important step in invasiveness and has been shown to correlate with metastatic potential in several cancer cell lines, including breast carcinoma. However, given the heterogeneity of tumors in vivo, EMT has not been a reliable marker of metastatic potential in cancer patients. Mena, a member of the enabled (ena)/vasodilator-stimulated phophoprotein (VASP) family, which controls cell motility, is upregulated in the invasive subpopulation of breast cancer cells. Mena is alternatively spliced to include one of four exons', ' +, ++, invasive (INV), or 11a. In the presence of MenaINV, tumor cells are able to invade even at epidermal growth factor (EGF) concentrations that would otherwise be undetectable by the tumor cells. Currently, there are several clinical and genetic characteristics which can predict sensitivity to erlotinib, an EGF receptor inhibitor, but further studies are necessary. Methods', ' The animal models used were the polyoma middle T antigen (PyMT) transgenic mouse and severe combined immunodeficiency (SCID) xenografted tumors derived from injection with a human breast carcinoma line, MDA-MB-231, and a rat adenocarcinoma line, MTLn3, with forced expression of MenaINV and Mena11a. Invasive cells and average primary tumor cells were collected using the in vivo invasion assay and Fluorescence activated cell sorting (FACS), respectively, and imaged via immunofluorescence. Results', ' We show that in both the PyMT and MDA-MB-231 animal models, invasive cells are significantly more mesenchymal than average primary tumor cells, indicating they have undergone EMT. The MTLn3-MenaINV cells are more mesenchymal-like, whereas the Mena11a are more epithelial-like. We also expect that cells with a high Mena INV/11a ratio invade despite the presence of erlotinib.']",
        "Doc_id":"ASCO_35482-65",
        "Doc_title":" Evaluation of Mena isoforms as a surrogate for epithelial mesenchymal transformation and erlotinib resistance in breast carcinoma.",
        "_version_":1606189010613436416},
      {
        "Meeting_name":" Epidermal growth factor-induced pyruvate dehydrogenase kinase 1 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation",
        "Background":"['Epidermal growth factor receptor (EGFR) activation is a major cause of metastasis in many cancers, such as head and neck squamous cell carcinoma (HNSCC). However, whether the induction of pyruvate dehydrogenase kinase 1 (PDK1) mediates EGF-enhanced HNSCC metastasis remains unclear. Interestingly, we found that EGF induced PDK1 expression in HNSCC. The tumor cell transformation induced by EGF was repressed by the depletion of PDK1. The down-regulation of PDK1 expression or inhibition of its activity significantly blocked EGF-enhanced cell migration and invasion. In addition, depletion of PDK1 impeded EGF-enhanced binding of HNSCC cells to endothelial cells and tumor cells metastastic seeding of the lungs. Knockdown of PDK1 also inhibited EGF-induced matrix metalloproteinase-1 (MMP-1), MMP-2, MMP-3, MMP-9, and fibronectin expression and Rac1/cdc42 activation. These results demonstrate that EGF-induced PDK1 expression enhances HNSCC metastasis via activation of the fibronectin signaling pathway. The inhibition of PDK1 may be a potential strategy for the treatment of EGFR-mediated HNSCC metastasis.']",
        "Doc_id":"AACR_2016-710",
        "Doc_title":" Epidermal growth factor-induced pyruvate dehydrogenase kinase 1 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation",
        "_version_":1606189012670742528}]
  }}
